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Aim and Outline of the Thesis
Oral mucositis is a frequent complication of cytoreductive chemotherapy and radiotherapy and, 
until recently, was viewed solely as non-specific toxic effect treatment on dividing epithelial cells. 
Many patients suffer from pain are unable to eat or drink normally and consequently suffer a 
poorer quality of life. Moreover, mucositis is often dose-limiting especially after myeloablative 
therapy for haematopoietic stem cell transplantation (HSCT). In the last few years it has become 
increasingly clear that mucositis is not restricted to the mouth but extends to the rest of the 
alimentary tract involving the oesophagus, stomach, and the small and large intestines. The 
explanation for this lies in the fact that the mucosa of the alimentary tract is composed of a lining 
of epithelial cells that are coated with mucous on the outside and are adjacent to submucosal 
tissue on the inside. This layer functions as an anatomical and immunological barrier and so 
the term “mucosal barrier injury” (MBI) is more appropriate to describe the complex biological 
events that occur along the entire digestive tract following intensive cytotoxic treatment.
The aim of this thesis is to define and diagnose MBI of the alimentary tract of HSCT recipients, 
to explore the relationship of MBI to other transplant related complications particularly microbial 
infections and to determine whether MBI of the alimentary tract could be treated with glutamine-
dipeptide. 
Chapter 2  Mucosal Barrier Injury in haematopoietic stem cell transplant recipients   
In this chapter we described the biology, pathology and clinical counterparts of 
mucosal damage after intensive chemotherapy with or without radiotherapy. We 
adopted the term “Mucosal Barrier Injury” as this encompassed the biological 
nature as well as the clinical manifestation known as mucositis and emphasised 
the fact that MBI induced by myeloablative therapy affected the entire alimentary 
tract of HSCT recipients
Chapter 3  Mucosal Barrier Injury; the initiation phase 
The activation of the transcription factor, nuclear factor-kappa B (NF-κB) by 
chemotherapy mediates the release of proinflammatory cytokines. This is probably 
the first step in initiating MBI. In this chapter we explored whether inhibition of NF-
κB by curcumin or caffeic acid phenethyl esther (CAPE) is able to prevent MBI of 
the small intestines after the administration of methotrexate or cytarabine. These 
studies were performed in-vitro using an intestinal cell culture model and in vivo 
in rats.
Chapter 4  Mucosal Barrier Injury to patients after cytotoxic therapy
A number of scales have been advocated and several are used in practice to score 
oral mucositis but little has been done to assess the gastrointestinal counterpart 
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of MBI. Accurate diagnosis of MBI of the intestines is virtually impossible since it 
requires biopsies to obtain histology and is too hazardous to patients who have 
received cytotoxic therapy principally because of the risk of bleeding. Pain and 
diarrhoea are universal symptoms of MBI but cannot be traced easily to a specific 
section of the alimentary tract. Hence we explored the possibility of using sugar 
permeability test to measure gut integrity and function using a solution of 4 different 
sugars; lactulose, L-rhamnose, D-xylose and 3-O-methylglucose. These tests were 
conducted alongside the scoring of oral mucositis and gut toxicity of patients given 
chemotherapy for acute leukaemia and of allogeneic HSCT recipients after intense 
myeloablative therapy. 
Chapter 5  Mucosal Barrier Injury following various myeloablative regimens for stem 
cell transplant
In this chapter we determined the MBI occurring among 129 recipients of an 
autologous or allogeneic HSCT as measured by oral mucositis, gut toxicity and 
sugar permeability testing in order to determine whether sugar permeability testing 
was able to discriminate between various myeloablative regimens.
Chapter 6  Mucosal Barrier Injury measured by citrulline
Serum citrulline is a reliable biochemical marker of the enterocyte mass of the 
small intestine of patients with villous-atrophy. Therefore we investigated the use 
of citrulline as marker of gut MBI of 32 allogeneic HSCT recipients who had all 
received the same myeloablative therapy with idarubicin, cyclophosphamide and 
total body irradiation
Chapter 7  Mucosal Barrier Injury: comparison of sugar permeability testing and 
citrulline
The sensitivity and specificity of serum citrulline compared with sugar permeability 
tests was analysed in 10 additional allogeneic HSCT recipients receiving the same 
conditioning regimen of idarubicin, cyclophosphamide and total body irradiation.
Chapter 8  Mucosal Barrier Injury: a randomised study of parenteral given glutamine-
dipeptide  
Here we describe the results of a prospective, randomised, double-blinded, 
placebo-controlled pilot study of parenteral nutrition supplemented with 0.57 g/kg 
glutamine-dipeptide in a homogeneous group of 32 allogeneic HSCT recipients to 
determine its effect on MBI.
14
_____  Chapter 1  _______________________________________________________________________________________________________________ ____________________________________________________________________________________  Aim and Outline of the Thesis  _____ 
15
Chapter 9  Mucosal Barrier Injury and inflammatory response in relation to 
bacteraemia
We prospectively collected plasma of recipients participating in the randomised 
study of glutamine-dipeptide to investigate the relationship of MBI measured by 
using oral mucositis scoring, citrulline and sugar permeability testing, the host 
inflammatory response measured by C-reactive protein, interleukin-8 and LPS-
binding protein and the onset of bacteraemia during MBI. 
Chapter 10  Mucosal Barrier Injury: paradigm for dysregulation of mucosal barrier and 
microbial flora 
Here we postulate that MBI is far more than simply a risk factor for severe 
infectious complications after anti-cancer treatment. Rather, MBI is a manifestation 
of the breakdown in the relationship between host (patient) and endogenous 
microflora. The delicate balance between microbes and a damaged host is known 
as the “damage-response” framework in which the outcome of that interaction 
determines microbial pathogenesis and not the particular microbial species. 
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Summary
Mucositis is an inevitable side effect of the conditioning regimens used for haematopoietic stem 
cell transplantation. The condition is better referred to as mucosal barrier injury (MBI) since it is 
primarily the result of toxicity and is a complex and dynamic pathobiological process manifested 
not only in the mouth but also throughout the entire digestive tract. A model has been proposed 
for oral MBI and consists of four phases, an inflammatory, epithelial, ulcerative and a healing 
phase. A variety of factors are involved in causing and modulating MBI including the nature of 
the conditioning regimen, the elaboration of pro-inflammatory and other cytokines, translocation 
of the resident microflora and their products for example endotoxins across the mucosal barrier, 
exposure to antimicrobial agents and whether or not the haematopoietic stem cell graft is from a 
donor. Neutropenic typhlitis is the most severe gastrointestinal manifestation of MBI, but it also 
influences the occurrence of other major transplant-related complications including acute GVHD, 
veno-occlusive disease and systemic infections. The pathobiology, clinical counterparts and the 
means of measuring MBI are discussed together with potential approaches for prevention, 
amelioration and, perhaps, even cure.
Introduction
Mucositis is an inevitable side effect of the intensive conditioning therapy used for haematopoietic 
stem cell transplantation [1] and usually refers to the mucosal ulceration of mouth and throat. 
However, it is generally accepted that oral mucositis is in reality the most obvious manifestation 
of damage or injury elsewhere particularly that of the gut. Hence, mucosal barrier injury (MBI) 
may be a more appropriate term for this biological process. There exists no clear definition of MBI 
which is defined by a constellation of signs and symptoms that vary in their clinical expression. 
Oral MBI is reported to affect 60% to 100% of transplant recipients [2,3] and is characterised by 
pain, oedema, erythema, lesions, pseudomembrane formation, excessive mucous production, 
reduced saliva and bleeding all of which reduces the patient’s ability to eat and drink. By contrast, 
there are no reliable data on the incidence of gut MBI although intestinal symptoms affect almost 
every transplant recipient to some extent and include nausea, vomiting, abdominal cramping 
and watery diarrhoea occasionally accompanied by macroscopic blood loss. The exact course 
and severity of bowel symptoms of MBI is also difficult to ascertain because many patients are 
in such pain due to oral MBI that they only gain relief from narcotic analgesia which induces 
constipation as a result of reduced gut motility. There are also a number of scoring systems for 
oral MBI [4] although none is universally accepted and all lack standardisation but, as yet, there is 
no system for registering gut MBI although there are published definitions for grading toxicity of 
individual signs and symptoms. Consequently much more is known about the course of oral MBI 
than its intestinal counterpart. Oral MBI is known to begin around the time conditioning therapy 
is completed, and has been shown to worsen until a peak is reached after which it declines 
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gradually until resolving completely. The onset and duration of mucositis has also been shown to 
mirror the course of neutropenia [5]. (Figure 1) This phenomenon may not be peculiar to any one 
specific regimen. It would therefore be of considerable interest were gut MBI shown to follow a 
similar course to oral MBI. 
Figure 1 The relationship between oral mucositis and neutrophil counts of allogeneic haematopoietic 
stem cell transplant recipients. Twenty-eight patients received idarubicin, cyclophosphamide 
and TBI 9 Gy as conditioning therapy for an allogeneic haematopoietic stem cell transplant. The 
course of mucositis closely mirrors that of neutropenia. Donnelly et al. 1992 [5].
MBI is a complex process that diminishes the quality of life and can predispose to more serious 
clinical complications including disseminated infection, veno-occlusive disease, acute graft-
versus-host disease (GVHD) and even death. However it seems more likely that gut MBI rather 
than oral MBI will present a greater risk to the patient even though it goes largely unrecognised. 
A pathobiological model for oral mucositis has recently been proposed which attempts to 
incorporate and explain all that is currently known about oral MBI [6]. This model describes four 
successive phases; (1) an inflammatory phase followed by (2) an epithelial phase leading to (3) 
an ulcerative/bacteriological phase and ultimately resolving in (4) the healing phase. This model 
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could also be applicable to the gut as a whole even though it is a more complex organ having a 
dynamic epithelial border with different functions and unique interactions with immune system 
and luminal microflora [7] (Figure 2)
Figure 2 Mucosal barrier injury occurs in four phases. The first phase is the inflammatory/vascular phase 
and is characterised by the induction of pro-inflammatory cytokines IL-1, TNF-alpha and IFN-
gamma by cytotoxic drugs and irradation while the epithelial cells are still intact. The second 
phase is the epithelial phase when cells cease dividing and die. This coincides with neutropenia. 
The third phase is when necrosis and ulceration occur and is when the resident microbial 
flora and their products e.g. endotoxin translocate into the bloodstream. Moreover, impaired 
local defences and lower levels of secretory IgA may allow local infection to develop. The final 
phase is when healing takes place and involves the action of naturally occurring substances 
including trefoils, EGF and TGF. The events that take place in the gut are almost certainly more 
complicated than those occurring in the oral cavity since the gastrointestinal tract is intrinsically 
more complex in terms of its function, it possesses the specialised  gastrointestinal-associated 
lymphoid tissue (GALT) system, and its resident microflora are more numerous and varied.
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Pathobiology
The inflammatory phase
Radiation and cytotoxic drugs induce the systemic release of pro-inflammatory cytokines, 
interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-α) from activated macrophages and 
monocytes. Ionising radiation also induces cytokine gene expression directly [8]. TNF-α and its 
receptors are activated and suggest that resident tissue macrophages and monocytes rather than 
circulating polymorphonuclear (PMN) cells are the main target in vivo [9]. Tissue macrophages 
are not eliminated by conditioning therapy and may persist up to 4 months after transplantation. 
In the gut, macrophages reside in the gastrointestinal-associated lymphoid tissue (GALT) 
which houses the vast majority of total circulating lymphocytes as well as other members of 
the lymphoreticular system such as monocytes and intraepithelial lymphocytes. Once released 
into the circulation, the cytokines increase expression of HLA histocompatibility antigens and 
critical adhesion molecules that amplify local tissue injury by inviting PMN cells and activated 
lymphocytes to invade [10]. This results in increased vascularity and most likely higher local levels 
of cytotoxic agents. In an animal model, exposure to bleomycin or 5-fluorouracil (5-FU) resulted 
in increased cellularity of subepithelial oral tissue, vascular dilation and leukocyte margination 
within 24 hours [11]. The generation of cytokines is self-limited during autologous transplantation 
and resolves within 7 –10 days [10]. 
The inflammatory response may be specific to different classes of chemotherapeutic 
agents and to the particular sequence of preparative regimens used in haematopoietic stem 
cell transplantation since a variety of different profiles of cytokines release have been reported 
[12,13,14]. For instance, elevated TNF-α levels were found in 13 (24%) of 56 patients given either 
cyclophosphamide and total body irradiation or cyclophosphamide and busulphan and these 
levels were predictive for transplant related complications within the first 6 months post BMT 
[14]. Serum levels of TNF-α and IL-1β have also been shown to be markedly higher with higher 
doses of TBI 1 week after transplant [13]. In contrast, busulphan, VP-16 and cyclophosphamide 
induced interferon-gamma production directly [12, 15]. Moreover, intestinal damage manifest by 
villous blunting, apoptosis and brush border loss (the surface area of villous cells amplified by 
numerous finger-like microvilli ) correlated well with cytokine levels [13].
In a clinical phase I/II study, use of the monoclonal antibody MAK 195F diminished the 
release of TNF-α but it was also observed that the kinetics of TNF-anti-TNF complexes were 
different after conditioning therapy with cyclophosphamide and TBI than with cyclophosphamide 
and busulphan which actually induced less TNF-α release [16]. Elevated cytokine levels detected 
as early as one week after transplantation might be related to engraftment in the absence of 
complications or to infectious disease, non-infectious events or GVHD rather than MBI [17] 
Moreover, other investigators have failed to find elevated levels of cytokines during or shortly 
after conditioning therapy [12,17,18].
Before total cell destruction, TNF-α, IFN-γ and IL-1 induce major changes in the functionality, 
permeability, brush border transport, glutamine utilisation (glutamine is the main source of 
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energy source for intestinal cells) and mucosal cell integrity [19,20,21,22]. IFN-γ and TNF-α induce 
dose-related cellular exfoliation, leading to the formation of a mucoid cap in an vain attempt to 
protect the mucosa [23].
Epithelial cells are also capable of producing and secreting TNF-α and IL-1α [24]. In an H-
2-incompatible transplanted SCID mice model, colonic TNF-α, IL-1α and IL-6 appeared 4 
hours after TBI and peaked by 24 hours. If no transplantation followed, TNF-α and IL-1α levels 
decreased rapidly 3-5 days later [17,18,25]. Epithelial cells are also capable of mounting an immune 
host response, and of taking up, processing and presenting soluble antigens as well as expressing 
MHC class II molecules [26]. Thus, taken together, these data support the view that the primary 
step in MBI is an inflammatory response.
The epithelial phase
Cytotoxic drugs and radiation interfere with rapidly dividing cells and the kinetics of proliferating 
mucosal cells influences their sensitivity to these agents. Normally, cell renewal takes place 
continuously in crypts from a proliferating pool of clonal undifferentiated stem cells and cell 
division is completed in about 24 hours [27]. Younger cells migrate up to the villous tips and 
slough off into the lumen at the extrusion zone. Anti-metabolites, for example cytarabine, are 
cell cycle dependent and interfere with the synthesis of DNA in dividing cells whereas the 
intercalating agents such as the anthracyclines are more effective during the G2 phase after 
mitosis is complete when the cell has time to restore errors. In contrast, alkylating agents such 
as cyclophosphamide generate lethal DNA lesions even in resting cells by forming cross-links 
between DNA strands while ionising radiation exerts its main effect during mitosis. Various 
chemotherapeutic drugs such as adriamycin, bleomycin and 5-FU increase cellular sensitivity to 
radiation in a synergistic manner [28]. This has also been observed clinically when idarubicin was 
given at the same time as cyclophosphamide and TBI [29].
Normally, the entire epithelium is renewed in 4-6 days, but decreased cell renewal is thought 
to lead to mucosal atrophy, thinning and necrosis although in rats, sublethal doses of alkylating 
agents mainly induced lower absorption rather than villous atrophy [30]. 
The ulcerative-bacteriological phase
Increased redness and swelling of the mucosa and underlying tissue are usually the first signs of 
oral MBI, mainly due to increased vascularity and vascular permeability (inflammatory phase) and 
thinning of epithelium (epithelial phase). This process usually culminates in the ulcerative phase 
within about 14 days of starting chemotherapy [1]. It is also during this phase that the resident 
microflora are assumed to play a role. Normally, these microorganisms contribute to maintaining 
the integrity of the integument and prevent pathogenic microbes from gaining a foothold. The 
ecological system tries to maintain its balance but once the mucosa is damaged, microbes 
may infect the submucosal tissue. Non-pathogenic streptococci specifically bind to, and use, 
the glycoproteins in the dental plaque that develops in the absence of normal food intake and 
saliva production. The non-cellular defence depends on amount and quality of mucus and saliva 
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produced which contain diverse host defence peptides (defensins), lactoferrin, lysozyme and 
immunoglobulins [31]. Secretory IgA inhibits bacterial adherence, specifically of oral streptococci, 
neutralises toxin and virus, prevents antigen uptake and possesses anti-inflammatory activity [32]. 
Several classes of host defence peptides can be found in saliva and on surfaces each possessing 
rapid lytic activity against the membranes of Gram-positive and Gram-negative bacteria as well as 
yeasts [33]. During conditioning therapy and after transplantation, the salivary immunoglobulins 
(IgA, IgG, IgM) have been shown to be lower than normal and the elimination of T-cells from 
engrafted bone marrow results in less initial capacity for immunoglobulin production and 
secretion [34]. Thus, the local immune defences of the oral cavity are impaired. 
It is common practice to administer antimicrobial agents, particularly the fluoroquinolones and 
local antiseptics such as chlorhexidine, to haematopoietic stem cell transplant recipients, leading 
inevitably to marked shifts in the resident oral flora towards the more resistant species particularly 
the viridans (alpha-haemolytic) streptococci. This shift is more profound in-patients with overt 
oral mucositis [35]. There has also been a corresponding increase in bacteraemia due to these 
streptococci with oral mucositis being an important risk factor in autologous haematopoietic 
stem cell transplant recipients [36]. Similarly, Donnelly et al. [37] reported a higher incidence of 
viridans streptococcal bacteraemia due to the marked mucositis associated with treatment 
intensification. One particular species, Streptococcus mitis, is apparently associated with sepsis 
and adult respiratory distress syndrome (ARDS), mainly after high-dose cytarabine [38,39]. This 
syndrome could be provoked by changes in the pulmonary endothelium and lung macrophages 
induced by cytotoxic chemotherapy which, in turn, induces cytokine production perhaps 
triggered by infection with Streptococcus mitis [40]. The stomach or small intestine could be also 
be a portal of entry if colonisation with these streptococci occurs as a result of the achlorhydria 
induced by H
2
-histamine antagonists and proton pump inhibitors since the use of these agents 
has been noted as a risk factor for the so-called “alpha-strep syndrome” [38]. Obviously, MBI is 
itself a risk factor for viridans streptococcal bacteraemia but it might not always indicate systemic 
infection since transient bacteraemia also occurs in healthy persons after dental manipulation [41]. 
Moreover, these bacteria do not elaborate exotoxins nor are they professional pathogens. Thus, 
viridans streptococcal bacteraemia might simply signal the presence of mucosal barrier injury 
rather than infection.
Although, to some extent, similar to the oral cavity, the gut harbours a much more complex 
ecosystem comprising a greater variety of aerobic and anaerobic bacteria that share a symbiotic 
relationship with the host. This relationship plays an important role in maintaining the gut’s 
histological structure and also provides so-called ‘colonisation resistance’ i.e. the ability of 
the gut to repel foreign bacteria. The intestinal microflora depends on prebiotics, the fibrous 
nutrients [42] that enhance probiotic bacteria, like bifidobacteria, lactobacilli, and Clostridium 
species. These are the species that are thought to provide the colonisation resistance by 
elaborating antibacterial compounds and competing for nutrients so preventing overgrowth by 
potentially pathogenic bacteria [43]. These probiotic bacteria also produce nutrients for mucosal 
cells. Certain antimicrobial agents, particularly those that affect cell-wall synthesis, exert a major 
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impact on the gut’s ecosystem by destroying the ‘protective’ anaerobic flora particularly the 
probiotic bacteria. When the gut epithelium is disrupted, bacterial translocation occurs and pro-
inflammatory bacterial oligopeptides, especially endotoxin (lipopolysaccharide or LPS) readily 
gain access [44]. In the normal host (whether animal or human) pathogenic bacteria such as 
Escherichia coli and Pseudomonas aeruginosa penetrate the mucosa and migrate to extra-intestinal 
sites such as the mesenteric lymph nodes, spleen and liver. The GALT system, together with the 
Kupffer cells of liver and spleen serve as a backup to trap endotoxins and kill bacteria. The rate of 
translocation of enterobacteria like E. coli and other gram-negative bacilli such as P. aeruginosa 
is strongly associated with the degree of neutropenia [45]. Microbial translocation is exacerbated 
by irradiation [46] and chemotherapy [47] as micro-organisms can be cultured in extra-intestinal 
sites as well as in blood [48]. Different modes of translocation exist and occur even before any 
histological damage is apparent. Anaerobic non-pathogenic bacteria rarely translocate but yeasts 
such as Candida albicans can do so more easily when disruption has occurred [49]. Endotoxin 
can be transported through the lymphatic channels, bypass the liver or enter the peritoneal 
cavity directly and can cause systemic endotoxaemia [50]. Endotoxin can also increase intestinal 
permeability directly [51] or by stimulating primed macrophages to release an excessive amount of 
cytokines, mostly TNF-α, thereby inducing mucosal inflammation and increasing permeability [52]. 
Higher levels of circulating endotoxin are obtained after giving intensive TBI containing regimens 
[13] suggesting that persistent low-grade endotoxaemia or the inflammation associated with MBI 
induce fever of unknown origin since endotoxaemia and gut mucosal damage occurred in 44 
(70%) of 63 HSC transplant recipients (both allogeneic and autologous) all of whom developed 
fever that could not be explained by infection [53]. 
Peptidoglycan (the major component of the cell wall of Gram-positive bacteria) may play 
a similar role as endotoxin as it is also biologically active in tissues and may induce a pro-
inflammatory response [54]. Although much less potent than endotoxin gram-for-gram, large 
amounts of peptidoglycan may well be released into the circulation when gut MBI is present 
simply because there are many more Gram-positive than Gram-negative bacteria in the gut. 
Exposure to antibiotics that cause lysis will also liberate cell wall fragments. 
Neutropenic typhlitis, a paradigm for gut MBI
Typhlitis, also called neutropenic enterocolitis, necrotising enterocolitis or ileocaecal syndrome, is 
a caecitis often extending to both the proximal and distal caecum that may be primarily a severe 
manifestation of gut MBI. Indeed, all factors that contribute to the development of MBI are present 
clinically. First, typhlitis occurs after the administration of cytotoxic drugs, particularly high-dose 
cytarabine, etoposide and anthracyclines at the nadir of neutropenia and thrombocytopenia. 
Secondly, prolonged exposure to antibiotics results in a marked shift in the gut microflora towards 
toxin producing bacteria [55] such as Staphylococcus aureus, Pseudomonas aeruginosa and Clostridium 
septicum [56,57]. In fact, Clostridium species are now more likely to predominate for reasons 
which are poorly understood such that bacteraemia due to C. tertium or C. septicum is almost 
pathognomonic for typhlitis. Antimicrobial pressure also predisposes to intestinal overgrowth by 
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Clostridium difficile in transplant recipients [58]. Necrosis of the mucosal surface of the ileocaecal 
region probably provides a favourable environment for the spores of Clostridium species to 
germinate and may be their portal of entry into the bloodstream. The pathogenesis of typhlitis 
would therefore seem to require various elements to be present simultaneously, namely, gut MBI, 
a perturbed resident microflora and profound neutropenia. Typhlitis is not only a paradigm for 
MBI but, because of the high mortality rate, it is also the most severe clinical form of MBI and 
deserves more attention both in terms of developing techniques for early diagnosis as well as in 
evolving strategies for prevention and treatment. Consequently we can expect to encounter more 
cases of typhlitis as chemotherapeutic regimens become more intense. 
The healing phase 
In general, the repair of oral MBI parallels haematological reconstitution as peripheral blood 
counts return to normal [3,5,59] with complete resolution occurring within 2-3 weeks [60]. In 
contrast, gut function does not return to normal for several more weeks, since malabsorption 
and diminished enzyme activity still persist even after structural repair. The healing of mucosal 
damage probably occurs in two phases commencing with the restitution of mucosal integrity 
and then remodelling of the mucosal architecture. The mucosal repair process depends on the 
severity of damage since superficial injury can be repaired rapidly by epithelial migration without 
mitosis [61]. However, proliferation in conjunction with angiogenesis is necessary for deep lesions 
involving large areas of necrosis to recover [62]. Trefoil peptides (mucin-associated peptides) are 
secreted by epithelial cells, with each region of the gut probably having its own variant [62]. These 
peptides act as rapid response molecules to injury by promoting cell migration, cell differentiation 
and wound healing [63]. Epidermal growth factor, transforming growth factor alpha, interleukin-11 
and fibroblast growth factor also appear to promote epithelium repair and regeneration [64]. In 
contrast, these agents appear to play only a limited role in the healing of the oral mucosa.
Acute Graft-versus-Host Disease
Gut MBI may evolve into acute GVHD since tissue damage caused by conditioning regimens plays 
a role in both conditions. Any mature donor T lymphocytes within the allograft that recognise 
host-antigens are activated by endotoxin and pro-inflammatory cytokines [10, 13]. Animal studies 
[25] and some studies in humans [13,14] suggest that high levels of pro-inflammatory cytokines 
predispose to acute GVHD, although others could not confirm this observation [12,15,17,65]. The 
early administration of the anti-TNFα monoclonal antibody MAK 195F changes the nature of the 
inflammatory response, reduces the number of febrile episodes and delays the onset and severity 
of acute GVHD [16]. The microflora might also play a role in triggering acute GVHD because less 
disease was observed in decontaminated mice chimeras [66,67]. Intestinal decontamination with 
metronidazole also significantly reduced the severity of acute GVHD in HLA-identical sibling 
transplants [68]. Taken together, these data suggest a role for MBI in triggering of acute GVHD 
because of either the release of cytokines induced by conditioning regimens or the translocation 
of microbial toxins. 
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Diagnostic tools
Intestinal permeability
Permeability refers to the property possessed by a epithelium that enables passage of a solute by 
unmediated diffusion [69]. Permeability can be measured in vivo by means of the urinary excretion 
of test substances or by detecting their presence in blood. Lactulose, various polymers of 
polyethylene glycol (PEG), 51Cr-labeled ethylenediaminetetraacetic acid (51Cr-EDTA) have all been 
used, but the results are markedly influenced by extraneous factors such as bowel transit time, 
gastric emptying and renal function. Nonetheless, permeability to 51Cr-EDTA is already increased 
two days after starting conditioning therapy and continues to increase until shortly after BMT, 
about 12 days later [70]. Others have shown that the intestinal toxicity induced by melphalan can 
be monitored using 51Cr-EDTA thus allowing the effectiveness of various treatments for reducing 
the intestinal toxicity to be assessed [71]. Unfortunately, 51Cr-EDTA is radioactive and not suitable 
for routine use. 
The uptake of antibiotics such as gentamicin and tobramycin may provide a safer means of 
determining increased permeability since such drugs are normally excluded by the intact gut but 
can be detected in plasma during mucositis when given by mouth [72]. Studies of epithelial cell 
handling of cytotoxic drugs, radiation and antimicrobial agents could offer new possibilities for 
documenting MBI [73,74]. 
Sugar absorption tests
The principal features of gut MBI are a loss of epithelial surface and a change in the permeability 
[69]. This can also be measured if at least two different probes are used at once since the 
extraneous factors equally affect the pre- and post-mucosal determinants and the urinary 
excretion ratio becomes an index of intestinal permeability. For example, monosaccharides such 
as mannitol and rhamnose are absorbed through aqueous pores in the cell membrane whilst 
disaccharides like lactulose gain access through the tight junctions located at the upper end of 
adjacent epithelial cells. Tight junctions are dynamic structures exerting physiologic control over 
the flow of solutes through paracellular spaces and play an important role in gut permeability. 
Reduction of urinary monosaccharide excretion represents a loss of epithelial cell surface area, 
while increased urinary disaccharide excretion indicates damage to the tight junctions. Sugar 
absorption tests (SAT) have proven their value in intestinal diseases but they lack diagnostic 
specificity. SATs offer an easy, reliable means of assessing the onset, duration and severity of gut 
MBI in patients treated with cytotoxic agents. Absorption is already increased after only two days 
treatment with chemotherapy [76] suggesting that cytokines might be interfering with the tight 
junctions (see inflammatory phase) rather than any direct inhibition of cell proliferation, which 
tends to occur later [77]. Altered permeability continues to progress until reaching a peak about 7 
days after conditioning therapy has been completed [78] and returns to normal about 4 weeks later 
[79]. This mirrors the oral MBI and neutropenia. (Figure 1)
It should be possible to discriminate patients at risk of developing serious toxicity to therapy 
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from those not at risk by using these SATs since a positive correlation was found between 
progressive non-oral clinical toxicity and increased permeability in transplant recipients [70,71]. 
Bow et al. also found that the absorption of D-xylose was at its lowest 2 to 3 weeks after 
remission induction treatment had been started in patients who developed systemic candidosis 
[80]. Malabsorption of D-xylose was also found to be an independent predictor of neutropenic 
enterocolitis and hepatosplenic candidosis and also correlated well with bacteraemia [80,81]. As 
yet, there are no objective means of determining gut MBI in use routinely and none has been 
validated for use in clinical trials to assess gut toxicity although the data available suggests SATs 
may be useful for helping adapt supportive care regimens for selected patients in order to reduce 
morbidity and perhaps mortality. 
A consensus in the way MBI is measured in clinical practice analogous to the validated scoring 
system of oral mucositis of the Mucositis Study Group [82] is a prerequisite for such studies. There 
is also a pressing need for much simpler tests of each phase of MBI. Data from chemotherapy 
induced cytokine expression of epithelial cells in single-cell testing or cell lines, quantitation of 
cytokine profiles in saliva or stools [83] and the results of basal cell kinetic studies like grading 
of epithelial cells viability by trypan blue dye exclusion obtained by oral washings [84] should be 
incorporated in clinical research and care. It should be possible to demonstrate overt mucositis 
using radionuclide imaging techniques, such as indium-labelled leukocytes [85] and technetium-
labelled diphytanoylphosphatidylcholine liposomes but there are only a few anecdotal reports 
and their clinical feasibility is expected to be minimal.
Intervention and treatment of mucosal barrier injury
Nutrition
Enteral nutrition stimulates gut-responsive hormones, prevents mucosal atrophy, improves 
mucosal blood flow and gastrointestinal motility, stimulates mucus formation and secretion 
of sIgA and reduces bacterial translocation [86]. In children without severe MBI, enteral and 
parenteral nutrition were equally effective in maintaining the nutritional status [87] and a diet 
containing lactose and bovine milk protein appeared to be well tolerated [88]. Oral administration 
of short-chain fatty acids (SCFAs) typically produced by the anaerobic flora of the gut reduces 
the inflammation and necrosis induced by cytarabine in mice [89]. These SCFAs are normally 
produced by the fermentation of dietary fibre and unabsorbed starch by the same gut microflora 
and are the preferred fuel of enterocytes. 
Total parenteral nutrition (TPN) is advocated for those patients who are either malnourished 
or who are expected to have inadequate oral intake for a prolonged period (usually 7-10 days) to 
restore the negative nitrogen and caloric balance. These patients are typically those with MBI that 
is sufficiently severe that it impedes adequate enteral nutrition leading to malnutrition, weight 
loss, malabsorption and micronutrient deficiencies. TPN does help to reduce the morbidity of 
malnourished patients completing a course of myeloablative therapy [1], but at the same time 
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it promotes villous atrophy, increases intestinal permeability, reduces luminal sIgA content 
and enhances bacterial translocation [90]. Nevertheless, the long-term outcome for allogeneic 
HSC transplant recipients is better with TPN, even when they are well-nourished [91] whereas 
autologous HSC transplant recipients gain little or no benefit [92].
Glutamine
Glutamine has attracted a lot of attention because it is the primary fuel for intestinal epithelia 
and the cornerstone of protein and nucleic acid synthesis but mucosal cells cannot synthesise 
enough themselves making glutamine conditionally essential during stress [93]. Administering 
glutamine to animals after irradiation and chemotherapy prevented mucosal atrophy, reduced 
bacterial translocation, endotoxaemia and infections [94-96]. It is much less clear whether 
glutamine given orally prevents human oral MBI, [97,98] although patients treated with high-dose 
chemotherapy experienced less diarrhoea [99]. Glutamine supplement given to HSC transplant 
recipients parenterally helps to preserve hepatic function, lowers the length of stay in hospital, 
improves the nitrogen balance and lowers the infection rate [100,101] but has no influence on the 
occurrence of mucositis or fever [102,103]. However, nothing is known about the effect of glutamine 
on gut integrity or function since permeability tests were not performed.
Cytoprotectants
Direct cytoprotectants such as sucralfate and diphenhydramine do not ameliorate oral MBI [1, 104- 
106]. Whereas indirect cytoprotectants, like transforming growth factor-β3 and epidermal growth 
factor, interfere with epithelial cell replication in animals and are being tested in clinical trials for 
their efficacy and safety in modulating oral MBI [107,108]. Recombinant-human GM-CSF given as a 
mouthwash shortened the duration of severe oral MBI [109,110] but the mechanism of action remains 
unclear. GM-CSF might have a direct pleiotropic effect on epithelial cell kinetics. Alternatively, the 
effect may be indirect as a result of the first neutrophils produced by haematopoietic progenitor 
cells migrating to the oral mucosa and thereby reducing local infection [111]. Other clinical trials 
exploring the effects of recombinant growth factors as transforming growth factor-β1 or TGF-
β3 and others on MBI are coming [112-114]. A clearly different approach consists of delivering 
monoclonal antibodies that bind and inactivate doxorubicin (MAD11) in intestinal cells [115].
Antimicrobial agents
It is common practice to try to reduce the bioburden of Gram-negative bacilli in the oral cavity 
by giving antimicrobial agents and maintaining good oral hygiene and also to provide remedial 
dental treatment when necessary to reduce oral complications [116]. Antibiotic lozenges containing 
tobramycin, polymyxin and amphotericin B reduce oral MBI [117] but the effect of chlorhexidine is 
unclear [118-121]. 
There have been no formal studies of the effect of antimicrobial agents whether given for 
prophylaxis or treatment on MBI although it is usually assumed that they are beneficial. If MBI 
is not primarily the result of infection as seems to be the case, treatment with antimicrobial 
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agents is unlikely to be of benefit and may even prove harmful in exerting selective pressure on 
the resident flora. Probiotics may help restore the balance of gut flora in cancer patients [122] but 
trials of sufficient size are lacking. IgM-enriched immunoglobulin has been shown to reduce 
endotoxaemia and febrile episodes in transplant recipients [53]. 
Future directions
Mucosal barrier injury is far more than simply a toxicological side effect of cytotoxic regimens. 
Enough evidence exists to indicate that MBI is a complex and dynamic pathological process 
but it is essential to understand its nature more fully.. A model for oral MBI already exists and 
shows that it is the net result of an almost complete breakdown of the epithelium initiated by the 
release of pro-inflammatory cytokines induced by the cytotoxic drugs followed by an arrest of the 
mucosal cell cycle and inhibition of repair leading to apoptosis. Infection, if it plays any role at all, 
is largely secondary. This model may go some way to explain the corresponding phenomenona in 
the gut although gut MBI is likely to be much more complex and more difficult to unravel mainly 
because the damage cannot be seen and the signs and symptoms are too imprecise.
Since gut permeability increases very soon after exposure to chemotherapy and irradiation 
it seems logical to pursue tests such as the SATs further and to look for other chemical probes. 
Certainly, a means of objectively monitoring MBI is necessary before drug products can be 
formally tested for their effects on MBI. 
At that moment there are several products ranging from cytokines and defensins to 
nutrients and probiotics which look promising. For example the growth factor interleukin-11 
(IL-11) by reducing pro-inflammatory cytokine expression and secretion by macrophages (phase 
I), it prevents apoptosis of intestinal crypt cells partially by inhibiting proliferation (phase II) 
and promotes recovery of these crypt cells while remodelling connective tissue (phase IV). 
Defensins, trefoil peptides and even sIgA-antibodies could offer additional tools to tackle hostile 
microbes for example IgA-IgG administered orally has been shown to reduce gut MBI in patients 
undergoing intensive cytotoxic therapy [123]. 
With the means of reliably detecting and monitoring gut MBI at our disposal, the process will 
graduate from being an expected though unpleasant side effect with little therapeutic options to 
a condition that might actually be preventable.
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Summary
The inhibition of nuclear factor-kappa B (NF-κB) by, for instance, curcumin is becoming an 
important new approach in combination with chemotherapy or irradiation for the treatment 
of a variety of cancers including haematological malignancies. A dose-limiting side effect of 
anti-cancer therapy in the gastrointestinal tract, is mucosal barrier injury. It is hypothesised 
that mucosal barrier injury is initiated and amplified by pro-inflammatory- and NF-κB-regulated 
mediators. Therefore, the effect of NF-κB inhibition was studied in the onset of mucosal barrier 
injury. In response to cytostatic drug treatment (arabinoside cytosine (Ara-C) and methotrexate 
(MTX)), NF-κB was activated in intestinal epithelial cells (IEC-6) resulting in a NF-κB related 
induction of TNF-α and monocyte chemoattractant protein-1 (MCP-1). NF-κB inhibition 
increased susceptibility of IEC-6 cells to Ara-C as well as MTX induced cell death when obtained 
by the addition of caffeic acid phenethyl ester (CAPE), but not using curcumin. In an animal 
model for MTX-induced mucosal barrier injury, the induction of NF-κB-related cytokines and 
chemokines was detected upon treatment with MTX. Despite increased susceptibility shown in 
vitro, inhibition of NF-κB resulted in a partial amelioration of villous atrophy normally seen in 
the small intestine upon MTX treatment. These results show the inhibition of NF-κB does not 
increase intestinal side effects of the anti-cancer treatment, suggesting a safe use of curcumin 
and CAPE in combination with anti-cancer treatment.
Introduction
Targeting nuclear factor-kappa B (NF-κB) is a promising new approach to treat a variety of cancers 
including haematological malignancies, this in combination with chemotherapy or irradiation. 
NF-κB is an ubiquitous transcription factor that regulates the transcription of many genes 
involved in immune- and inflammatory responses as well as cell survival [1]. In non-stimulated 
cells, NF-κB is localised in the cytoplasm associated with inhibitory proteins of the inhibitor κB 
(IκB) family, rendering NF-κB inactive. The best understood pathway of NF-κB activation is the 
activation by IκB kinases [2,3]. In response to multiple activating signals, IκB is phosphorylated, 
and subsequently ubiquitinated. This ubiquitination leads to rapid proteasomal degradation of 
IκB, unmasking the nuclear localisation signal of NF-κB. NF-κB is subsequently translocated 
into the nucleus, resulting in activation and transcription of several genes [4,5,6]. Transcription of 
both pro-inflammatory protein TNF-α as well as chemokine monocyte chemoattractant protein-1 
(MCP-1) is regulated by NF-κB [7,8]. In addition, IκBα and p105 are up-regulated by NF-κB which 
is thought to ensure a successful feedback, terminating the NF-κB signal eventually resulting in 
an efficient regulation mechanism [9,10]. 
NF-κB associated mediators, like certain cytokines and chemokines, play an important role 
in the onset and augmentation of various inflammatory diseases in the gastrointestinal tract. A 
deregulated function of NF-κB is associated with Crohn’s disease and ulcerative colitis, as well as 
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other inflammatory diseases like asthma and rheumatoid arthritis [11,12,13,14]. Mucosal barrier injury, 
an important dose limiting side effect of anti-cancer treatment, is defined and characterised by 
an increased villous atrophy and subsequently induced intestinal permeability. It is hypothesised 
that, in the onset of mucosal barrier injury the release of cyto- and chemokines is crucial [15,16]. 
Additionally, DNA-damage induced by anti-cancer therapy, is known to activate NF-κB [3,17,18]. 
Therefore, the inhibition of NF-κB could be beneficial in the reduction of mucosal barrier injury. 
However, it should be realised that NF-κB activation is essential for cell proliferation and cell 
survival [11,19,20]. Moreover, it has been postulated that NF-κB inhibition increases susceptibility 
of various cancers to chemotherapeutic- or radiation-induced apoptosis [21,22]. For instance, the 
blockade of NF-κB activity in prostate cancer cells inhibits angiogenesis, invasion and metastasis. 
In human ovarian cancer cells also an inhibition of tumorigenicity could be detected [23,24]. This 
suggests that inhibition of NF-κB during anti-cancer therapy, may increase the susceptibility of 
both the transformed cancer cells and the non-transformed cells, that is, the intestinal epithelia, 
to anti-cancer treatment. Taking all these findings into account, it can be hypothesised that 
inhibition of NF-κB might have positive as well as negative health effects during anti-cancer 
therapy. 
A well known NF-κB inhibitor is curcumin originating from powered rhizomes of the plant 
Curcuma longa Linn. Curcumin is known for its wide ranges of beneficial effects, such as anti-
inflammatory and cancer chemopreventing activities [25]. These activities include anti-oxidation 
[26], suppression of c-jun/AP-1 [27], inhibition of prostaglandin biosynthesis [28], and inhibition of the 
activity and expression of the enzyme cyclooxygenase [29,30]. A second NF-κB inhibitor is caffeic 
acid phenethyl ester (CAPE). It does not affect other transcription factors like AP-1 or Oct-1 [31]. 
Furthermore, besides the inhibition of NF-κB, CAPE suppresses lipid peroxidation [32], displays 
anti-oxidant activity [33], inhibits ornithine decarboxylase, protein tyrosine kinase and lipoxygenase 
activities [34]. Both inhibitors could effectively be used in vivo to inhibit NF-κB activation during 
anti-cancer treatment.
The present study addresses, the use of curcumin and its effects on the small intestine 
during methotrexate (MTX) treatment in rats. In addition, the inhibition of NF-κB by CAPE was 
investigated in the onset of mucosal barrier injury as a deleterious side effect of anti-cancer 
treatment, that is, chemotherapy. 
Material and methods
Cells
The non-transformed small intestinal rat epithelial cell line (IEC-6, CRL-1592) was obtained from 
the ATCC (Rockville, MD, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium 
adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 50 IU/ml Penicillin, 50 µg/ml 
Streptomycin and 10 % foetal calf serum (FCS). Media and supplements were obtained from 
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Gibco BRL (Breda, The Netherlands). The cell line was kept in a continuing culture in a humidified 
atmosphere at 37 ºC and 5 % CO
2
 and was used in the experiments between passage 18 and 35.
Immuno-fluorescence localisation of NF-κB
For localisation of the NF-κB subunit, that is, p65, an immuno-fluorescence technique was used. For 
this technique the IEC-6 cells were plated on a chamber slide system (Nunc, Invitrogen, Merelbeke, 
Belgium). Cells were stimulated for 24 hours with 2.5 µg/ml of the chemotherapeutic agent 
arabinoside cytosine (Ara-C) (cytarabine; Sigma, Zwijndrecht, The Netherlands), with or without 
0.25 µg/ml CAPE (Calbiochem, Darmstadt, Germany) or 2.5 µg/ml curcumin (ICN Biomedical, 
Zoetermeer, The Netherlands) both inhibitors of NF-κB. After fixation with 4 % paraformaldehyde for 
30 minutes, permeability of the cells was induced using 0.1 % Triton X-100 (Sigma) and 0.5 % Bovine 
Serum Albumin (BSA, Sigma) in phosphate-buffered saline (PBS) for 30 minutes. After washing 
the cells with PBS containing 0.1 % Triton X-100 and 0.01 % BSA, the cells were incubated with 
a-p65 (0.1 µg/ml mouse-anti-rat monoclonal antibodies (mAb), Santa Cruz Biotechnology, 
Heidelberg, Germany) for 1 hour at room temperature, followed by incubation for 1 hour with a 
secondary anti-mouse-FITC (Sigma, Goat anti-mouse IgG). After extensive washing with PBS, the 
slides were mounted with a water based immu-mount (Shandon, Pittsburgh USA) and analysed 
using the KS300 image analysis software (Zeiss, Weesp, The Netherlands). 
Quantification of NF-κB activation
IEC-6 cells were incubated with 2.5 µg/ml Ara-C or with 2.5 µg/ml MTX in Petri dishes (Costar, 
Badhoevedorp, The Netherlands) and harvested at 0, 8, 16 and 24 hours with cell lysis buffer 
containing, 20 mM HEPES (pH 7.5), 350 mM NaCl, 20 % glycerol, 1 % Igepal-CA630, 1mM 
MgCl
2
, 0.5 mM EDTA, 0.1 mM EGTA. In order to prevent protein degradation and additional NF-
κB activation the lysis buffer contained 0.2% PMSF and a protease inhibitor cocktail (Boehringer 
Mannheim, Germany). Additional plates of cells were co-incubated with either 0.25 µg/ml CAPE 
or 2.5 µg/ml or curcumin and harvested at 24 hours. A total of 10 µg cell lysate was used for 
the detection of p65 binding to DNA using a TransAM NF-κB ELISA (Active Motive, Rixensart, 
Beligium). The method was performed according manufacturer’s protocol. Briefly, 10 µg of total 
cell lysates were incubated for 1 hour in 50µl of binding buffer (4 mM Hepes (pH 7.5), 120 mM 
KCl, 8% glycerol, 1% BSA) in a 96 wells plate pre-coated with the NF-κB consensus site (5’-
GGGACTTTCC-3’) [35]. Only the activated (nuclear) NF-κB subunit p65 binding will be detected, 
since cytosolic NF-κB bound to IκB is unable to bind DNA. After washing with supplied buffer, 
the wells were incubated for 1 hour with 0.1 µg/ml α-p65 monoclonal antibody, followed by an 
incubation with the supplied horse radish peroxidase-conjugated antibody (0.2 µg/ml). Finally, 
the presence of activated p65 was visualised using 3,3’,5,5’-tetramethylbenzidine substrate, and 
stopped with H
2
SO4, followed by detection on at 450 nm. 
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Cellular viability
The metabolic activity of IEC-6 cells plated in 96 wells plate was measured for the time periods as 
indicated in the figures with 2.5 µg/ml Ara-C or 2.5 µg/ml MTX in the presence or absence of the 
NF-κB inhibitors CAPE (0.25 µg/ml) or curcumin (2.5 µg/ml). After 4 hours incubation at 37 ºC 
with 50 µl tetrazolium salt 2,3-bis[2-methoxy-4-nitro-5-[(sulfenylamino)carbonyl]-2H-tetrazolium-
hydroxide] (XTT) solution as provided in the kit from Boehringer Mannheim, formation of the 
formazan dye by metabolically active cells was measured at 490 nm.
Flowcytometry
Cells were incubated for 48 hours with 2.5 µg/ml Ara-C with or without 0.25 µg/ml CAPE or 
2.5 µg/ml or curcumin in Petri dishes (Costar) and prepared for flowcytometry as described 
previously [36]. Briefly, after fixation using 250 µl 96 % (-20 °C) ethanol for at least 30 minutes, cells 
were centrifuged at 4 °C for 5 minutes at 2000 rpm, and were subsequently washed twice with 
1 ml PBS. For cellular DNA-labelling, cells were incubated for 45 minutes at room temperature 
in the dark with 500 µl propidium iodide (5 µg/ml, Sigma) DNAse free RNAse (0.05 mg/ml, 
Boehringer) solution. Finally cells were analysed using a Flowcytometer (Coulter, Mijdrecht, The 
Netherlands). 
RT-PCR
Total RNA was isolated from 2 x 106 IEC-6 cells or 20 mg tissue using the RNeasy kit from Qiagen 
(Hilden, Germany) according to manufacturer’s protocol. The total RNA fractions were treated 
with 30 Units DNAse (Qiagen) during isolation for 30 minutes at room temperature, to obtain 
pure samples of total RNA. Subsequently, mRNA was than converted to cDNA by incubating 1 µg 
total RNA for 45 minutes at 42 °C with 0.5 µg Oligo(dT)
12-18
 primers and 200 Units SuperscriptTMII 
RNase H- Reverse Transcriptase, both obtained from Gibco BRL in the conditions described 
by the manufacturer. Finally, using specific primers for rat TNF-α and MCP-1 obtained from 
Biosource Inc (Nivelles, Belgium), PCR products were induced. The quantification of the PCR 
products separated on a 2 % agarose gel was performed using a Lumi-imagerTM (Boehringer 
Mannheim, Germany). 
MTX-animal model 
The animal experiments were approved by the Animal care and Ethics Committee (DEC Consult, 
The Netherlands) and were performed according to the UKCCCR guidelines [37]. Female Wag/Rij 
rats (Charles River, Wiga, Germany), 8 weeks of age at the time of the first MTX injection with 
an average weight of 111.2±3.7 g were used. The animals were housed in pairs in a conventional 
environment under controlled humidity and a 12:12-h-reversed light/dark cycle, with free access 
to chow and water. At 7 days before the first MTX injection, all rats were switched to a semi-
synthetic diet (Hope-farms, Woerden, The Netherlands) containing a constant amount of 1 
mg/kg folic acid. At the same time they were trained to expect to be given a supplement twice 
daily at 9:00 and 16:00 using a placebo containing 2.5 % casein, 2.5 % sucrose and strawberry 
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vanilla flavour dissolved in water, which was added in addition to the normal chow. The placebo 
and semi-synthetic diet were given to the animals until the end of the experiment. The dosage 
schedule of MTX treatment leading to intestinal damage and regeneration without causing death 
was obtained from pilot studies. 
To investigate the onset of mucosal barrier injury in this MTX-model, 20 rats were injected 
i.v. on day 0 with 20 mg/kg body weight MTX (Ledertrexate SP Forte, AHP Pharma Hoofddorp, 
The Netherlands), followed by a second MTX injection of 20 mg/kg body weight 24 hours later. 
A control group of four rats received 0.9 % NaCl solution instead of MTX. The body weight of 
the animals was monitored daily. The animals were killed in groups of 4, that is, directly after the 
first MTX injection (day 0) and subsequently in 24 hour periods until the last group was killed 96 
hour after the first MTX injection. 
In order to investigate the effect of NF-κB inhibition, 24 rats (n = 4 per group) were used, 
undergoing the same treatment as described above, of which 2 groups were supplemented with 
2.5 mg/kg/day CAPE (n = 8) or 2.5 mg/kg/day curcumin (n = 8). These NF-κB inhibitors were 
added to the placebo and given in addition to normal chow starting one day before the first MTX-
injection, until the end of the experiment. In this experiment, the animals were killed on day 4 
(96 h) for histopathology measurements, and on day 2 (48 h) for the analysis of cytokine and 
chemokine responses. All animals were killed under sedation using 2 - 3 % Isoflurane (Abbot 
Laboratories, Kent, Great Britain) and segments of the small intestine were taken from the animals 
for (immuno-) histochemistry or mRNA-analysis. All segments were carefully rinsed once with ice 
cold PBS and frozen immediately in liquid nitrogen or were fixed in 4 % paraformaldehyde (pH 
7.4) (Sigma) for 16 hours, dehydrated and embedded in paraffin. 
Immuno-histology
To examine histopathological changes in the intestine, 5 µm sections were cut, and 
rehydrated, before staining with 1 mg/ml haematoxylin (Sigma) and 10 mg/ml eosin (Sigma). 
Histopathological changes were measured as absorption surface-distance ratios as described by 
Howart et. al.[38], using an image analyses software (Zeiss, KS300 image analysis software). The 
effects were studied and analysed at a magnitude of 10x for each rat. At least 30 measurements 
per rat were performed without knowledge of the treatment of the animal. Directly after 
rehydration, myelo peroxidase positive (MPO+) cells were detected on similar slices and were 
visualised using 3,3’-diaminobenzidine staining tablets (Sigma) that were dissolved in water. The 
cells were counted at a magnitude of 60x in frames of 0.05 mm2. At least 30 measurements per 
rat were performed without knowledge of the treatment of the animal.
The localisation of TNF-α in the small intestine was performed on frozen sections (7 µm) 
using an acetone fixation followed by the incubation with mouse anti-rat TNF-α (0.5 µg/ml 
mouse mAb, Santa Cruz Biotechnology,) for 1 hour. Thereafter, sections were incubated with 0.5 
µg/ml anti-mouse IgG (Vector Laboratories, Brunschwig Chemie, Amsterdam, The Netherlands) 
for 1 hour, followed by thorough washing with PBS. Using ABC-complex and AEC substrate 
(Vector Laboratories) the final “staining” was performed. After thorough washing, the slides were 
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mounted with water based immu-mount (Shandon, Pittsburgh USA) and analysed using KS300 
image analysis program (Zeiss). 
Statistical analysis
The Student’s two tailed t-test was used to analyse differences in the morphology measurements, 
as well as the MPO+ cell influx between the control group not receiving MTX and the groups 
receiving MTX injections at the different time points as indicated. Similar analysis on morphology 
and MPO+ cell influx was carried out to observe significant differences between the MTX treated 
rats receiving only placebo and the rats treated with MTX receiving either curcumin or CAPE. 
Same statistical analysis was performed on in vitro data. P-values < 0.05 were considered 
statistically significant. 
Results
To study the role of NF-κB on epithelial cell survival during chemotherapy treatment, first the 
activation of NF-κB was measured. Secondly, two different components were used to inhibit NF-
κB that is, curcumin and CAPE. The activation of NF-κB in response to Ara-C as well as MTX 
has been studied using immuno-fluorescence labelling of p65, in the IEC-6 of rat origin. NF-κB 
translocation to the nucleus could be visualised after 8 hours of incubation with 2.5 µg/ml Ara-C 
and 16 hours after incubation with 2.5 µg/ml MTX (data not shown). In Figure 1, the translocation 
of p65 to the nucleus after stimulation for 24 hours with both cytostatic drugs is visualised. In 
addition, incubation with 0.25 µg/ml CAPE a pharmaceutical NF-κB inhibitor, resulted in the 
inhibition of NF-κB activation during stimulation with 2.5 µg/ml Ara-C as well as during incubation 
with 2.5 µg/ml MTX (Figure 1d). No fluorescence p65 labelling could be conducted with curcumin, 
because of its autofluorescence properties. Using a TransAM p65 detection assay (Active motive), 
the DNA binding of activated p65 in response to both cytostatics was quantitated (Figure 2). 
Incubation for 8 hours with 2.5 µg/ml Ara-C results in a significantly (p < 0.01) higher induction of 
NF-κB (0.299±0.006) in comparison with an 8 hour incubation of 2.5 µg/ml MTX (0.239±0.016). 
Furthermore, the NF-κB activation induced with the incubation of 2.5 µg/ml MTX (0.421±0.050) 
or 2.5 µg/ml Ara-C (0.499 × 0.036) after 24 hours could be blocked with the addition of either 0.25 
µg/ml CAPE or 2.5 µg/ml curcumin. Cellular viability of the non-transformed IEC-6 incubated with 
Ara-C as well as with MTX decreased in a dose- (data not shown) and time- dependent fashion 
(Figure 2b). Not until 48 hours of incubation with 2.5 µg/ml MTX or 2.5 µg/ml Ara-C, a significant 
reduction (p < 0.05) in cellular viability could be detected of 23±10 % and 76±11 % respectively. 
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Figure 1 a-d  Visualisation of chemotherapy induced NF-κB activation (i.e., nuclear localisation of NF-κB). 
For immunofluorescence localisation of p65 IEC-6 (a) were incubated with 2.5 µg/ml MTX (b) 
or 2.5 µg/ml Ara-C (c) with or without 0.25 µg/ml CAPE (d) for 24 hours. Cells were fixed and 
NF-κB was detected using anti-p65 mAb followed by visualisation with FITC (green).
Since both MTX and Ara-C induced the activation of NF-κB (Figure 2) and Ara-C gave a more 
pronounced effect on cell viability, Ara-C was used to study the effect of NF-κB activity on cell 
viability and cell death. The effect of NF-κB inhibition by CAPE or curcumin, on the induction of 
cell death by Ara-C, was tested using flowcytometry. The induction of cell death by 2.5 µg/ml Ara-
C (28.0±1.6 %) as shown in figure 3a and b is characterised by a reduction of cells in G1–phase. 
As shown in figure 3c, the fraction of cell death induced by Ara-C was increased significantly 
(p < 0.001) to 45.0±4.0 % when co-incubated with 0.25 µg/ml CAPE indicating an increased 
susceptibility of the intestinal epithelial cells to Ara-C induced cell death. However, when NF-κB 
inhibition was achieved by co-incubation with 2.5 µg/ml curcumin, the cell death fraction was 
reduced significantly (p < 0.001) to 19.4±0.9 %. Cellular viability as measured using the XTT 
analysis as described above showed similar effects (Figure 3d). The cellular viability of IEC-6 cells 
after Ara-C treatment (34.2±2.3 %) was significantly rescued (p < 0.05) to 50.1±4.2 % when cells 
were co-incubated with 2.5 µg/ml curcumin, but was significantly (p < 0.05) reduced to 23.2±5.5 
% when co-incubated with 0.25 µg/ml CAPE. This indicates that although both curcumin and 
CAPE inhibit NF-κB effectively, the effect on the susceptibility to Ara-C induced cell death and 
viability differs in these non-transformed small intestinal epithelial cells.
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Figure 2 a-b CAPE and curcumin block the activation of NF-κB induced by MTX or Ara-C. IEC-6 cells 
were cultured with 2.5 µg/ml Ara-C or with 2.5 µg/ml MTX, and harvested at the time points 
indicated in the presence of protease inhibitors. A total of 10 µg total cell lysate was used to 
measure activated p65 (a). The bars show mean ± sd of arbitrary units from a triplicate of a 
representative experiment. * Significant difference (p < 0.05) between the levels of activated 
p65 at 8h by MTX vs. Ara-C. # Significant induction (p < 0.01) of activated p65 compared to 
T = 0. *** Significant differences (p < 0.001) between the cell incubated with both cytostatics 
with or without 0.25 µg/ml CAPE or 2.5 µg/ml curcumin at 24 h. (b) Shows the cellular 
viability of IEC-6 cell cultures as described above at time points indicated as measured with 
XTT assay. The bars show mean ± sd of cellular viability as % of control cells not treated with 
either cytostatic drugs or NF-κB inhibitors from a representative experiment.
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Figure 3 a-d Inhibition of NF-κB by CAPE but not by curcumin increases susceptibility of IEC-6 cells to 
Ara-C induced cell death. The percentage of cell death is detected by flowcytometry analysis 
of propidium iodide labelled IEC-6 cells incubated with 2.5 µg/ml Ara-C, with or without 0.25 
µg/ml CAPE or 2.5 µg/ml curcumin. A total of 10,000 cells were counted and divided into 
four sections representative for their DNA content, as indicated in (a) (control cells) and (b) 
(Ara-C treated cells). The bars (c) show the % of cell death as mean ± sd of three independent 
experiments. *** Significant differences in the apoptotic fraction (p < 0.001). Cellular viability 
was measured using XTT assay (d). IEC-6 cells were cultured with 2.5 µg/ml Ara-C with or 
without 0.25 µg/ml CAPE or 2.5 µg/ml curcumin at 72 h. The bars show mean ± sd of cellular 
viability as % of control cells not treated with either cytostatic drugs or NF-κB inhibitors from 
a representative experiment.
48
_____  Chapter 3  _______________________________________________________________________________________________________________ _____________________________________________________  Role of NF-kappaB inhibition in mucosal barrier injury  _____ 
49
In addition to the NF-κB activation by Ara-C, an induction varying from 18- to 129-fold mRNA 
specific for TNF-α and MCP-1 respectively, was observed after 16 hours of incubation with 2.5 µg/
ml Ara-C in a time dependent fashion (Figure 4a). Treatment with MTX resulted in a comparable 
induction of both TNF-α and MCP-1 (data not shown). The production of TNF-α and MCP-1 seen 
in response to Ara-C as well as MTX (data not shown) was reduced, although to a different extent, 
when IEC-6 cells were incubated with 2.5 µg/ml curcumin, indicating a functional inhibition of 
Ara-C induced NF-κB activation by curcumin (Figure 4b).
 
Figure 4 a,b Inhibition of NF-κB by curcumin functionally reduces Ara-C induced cytokine and chemokine 
response. IEC-6 cells were cultured in the presence of 2.5 µg/ml Ara-C and mRNA was isolated 
at time points indicated for RT-PCR (a). (b) Represents IEC-6 cells, which were incubated with 
2.5 µg/ml Ara-C with or without 2.5 µg/ml curcumin for 24 hours. PCR products specific for TNF-
α and MCP-1 were normalised to β-actin expressions. The bars represent mean ± sd of three 
independent experiments as fold induction compared to cells cultured in the absence of Ara-C.
To determine the effect of curcumin supplementation on chemotherapy mucosal barrier injury, 
a well-described rat model for MTX-induced intestinal damage was used [39]. First of all NF-
κB activation and its mediators were determined in the onset of mucosal barrier injury. CAPE 
was used in these studies as a second NF-κB inhibitor known to increase the susceptibility to 
chemotherapy induced cell death. In accordance with in vitro data as depicted in figure 4 on 
IEC-6 cells, an induction of 17- to 30-fold of rat specific mRNA for TNF-α and MCP-1 could be 
detected in vivo in the duodenum as soon as 24 hours after the first MTX injection (Figure 5a). 
Also, an MTX induced cytokine and chemokine response could be detected in the jejunum and to 
a lesser extent in the ileum (data not shown). No data was obtained in vivo of earlier time points 
to establish a dose and time dependent relation of the cytokine and chemokine mRNA induction. 
To locate the cells responsible for the MTX induced TNF-α production, an immuno-histological 
analysis on frozen sections was performed. As shown in Figure 5b, a specific increase in TNF-α 
was found in the crypt cell area in response to the MTX treatment, indicating the epithelial cells 
in this region are responsible for the induction of TNF-α. 
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Figure 5 a-d  Methotrexate induced damage of the small intestine is associated with cytokine and 
chemokine responses, localised in the crypt cell compartment of rats. Small intestinal 
damage was induced using two injections of 20 mg/kg methotrexate. The induction of 
PCR-products from mRNA specific for TNF-α and MCP-1 in the duodenum normalised for 
β-actin are shown as fold induction compared to duodenum values of rats at day 0 (a). Bars 
represent mean ± sd of three independent experiments. (b) Shows Cross-sections of the 
duodenum of rats non-treated or treated with MTX respectively. The sections were stained 
for the presence of TNF-α using specific monoclonal antibodies and AEC substrate, which 
gives a red colouring. The sections were counter-stained with haematoxylin, and pictures of 
representative area were made at magnification of 40x using KS 300 (Zeiss). At time points. 
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For further validation of the model also other intestinal damage parameters were analysed. The 
absorption surface and therefore histopathological effects of the duodenum were significantly 
reduced to 38±6 % (p < 0.001) starting on day 3 (Figure 5c), followed by a significant reduction 
in the jejunum (p < 0.05) on day 4 (data not shown). Intestinal damage is often associated 
with the influx of active MPO+ granulocytes. Moreover, in this model of MTX-induced intestinal 
damage an influx of MPO+ cells was observed (Figure 5d). In the duodenum, already on day 2, 
a significant increase of 13.5±1.1 MPO+ cells / 0.05 mm2 (p < 0.001) is observed, followed by a 
significant induction in the jejunum (p < 0.05) on day 3 (data not shown).
Animals (four per group) were supplemented daily with 2.5 mg/kg CAPE or 2.5 mg/kg 
curcumin to establish the effect of these components on the onset of mucosal barrier injury. The 
supplementation started 24 hours before the first MTX injection until the end of the experiment. 
To confirm whether supplementation with CAPE functionally inhibits NF-κB activation in the small 
intestine, sections were analysed for the induction of mRNA specific for TNF-α and MCP-1 as well 
as the influx of MPO+ cells was measured. As shown in Figure 6a, CAPE functionally reduces 
the NF-κB associated mediators analysed in the duodenum. The induction of TNF-α and MCP-
1 seen in the duodenum of rats receiving only MTX was reduced 3.7 and 3.2 times respectively 
when the animals were supplemented with CAPE. In accordance with the inhibition of the NF-κB 
mediators an inhibition of MPO+ cell influx could be detected of rats when supplemented with 
CAPE (Figure 6d). However, no inhibition on the influx of MPO+ cells could be detected in the 
rats receiving curcumin. Figure 6c shows the effect of CAPE and curcumin in vivo on the onset of 
villous atrophy. A significant re-establishment of the villous morphology could be detected in the 
duodenum when supplemented with curcumin but not when supplemented with CAPE. 
The effect of MTX treatment as well as the supplementation of CAPE or curcumin on 
the body weight of the animals during the experiment is shown in figure 6b. The treatment 
of MTX resulted in a reduction in body weight of 5 %, which could partly be diminished by 
supplementation with curcumin. Moreover no increased signs of the intestinal damage, that is, 
weight loss, morphological changes, or MPO+ cell influx could be detected in any region of the 
small intestine of rats supplemented with either CAPE or curcumin during treatment with MTX. 
Furthermore, the dosage of curcumin in vivo, have been increased up to 125 mg/kg and still no 
toxicity was observed in the small intestine (data not shown).
indicated, histopathology (c), MPO+ cell influx (d) were measured in the duodenum of rats 
(n = 4 per group) treated with MTX on two consecutive days with a 24 hour interval. For each 
rat, histopathology was measured at least in 3 different cross-sections at a magnification of 
10x. Bars show mean % of control ± SEM for four rats per group receiving MTX and killed at 
the time points indicated. For MPO+ cell influx over 30 fields from 0.05 mm2 were analysed 
per animal, at a magnification of 60x. Bars show mean ± SEM of four rats per group. In both 
figures statistical differences between the control group not receiving MTX and the groups 
receiving MTX are indicated with * (p < 0.05), ** (p < 0.01) and *** (p < 0.001). 
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Figure 6 a-d Supplementation with CAPE or curcumin did not increase methotrexate induced villous 
atrophy and MPO+ cell influx. For establishment of functional inhibition of cytokine and 
chemokine induction in vivo mRNA isolated from duodenum at day 2 after the first MTX 
injection and were analysed using semi-quantitative RT-PCR for TNF-α and MCP-1 (a). Bars 
represent normalised arbitrary units as fold induction compared to rats not receiving MTX, 
from the specific PCR products as indicated in the figure. Mean ± sd is displayed from 2 rats 
per group. For analysis of intestinal histopathology (c) and MPO+ cell influx (d), the rats 
were killed 4 days after the first MTX injection. The rats (n = 4 per group) were treated with 
MTX on two consecutive days, and supplemented with 2.5 mg/kg/day CAPE or 2.5 mg/kg/day 
curcumin during treatment. Intestinal histopathology was visualised using haematoxylin 
staining on deparafinised sections, bars reflect means ± sd as percentage of control from rats 
not receiving MTX treatment. MPO+ cells were visualised using 3,3’-diaminobenzidine DAB-
staining on deparafinised sections, over 30 fields from 0.05 mm2 was analysed per rat. Bars 
reflect means ± sd from 4 rats per group in both figures. Figure 5b shows the body weight 
measured as percentage of weight at day 0 representing mean ± sd of 4 rats. * Indicates 
significant differences between MTX treated rats receiving placebo and MTX treated rats 
supplemented with CAPE or curcumin.
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Discussion
The activation of NF-κB is not only associated with the induction of inflammatory reactions but 
also plays an important role in the survival of cells under various cellular stresses [1,40]. It has 
been hypothesised that through the activation of NF-κB both these processes might modulate 
the onset of mucosal barrier injury. In more detail, inhibition of the inflammatory responses 
during chemotherapy might reduce the onset of mucosal barrier injury, whereas inhibition of 
cell survival regulated by NF-κB might increase villous atrophy the dose limiting side effects of 
chemotherapy treatment. Therefore, the inhibition of NF-κB by, for instance, curcumin, might 
have positive as well as negative health effects during anti-cancer therapy. In addition, CAPE was 
used as a second NF-κB inhibitor to study the possible role for NF-κB in the onset of intestinal 
atrophy during chemotherapy.
As shown in this study, both the cytostatic drugs MTX and Ara-C induced NF-κB activation in 
IEC-6 cells, which was followed by the production of pro-inflammatory cytokines and chemokines 
as well as the induction of cell death. Also in vivo the production of pro-inflammatory cytokines 
and chemokines after MTX injection could be measured on both mRNA and protein level. The 
NF-κB related TNF-α production could be especially detected in the crypt cells, suggesting that 
cytokines and chemokines are produced in particularly by the epithelial stem cells in response 
to MTX treatment. These results demonstrate the production of pro-inflammatory cytokines and 
the activation of NF-κB after chemotherapy in vitro and indirectly in vivo. This is in accordance 
with the hypothesis that chemotherapy induces a pro-inflammatory response in the intestine 
as previously suggested [15,16]. Besides a direct effect of MTX induced NF-κB activation on the 
induction of an inflammatory response in the epithelium as shown in Figures 5a,b and 6a, the 
activation of NF-κB might also be related in a later stage to barrier destruction. This might 
subsequently lead to the influx of bacteria, resulting in an indirect cytokine response. However, 
this will not be related to the early onset of mucosal barrier injury.
A significant activation of NF-κB and subsequently the NF-κB regulated cytokine production 
could be measured after 16 hours of incubation with either MTX or Ara-C,which is in contrast 
with the finding by others. These previous results indicate that MTX inhibits TNF-α induced 
NF-κB activation [41]. This discrepancy in findings is probably due to differences in incubation 
periods used. The TNF-α induced NF-κB activation could only effectively be inhibited when 
pre-incubation with MTX, and thus pyrimidine pool depletion was established before TNF-α 
incubation. This indeed might occur before DNA-damage induced NF-κB activation is achieved. 
Furthermore, TNF-α induced NF-κB activation is receptor mediated, whereas early DNA-damage 
induced NF-κB activation is not. This indicates different routes of activation. The activation of 
NF-κB might be related to this induction of cell death. This is, however, probably not the case, 
since cellular viability did not decrease significantly until 48 hours of incubation with either Ara-C 
or MTX. 
With respect to the role of NF-κB and cytokines on cell survival of epithelial cells in the 
intestine after chemotherapy treatment, differences between the inhibitors used were obtained 
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in both IEC-6 cells and MTX treated rats. The inhibition of NF-κB in IEC-6 cells by CAPE resulted 
in an increased susceptibility of IEC-6 cell to Ara-C induced cell death, whereas inhibition of 
NF-κB by curcumin resulted in decreased susceptibility to Ara-C induced cell death (Figure 3). 
Both agents did inhibit NF-κB activation in IEC-6 cells after incubation with Ara-C and MTX 
(Figure 2). The difference between both agents may in part be due to the fact that inhibition 
of NF-κB by curcumin and CAPE are achieved at two different levels. Curcumin inhibit NF-κB 
through the suppression of phoshorylation and degradation of IκBα [42,43,44]. CAPE modifies the 
NF-κB protein so that it can no longer bind to DNA without any effect on IκBα phosphorylation 
or IκBα degradation [31,45]. Perhaps, by inhibiting the phosphorylation and degradation of IκBα, 
degradation of other proteins are also inhibited, whereas the inhibition of NF-κB binding to 
DNA could induce apoptosis. The difference in the NF-κB inhibitor pathway and response to 
chemotherapy induced cell death is currently under investigation. The differences between CAPE 
and curcumin cannot be explained by differences in cytokine production inhibition. Both agents 
inhibited the production of cytokines (Figure 4). In addition, cytokines it self did not influence Ara-
C induced cell death or viability in IEC-6 cells, because addition of cytokines or cytokine specific 
antibodies to IEC-6 cells during incubation with Ara-C did not have any effect on the induction of 
cell death (data not shown). Irrespective of its mechanism, in the in vitro study with IEC-6 cells, it 
was shown that curcumin inhibits the Ara-C induced cell death (Figure 3). This is in contrast with 
previously described results. Prostate cancer cells become more susceptible to cytostatic drug 
induced apoptosis when incubated with curcumin [21]. Perhaps, differences between transformed 
and non-transformed cells account for these different findings. 
To study the effect of curcumin supplementation and the inhibition of NF-κB in vivo on 
chemotherapy-induced mucosal barrier injury, both CAPE and curcumin were tested in an 
animal model, wherein rats were treated with MTX. The inhibition NF-κB activation using 
curcumin as shown by Sugimoto et al., [46] in addition to our data, is effective throughout the 
entire gastrointestinal tract. Although inhibition of NF-κB by CAPE, did increase susceptibility of 
IEC-6 cells to Ara-C induced cell death, supplementation with CAPE did not increase the small 
intestinal damage induced by MTX in vivo. Supplementation of CAPE, however, did show an 
inhibition on the MPO+ cell influx in the duodenum, which correlates with the reduced MCP-1 
response (Figure 6). This again suggests an effective NF-κB inhibition by the supplementation 
of CAPE, since both TNF-α and MCP-1 are NF-κB regulated. The latter result might suggest that 
the influx of MPO+ cells has only a minor effect on the onset on mucosal barrier injury. Despite 
the fact, that curcumin reduced in vitro the cytokine response, in vivo supplementation with 
curcumin did not have any effect on the influx of MPO+ cells (Figure 6). Since supplementation 
of curcumin shows a significant protection on villous atrophy, this result is in contrast with the in 
vitro data, where curcumin inhibited chemotherapy induced cell death, at the same concentration 
at which the activation of NF-κB and subsequently the cytokine and chemokine production was 
inhibited. In summary a reduction of villous atrophy was achieved without inhibition of the 
inflammatory response as measured by MPO+ cell influx. This again suggests a minor role for the 
inflammatory response in the onset of mucosal barrier injury. The results also directly indicate 
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that the use of CAPE and curcumin does not stimulate the onset of mucosal barrier injury. Since 
both compounds do not worsen villous atrophy, this also implies that the use of NF-κB inhibitors 
in order to increase the susceptibility of cancer cells to cytostatic drug induced cell death, does 
not have a negative effect on the onset of mucosal barrier injury. However, since the effects in 
vitro using curcumin and CAPE does have a detrimental effect on chemotherapy induced cell 
death, caution should be exercised when extrapolating these data to the clinic, assuming that 
the use of NF-κB inhibitors in the clinic to sensitise cancer cells to the chemotherapy treatment 
moves forward [47,48]. However, due to the differences in pathways to inhibit NF-κB, like with 
curcumin and CAPE, and also using proteasome inhibitors like PS-341 [47,48], the effect on the 
deleterious side effects normally seen during anti-cancer treatment, will need extra attention 
during the trials. 
It should be realised that it is not known so far as to whether the NF-κB inhibition obtained 
by CAPE and curcumin in the doses tested in this study, will increase the susceptibility of 
various cancers in vivo to cytostatic drug induced cell death. In mice a dosage of 0.2 % w/v 
curcumin in diet inhibited the development or promotion/progression to disease stages of 
azoxymethane-induced colonic adenocarcinomas in mice [25,49]. Moreover, a 64 % reduction in 
adenoma formation in the intestine of Min-mice, which harbour genetic mutation similar to 
the predisposition to development of adenomatous polyposis in humans was seen using 0.1 
% curcumin [50]. Taking into account that rats eat approximately 5 g /day which suggests that 
with 0.2 % curcumin in the diet an effective concentration of 10 mg/day is required for the 
chemopreventive properties of curcumin. The highest concentration of curcumin tested in vivo in 
our studies was 12.5 mg/day without signs of intestinal toxicity. An effective dosage of curcumin 
to inhibiting NF-κB systemically however remains to be elucidated in humans. 
In conclusion, MTX induced NF-κB activation in epithelial cells resulted in production of pro-
inflammatory cytokines and chemokines both in vitro and in vivo, which subsequently could be 
reduced by curcumin and CAPE. Moreover, in vivo supplementation of both curcumin and CAPE 
did not increase susceptibility to MTX induced small intestinal damage.
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Summary
We scored oral mucositis, and gut toxicity and measured sugar permeability testing among 56 
recipients of a haematopoietic stem cell transplant (HSCT) given myeloablative conditioning with 
idarubicin, cyclophosphamide and TBI, and a group of 18 patients given cytotoxic chemotherapy 
for newly diagnosed acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS). Gut 
integrity was already disturbed in the AML/MDS group as measured by the lactulose/rhamnose 
ratio (L/R ratio = 0.09) before therapy and was severely perturbed (L/R ratio > 0.13) for a month 
after HSCT. Oral mucositis and to a lesser extent gut toxicity was only significantly correlated 
with disturbed permeability in the transplant group. The data suggest that sugar permeability, 
oral mucositis and gut toxicity measure different features of mucosal damage after intensive 
cytotoxic therapy.
Introduction
Oral mucositis is reported to affect 60 to 100 % of haematopoietic stem cell transplant 
(HSCT) recipients when myeloablative preparative regimens are used [1]. Less is known about 
the gastrointestinal counterpart, although gut injury results in significant morbidity and even 
mortality [2]. While the severe pain of oral mucositis is often the most obvious and troublesome 
symptom, the extent of gut mucosal injury is difficult to determine because the signs and 
symptoms such as nausea, vomiting, diarrhoea and abdominal cramps affect almost every HSCT 
recipient. An alternative means of defining gut injury might be to employ sugar permeability 
tests as these are generally accepted as surrogate markers of gut disease or damage in patients 
treated for cancer [3]. Sugar permeability tests are also non-invasive and can test changes in the 
permeability and absorption (loss of epithelial surface) which are the principle features of gut 
injury. The conditioning regimen used for HSCT is reported to be an independent risk factor of 
oral mucositis [4]. In our institution, a higher leukaemia-free survival was found for patients with 
standard risk acute leukaemia who had been prepared for an allogeneic HSCT with an intensified 
myeloablative regimen comprising idarubicin (4-demethoxydaunorubicin), cyclophosphamide 
and TBI [5]. However, the patients experienced prolonged and worsened oral mucositis which was 
ascribed to the addition of idarubicin [6]. It is not known whether this was also true of the gut. 
Therefore, we employed a sugar permeability test consisting of a solution of the disaccharide 
lactulose and the monosaccharides 3-O-methylglucose, L-rhamnose and D-xylose in a cohort of 
HSCT recipients given idarubicin as part of their myeloablative therapy. Lactulose is absorbed 
by paracellular transport that is, via open tight-junctions and villous tip extrusion zone and 
any increase of urinary excretion represents loss of integrity. The other three sugars measure 
absorption: 3-O-methylglucose measures ATP-dependent transcellular transport, D-xylose 
detects carrier-mediated transcellular transport and L-rhamnose monitors passive transcellular 
diffusion, a decrease in urinary excretion of each sugar represents loss of epithelial cells and/or 
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function. (Table 1) We also determined the extent of oral mucositis and gut toxicity. As a control, 
we investigated cohort of patients given intensive cytotoxic therapy for newly diagnosed acute 
myeloid leukaemia (AML).
Table 1 Permeation profiles of the different sugars of the permeability test
Sugars Passage Transport
Lactulose Paracellular Passive
Rhamnose Transcellular Passive
D-Xylose Transcellular Carrier-mediated
3-O-Methylglucose Transcellular ATP-dependent mediated
Patients, methods and materials
Patients
From June 1999 to September 2002, 68 patients gave their informed consent to participate in 
studies approved by the Ethics Committee that required permeability testing before and during 
intensive treatment for an haematological malignancy in the Department of Haematology 
at the University Medical Centre, St. Radboud Hospital. A further six patients also agreed to 
undertake these tests although they did not participate in any formal study. Patients were to 
receive either a remission-induction treatment for AML or myelodysplastic syndrome (MDS) or 
an autologous or allogeneic HSCT after being conditioned with idarubicin, cyclophosphamide 
and total body irradiation (IDA-Cy-TBI). Grafts for allogeneic sibling-related transplant were 
predominantly prepared by counterflow centrifugation resulting in less than 2% lymphocytes. 
Immunoprophylaxis was achieved using cyclosporin A given as continuous infusion. All transplant 
recipients were managed with a central venous catheter and started parenteral nutrition during 
conditioning. Antimicrobial prophylaxis and therapy were the same for all patients and were 
given in accordance with a standard protocol.
A group of patients who were given remission induction therapy for de-novo AML or MDS 
acted as a control, since they had not received any prior anti-cancer treatment that might have 
influenced gut integrity. Intensive induction was given according to EORTC studies: 06931 (AML-
10), 06991 (AML-12), 06961 (CRIANT) and 06954 (AML-13). 
Mucositis assessment
Patients were monitored daily for the presence of oral mucositis for lesions, erythema, oedema, 
pain, bleeding, dryness and viscous mucous with each item being allocated a score of 0 (or 
normal) to 3 (or severe). The separate values were summed to yield a daily oral mucositis score 
(DMS) with 3 grades: DMS grade I (1-7 points) represents mild mucositis, grade II (8-14 points) 
moderate mucositis and grade III (>14 points) severe mucositis [7]. Gut toxicity was scored 
likewise from 0 to 3 based on the frequency of vomiting and diarrhoea, and the occurrence of 
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nausea, abdominal complaints, faecal incontinency and volume of diarrhoea. Summation of the 
separate score yielded the daily gut score (DGS) grade I (1-6 points) represents mild toxicity, 
grade II (7-12 points) moderate toxicity and grade III (>12 points) severe toxicity. All gut toxicities 
developing after chemotherapy had ceased were ascribed to mucositis unless there was a more 
plausible alternative cause, such as an adverse drug reaction or a proven infectious cause, such 
as toxigenic enterocolitis.
Sugar permeability test
An isotonic solution was prepared by dissolving 5 g lactulose (LAC), 1 g L-rhamnose (RHA), 0.2 
g 3-O-methylglucose (OMG), 0.5 g D-xylose (XYL) in 100 ml demineralised water. The sugar 
test was produced according to good manufacturing practice by our own hospital pharmacy 
department. The first sugar permeability test (baseline day) was performed before starting 
remission-induction or conditioning therapy. After an overnight fast, the subjects emptied their 
bladders and then drank the solution. A light breakfast with a drink was allowed after 2 hours. 
Urine was collected for 5 hours, after which the total volume passed was recorded and aliquots 
of approximately 5 mL were stored in -80°C until analysis was performed. The test was repeated 
every Wednesday after baseline. 
Determination of the sugars in urine
The concentration of each sugar was determined using the method of Jansen et al [8]. Briefly, 
before analyses, samples were thawed and centrifuged at 3,000g for 30 minutes to remove any 
precipitates that might have been formed during storage. Next, 100 µL of internal standard sugar 
(1.0 mmol/L D-glucoheptose (99%), Sigma, Zwijndrecht, The Netherlands) was added to 100 
µL aqueous sugar standard or urine before being completely dried using a SpeedVac (Savant 
Plus, Thermoquest, Breda, The Netherlands). Sugar-rings were made accessible for 100 µl of 
N-Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA), (ICN Biochemicals, Aurora, Ohio) 
by adding 100 µL ortho-methylhydroxylamine (Fluka, Switserland) solution of 20 g/L pyridine 
(Fluka) and incubating at 60°C for 1 hour while vortexing (Vibrax). At the end of this time, 100 µl 
MSTFA was added, and the mixture was again incubated at 60°C while vortexing for 30 minutes. 
Extraction of the stable derivatives was achieved by adding 1 mL water and 2 mL hexane (Merck, 
Darmstadt, Germany) and then thoroughly mixing for at least 1 minute. Then the hexane layer 
containing the derivatives was transferred to a new glass tube, the hexane was evaporated in 
a SpeedVac to complete dryness and the derivatives were re-dissolved in a mixture of 75 µL 
MSTFA with 75 µL pyridine and incubated for 30 minutes at 60°C while vortexing. Samples were 
transferred to airtight vials and 1 µL was injected into a gas chromatograph connected to a Flame 
Ionisation Detector (Varian 3800 GC, Tempe, Arizona) using a split ratio of 1:25 at 250°C. The 
separation was carried out on an Alltech DB-5 column (0.25 mm ID, 0.25 µm film thickness, 
length 30 m (Alltech, Deerfield IL). The helium flow was 1 mL/min, and the split-rate was between 
carrier gas and the sample was 25:1. The column temperature program started at 125°C for 5 min 
then increased initially by 3°C/min to 180°C, and by 5°C/min to 230°C which was sustained for 
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5 minutes. The sugar-derivatives were detected using the FID detector set at 250°C. Data were 
collected on-line using Star Chromatography software (Varian, Tempe, Arizona, USA) and peak 
areas were corrected to the internal standard. 
The concentration of each sugar was then estimated in µmol/L using standard calibration 
curves and urinary recovery of each sugar was calculated as a percentage of intake. The coefficient 
of variance for LAC, XYL, RHA and OMG were 2.3%, 3.7%, 3.1% and 2.3%. Expressing the urinary 
excretion of two sugars, for example lactulose and rhamnose, as a ratio minimises the influence 
of extraneous factors such as gastric emptying and bowel transit time. Therefore the lactulose/
rhamnose ratio (L/R) was used as an index of intestinal permeability or integrity and a L/R ratio 
of 0.02 or less was considered to be normal. The D-xylose/3-O-methylglucose (XYL/OMG) ratio 
was used as an index of absorptive capacity and a ratio of 0.65 was considered normal [9]. 
Data analysis
The DMS and DGS that had been noted on the days that the sugar permeability test was 
performed or, if missing, scores recorded the day before or after, were used for the analysis which 
was undertaken using SPSS 10.
The Mann-Whitney U test was used for significance calculations of differences in DMS and DGS 
between baseline and consecutive samples within a treatment group and between treatment groups 
on the same sampling days. Sugar concentrations were transformed to logarithmic values in order 
to obtain a normal distribution. Urinary recovery was used to calculate the ratios and expressed as 
the mean ± the standard deviation and a 2-sided unpaired student’s t-test was used to calculate 
significant differences with respect to baseline and analysis of variance for differences between 
groups. A p-value < 0.05 was considered statistically significant. Pearson’s ρ test and Kendall’s τ 
test were used respectively to estimate correlations between parametric and non-parametric data. 
Results
Baseline data
Demographic data of the control group and the transplant group are reported in Table 2. There 
were slightly more males than females in each group but their median age was similar.
At baseline, DMS and DGS were significantly higher in the control group (p < 0.001). The 
sugar concentrations and urinary recoveries were not significantly different between each group 
and the urinary recovery of RHA, XYL, OMG and LAC is depicted in Table 3. The recovery of RHA, 
XYL and OMG was lower in both groups.
Subsequently, the L/R ratio was significantly (p < 0.001) higher in the control group (0.09±0.05) 
than in the transplant group (L/R 0.04±0.02), and both baseline L/R ratios were higher than the 
as normal reported value of less than 0.02. (Table 4) The XYL/OMG ratio was not significantly 
different between both groups (0.57±0.15 and 0.65±0.15) before starting therapy and was 
comparable with the reference ratio of 0.65. 
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Table 2 Demographic data. AML acute myeloid leukaemia, MDS myelodysplastic syndrome, ALL acute 
lymphoblastic leukaemia, NHL non-Hodgkin’s lymphoma, CLL chronic lymphocytic leukaemia, 
CML chronic myeloid leukaemia, MPD myeloproliferative disease
Regimen No. of 
patients
Age
Median(range)
Gender
M/F
Diagnostic 
groups
Type of 
transplant
Remission-induction 18 50 (28-64) 11/7 AML (15)
MDS (3)
not applicable
Idarubicn
Cyclophosphamide
TBI
56 47 (22-64) 31/25 ALL (13)
AML (18)
NHL (10)
CLL (1)
CML (5)
MDS (5)
MPD (4)
autologous (8)
allogeneic (48)
Table 3 Urinary recovery of sugars (percent) in both groups at baseline and after cytotoxic therapy
Remission induction
Period          1           2          3          4          5
Lactulose 0.53 ± 0.46 0.86 ± 0.98 0.69 ± 0.73 0.26 ± 0.19 0.30 ± 0.30
Rhamnose 7.2 ± 5.5 9.1 ± 10.2 6.6 ± 4.9 3.6 ± 3.0 4.6 ± 3.1
D-Xylose 19.6 ± 8.5 26.5 ± 19.5 21.7 ± 11.1 13.9 ± 9.8 17.0 ± 9.8
3-O-Methyl glucose 38.2 ± 30.0 55.9 ± 59.1 55.4 ± 45.2 28.4 ± 20.1 30.9 ± 21.5
Idarubicin, Cyclophosphamide and TBI
Period          1          2          3         4          5
Lactulose 0.30 ± 0.22 0.38 ± 0.32 0.50 ± 0.54 0.44 ± 0.35 0.22 ± 0.19
Rhamnose 7.3 ± 4.4 8.3 ± 4.6 5.3 ± 4.1* 2.7 ± 2.2* 2.0 ± 1.9*
D-Xylose 19.3 ± 10.0 21.0 ± 10.8 15.4 ± 11.9* 11.9 ± 6.7* 10 ± 8.3*
3-O-Methyl glucose 30.8 ± 17.4 34.1 ± 16.7 26.7 ± 20.2* 30.6 ± 16.2* 23.3 ± 19.7*
Period          6          7
Lactulose 0.25 ± 0.22 0.17 ± 0.17
Rhamnose 2.0 ± 1.5* 1.7 ± 1.4*
D-Xylos 9.9 ± 7.4* 7.0 ± 6.1*
3-O-Methyl glucose 24.7 ± 20.7 a 13.8 ± 12.9 b
* p < 0.0001
a p = 0.03
b p = 0.04
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Time course of mucosal damage 
DGS was only higher in the first week (p = 0.001) and DMS during the first two weeks (p = 0.02) 
after starting induction therapy in the control group. No significant change with respect to the 
baseline of any sugar ratio based on either the sugar concentration or urinary sugar recovery 
occurred in this group (Table 4). In general, urinary excretion of lactulose increased initially after 
starting therapy but normalised after the third week in both groups. Urinary excretion of the other 
sugars significantly decreased (p < 0.001) only in the transplant group from HSCT day 0 until 
the end of follow-up. (Table 3) In contrast to the control group, the permeability index, L/R ratio, 
increased significantly (p < 0.0001) after the start of IDA on HSCT days 0, +7, + 14, +21 and +28 
(Figure 1a). The ratio of XYL/OMG decreased significantly (p < 0.005) during that period (Figure 
1b). The mean DMS and DGS were already significant (p < 0.0001) higher on day –7 in the IDA-
group and remained so till HSCT +28. (Figure 2a-b) When DMS was greater than 8 or the DGS 
was greater than 5, indicating moderate clinically scored mucositis, the L/R ratio was significantly 
(p =0.001) higher in these transplant recipients.
Table 4  Mean ± SD of daily oral mucositis score (DMS), daily gut toxicity score (DGS), lactulose/rhamnose 
(L/R) ratio and Xylose/3-O-methylglucose (XYL/OMG) ratio in both groups in consecutive periods
Remission induction
period      DMS      DGS        L/R  XYL/OMG
1 1.19 ± 2.11 1.06 ± 0.93 0.09 ± 0.05 0.57 ± 0.15
2 2.27 ± 1.94a 2.80 ± 1.57 c 0.19 ± 0.37 0.54 ± 0.13
3 3.27 ± 2.74 b 1.53 ± 0.92 0.11 ± 0.08 0.46 ± 0.18
4 2.75 ± 3.17 1.62 ± 1.04 0.09 ± 0.05 0.51 ± 0.16
5 1.33 ± 1.97 1.50 ± 0.55 0.07 ± 0.05 0.59 ± 0.11
6 - - - -
7 - - - -
Idarubicin, Cyclophosphamide and TBI
period      DMS       DGS        L/R   XYL/OMG
1 0.02 ± 0.13 0.09 ± 0.48 0.04 ± 0.02 0.65 ± 0.15
2 0.62 ± 1.44 1.21 ± 1.18 0.06 ± 0.09 0.62 ± 0.17
3 5.09 ± 2.63 2.86 ± 2.22 0.13 ± 0.15 0.56 ± 0.16
4 7.98 ± 3.56 2.63 ± 2.22 0.20 ± 0.16 0.42 ± 0.14
5 3.96 ± 2.50 2.75 ± 2.35 0.17 ± 0.07 0.45 ± 0.10
6 2.24 ± 2.14 2.56 ± 1.46 0.19 ± 0.26 0.44 ± 0.14
7 2.00 ± 2.27 1.63 ± 1.51 0.14 ± 0.14 0.50 ± 0.12
1. in the IDA-Cy-TBI group is significance with respect to baseline depicted in italics. p < 0.0001 for DMS, DGS and L/R 
 ratio, p < 0.005 for XYL/OMG
2. DMS a p = 0.04, b p = 0.02
3. DGS c p = 0.001 
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Figure 1a-b Box-plots of sugar ratios after myeloablative therapy with idarubicin, cyclophosphamide and 
TBI. a. the lactulose/rhamnose ratio b. the xylose/3-O-methylglucose ratio.
a
b
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Figure 2a-b Box-plots of daily oral mucositis score (DMS) and daily gut toxicity score (DGS) after 
myeloablative therapy with idarubicin, cyclophosphamide and TBI. a. DMS b. DGS.
  
 
a
 
 
b
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Correlations
Correlations between all mucosal damage parameters were highly significant (p <0.0001) in 
the IDA-group. DMS and L/R ratio correlated the best: r = 0.55, r2 = 0.30, n=228. (Figure 3a) 
The correlation of DMS with XYL/OMG was: r = -0.43. For DGS, these correlations were L/R r 
= 0.40 (Figure 3b) and XYL/OMG r = -0.32. The correlation of DMS and DGS was r = 0.42, n= 
300. However, the correlations between the parameters of mucosal damage were mostly non-
significant in the control group. Only DMS correlated significantly with L/R ratio: r = 0.28, n= 55 
(p= 0.04).
Figure 3a-b Correlation plot of lactulose/rhamnose (L/R) ratio with daily oral mucositis score (DMS) and 
daily gut toxicity score (DGS) a. DMS:  r = 0.55, r2 =  0.30, n=228 b. DGS: r = 0.40, r2 =  0.09, 
n=228.
Discussion
Both groups showed altered permeability and absorption at the start of chemotherapy in 
respect to normal volunteers tested in the same manner (RHA 12.7±3.9%, XYL 33.8±7.5%, OMG 
49.1±14.3% and LAC 0.38±0.22%, L/R 0.03±0.01 and XYL/OMG 0.71±0.12; Numico Research 
BV, data on file). We failed to find literature evaluating the gut permeability measured by L/R 
ratio at first diagnosis of patients with acute leukaemia. Only one report concerning ten patients 
with newly diagnosed breast cancer showed a higher L/R ratio of 0.14±0.09 than determined in 
controls (0.023±0.010) [10]. Sundstrom et al. used a different probe of lactulose and mannitol and 
a b
70
_____  Chapter 4  _______________________________________________________________________________________________________________ ____________________________________________________  Measuring mucosal damage induced by cytotoxic therapy  _____ 
71
also found a higher ratio in 16 patients with AML de novo [11]. We too, found a higher baseline L/R 
ratio of 0.09±0.05 in patients with newly AML, suggesting that the gut function is already altered 
in those patients having cancer even before any therapy is given. The L/R ratio reflects both an 
increase in lactulose permeation, through loss of integrity of the mucosal barrier constituted by 
tight junctions between epithelial cells and decrease in passive rhamnose absorption indicating 
a lowered surface area. The alteration in L/R ratio before starting chemotherapy was largely 
the result of the lower recovery of rhamnose. The mediated absorption of xylose and 3-O-
methylglucose was also lower. It is therefore, tempting to speculate that this was caused by the 
presence of active leukaemia via the production of pro-inflammatory cytokines that depressed 
gut function [12]. These patients had also a higher DMS and DGS score at baseline that might 
also reflect active disease. The urinary recoveries were also lower before starting myeloablative 
conditioning but this might have been the result of previous exposure to cytotoxic therapy rather 
than active disease since the haematological malignancy was either in remission or inactive. The 
L/R ratio we found before myeloablative therapy was in the same range (0.04±0.02) as reported 
for 35 patients undergoing an autologous HSC transplant after high-dose chemotherapy [13]. 
Permeability increased whilst absorption decreased after conditioning with IDA-Cy-TBI 
with respect to patients given remission-induction chemotherapy for AML/MDS. Sugar tests 
measure different aspects of gut toxicity than do clinical measures and there was only a marginal 
correlation with oral mucositis. Moreover, the L/R ratio remained unchanged throughout the 
following weeks after induction therapy just as Sunstrom et al found when using their lactulose/
mannitol probe [11]. 
The highest L/R ratio of 0.20±0.16 was seen on HSCT day +7, when Keefe et al also noted a 
maximum L/R ratio of 0.62 [13]. The L/R ratio has almost returned to within the normal range by 
HSCT day +28 (that is, 6 weeks after starting chemotherapy) in Keefe’s group, whereas the L/R 
ratio in our transplant group remained elevated. The protracted declining XYL/OMG ratio after 
conditioning reflects loss of mediated transport capacity of the gut since there was less uptake 
of xylose, which takes place predominantly in the duodenum and jejunum. OMG transport was 
less affected presumably because of the huge reserve capacity of the gut [14]. The prolonged 
disturbance of the ratios suggest that both increased permeability and decreased absorptive 
capacity of the gut persists long after morphological restoration of the direct toxic effects on the 
epithelium [15]. It is conceivable that evolving acute graft-versus host disease of the gut might have 
played a role but this would have to be investigated by endoscopy which is not done routinely. 
While these ratios are non-specific they do indicate when disruption of the mucosal barrier can 
be expected following treatment with a specific myeloablative regimen. 
The pattern of increase in DMS and to a lesser extent in DGS resembled that found for 
permeability and absorptive capacity and the correlation reached statistical significance but was 
only marginal from a clinical perspective. We found a better correlation between oral mucositis 
and perturbed permeability (r= 0.55) than with gut toxicity unlike Johansen et al who observed 
a correlation (r= 0.63) between permeability using 51Cr-EDTA, which measures paracellular 
transport and gut toxicity using the WHO criteria [16]. The correlation between permeability and 
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gut toxicity for our HSCT recipients was much lower suggesting that permeability tests cannot 
predict the onset or severity of either oral mucositis or gut toxicity or vice versa. Similarly there 
was virtually no correlation between the DMS and DGS amongst HSCT recipients suggesting 
that each instrument measure different aspects of the mucosal damage that follows intensive 
cytotoxic therapy. The instruments are also non-specific but can be used to assess the onset of 
mucosal barrier injury for specific chemotherapy regimens. Each instrument also indicated that 
mucosal barrier injury developed concurrently with bone marrow aplasia essentially placing the 
patient in double jeopardy since there is neither a natural obstacle to opportunistic pathogens 
translocating from the gut to the tissues nor are there effective phagocytes to tackle them. It 
seems prudent to employ the sugar test because it provides an objective measure for estimating 
gut toxicity together with an established instrument for measuring oral mucositis to explore 
the relationship between mucosal barrier injury and the complications that occur following 
myeloablative therapy. 
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Summary
We determined gut mucosal barrier injury (MBI) among 129 recipients of an allogeneic 
or autologous haematopoietic stem cell transplant (HSCT) who had been given different 
myeloablative regimens by measuring integrity using the lactulose/rhamnose ratio and absorption 
using the ratios of rhamnose/3-O-methylglucose and xylose/3-O-methylglucose. Regimens that did 
not contain idarubicin induced oral mucositis and perturbed gut integrity and absorption earlier 
than did those containing the anthracycline. By contrast, regimens containing idarubicin induced 
more severe and prolonged oral and gut MBI. Gut integrity and absorption of most patients were 
still abnormal at discharge from hospital. These results confirm that the integrity and absorptive 
capacity of the gut is affected adversely by myeloablative regimens in general, although only two 
patterns of mucosal injury emerged depending on whether or not idarubicin was used.
Introduction
Mucosal barrier injury (MBI) of the oral cavity is reported to affect more than 60% of 
haematopoietic stem cell transplant (HSCT) recipients given myeloablative preparative regimens. 
Wardley and colleagues showed that the character, onset and progression of oral mucositis were 
markedly influenced by the nature of the conditioning therapy. For instance, high-dose melphalan 
aggravated oral mucositis whereas its onset was delayed after busulphan [2]. 
Much less is known about the gastrointestinal counterpart of oral mucositis although gut injury 
results in significant morbidity and mortality [3]. Sugar permeability tests can determine objectively 
changes in permeability (integrity and absorption) and have been found to complement the signs 
and symptoms associated with gut toxicity such as nausea, vomiting, diarrhoea and abdominal 
cramps [4]. However, it is not known whether gut MBI, is also affected differently by the various 
myeloablative regimens. Moreover, our standard conditioning regimen consists of idarubicin, 
cyclophosphamide and TBI [5] and is known to induce prolonged and severe oral mucositis [6]. 
Therefore, we employed a sugar permeability test to determine differences in gut permeability, 
integrity and absorption of a cohort of HSCT recipients given different myeloablative regimens [1]. 
Patients, methods and materials
Patients
From June 1999 to September 2002, 83 patients admitted to the Department of Haematology at 
the University Medical Centre, St. Radboud Hospital for intensive treatment of haematological 
malignancy had consented to participate in prospective studies approved by the Ethics 
Committee, which required sugar permeability testing before and during the trials. A further 46 
patients had also agreed to undertake these tests although they did not participate in any formal 
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study. Hence, a total of 129 patients received either an autologous or allogeneic HSCT after being 
conditioned with one of the myeloablative regimens shown in Table 1. 
Table 1 Demographic data of HSCT recipients treated with myeloablative regimens
Regimen Type of HSCT Specification Doses Days 
Patients 
(n) M/F
Age (mean) 
(range) Disease
BEAM autologous BCNU 
Etoposide 
Cytarabine
Melphalan 
300 mg/m2 
200 mg/m2 
200 mg/m2 
140 mg/m2 
d-6 
d-5,-4,-3,-2 
d-5,-4,-3,-2 
d-1
13
8/5
42 (21-62) NHL
HDM autologous Melphalan 100 mg/m2 d-3,-2 10
9/1
55 (42-65) MM
Cy-TBI autologous (5)
allogeneic (21)
Cyclophosphamide
Total body irradiation
60 mg/kg 
4.5 Gy 
d -6,-5 
d-2,-1
26
18/8
48 (32-59) MM (14)
AML (1)
CML (3)
CLL (3)
NHL (5)
IDA-Cy-TBI autologous (8)
allogeneic (48)
Idarubicin
Cyclophosphamide
Total body irradiation
42 mg/m2
60 mg/kg 
4.5 Gy 
Start d-12 48h 
d -6,-5 
d-2,-1
56 
31/25
47 (22-64) ALL (13)
AML (18)
NHL (10)
CLL (1)
CML (5)
MDS (5)
MPD (4)
ATG-Cy-TBI allogeneic -
voluntary 
unrelated
Cyclophosphamide
Antithymocyte glob.
Total body irradiation
60 mg/kg 
2 mg/kg 
4.5 Gy
d-7,-6 
d-6,-5,-4,-3
d-2,-1
12
9/3
31 (19-47) CML (6)
ALL (2)
AML (2)
CLL (1)
MM (1)
IDA-Bu-Cy autologous (6)
allogeneic (6)
Idarubicin
Busulphan
Cyclophosphamide
42 mg/m2
4 mg/kg
60 mg/kg 
Start d-12 48h
d-7,-6,-5
d-3,-2
12
6/6
48 (27-60) AML (11)
NHL (1)
Cyclosporine 3 mg/kg/day was given to allogeneic HSCT recipients alone for prophylaxis against 
GVHD from HSCT day –1 to +14 followed by 2 mg/kg/day until oral intake was possible. All HSCT 
recipients were managed with a central venous catheter and given parenteral nutrition from the 
day of transplant onwards. Patients were given ondansetrone for antiemesis and haematopoietic 
growth factors were not routinely used. Infection prophylaxis consisted of ciprofloxacin and 
acyclovir or valaciclovir. Cotrimoxazole was given for prophylaxis against Pneumocystis carinii. 
Fluconazole was only given to patients who were colonised by Candida albicans.
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Mucositis assessment
Patients were monitored daily for the presence of oral mucositis for lesions, erythema, oedema, 
pain, bleeding, dryness and viscous mucous with each item being allocated a score of 0 (or 
normal) to 3 (or severe). These values were summed to yield a daily oral mucositis score (DMS) 
with 3 grades: DMS grade I (1-7 points) for mild mucositis, grade II (8-14 points) for moderate 
mucositis and grade III (>14 points) for severe mucositis. DMS grade II is comparable with WHO 
grade 3 [7]. Gut toxicity was determined from the frequency of vomiting and diarrhoea, and the 
occurrence of nausea, abdominal complaints, faecal incontinency and the volume of diarrhoea. 
Each item was scored from 0 to 3 and the values were summed to yield the daily gut score (DGS) 
with grade I (1-6 points) representing mild toxicity, grade II (7-12 points) moderate toxicity and 
grade III (>12 points) severe toxicity. All gut toxicities developing following chemotherapy were 
attributed to mucositis unless there was a more plausible alternative cause such as an adverse 
drug reaction or a proven infection.
Sugar permeability test 
An isotonic solution was prepared by dissolving 5 g lactulose (LAC), 1 g L-rhamnose (RHA), 
0.2 g 3-O-methylglucose (OMG), 0.5 g D-xylose (XYL) in 100 ml demineralised water. The test 
solution was produced according to good manufacturing practice by our own hospital pharmacy. 
After an overnight fast, subjects emptied their bladders and then drank the solution. A light 
breakfast with a drink was allowed after 2 hours. Urine was collected for 5 hours after which the 
total volume passed was recorded, and aliquots of approximately 5 mL were stored in -80°C until 
analysis was performed. The first sugar permeability test was performed immediately before 
starting myeloablative therapy and formed the baseline. The test was repeated every Wednesday 
until discharge to allow changes in MBI to be followed adequately, while avoiding any potential 
interference from clinically apparent acute GVHD.
Determination of the sugars
Lactulose is a disaccharide and is absorbed by paracellular transport that is, via open tight 
junctions and villous tip extrusion zone, so any increase in urinary excretion represents loss of 
integrity. The other sugars are monosaccharides with L-rhamnose being used to monitor passive 
transcellular diffusion, D-xylose to detect carrier-mediated transcellular transport and 3-O-
methylglucose to measure ATP-dependent transcellular transport. A decrease in urinary excretion 
of any of these sugars represents a smaller surface area implying a loss of epithelial cell function 
or number. The concentration of each sugar was determined by gas chromatography employing 
flame ionisation for detection and D-glucoheptose as an internal standard [8]. Data were collected 
on-line using Star Chromatography software (Varian, Tempe, Arizona, USA) and peak areas were 
calculated and adjusted to the internal standard. The concentration of each sugar was then 
estimated in µmol/L using standard calibration curves and the urinary recovery of each sugar was 
calculated as a percentage of oral intake. The coefficients of variance for lactulose, D-xylose, L-
rhamnose and 3-O-methylglucose were 2.3%, 3.7%, 3.1% and 2.3% respectively. Urinary excretion 
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of two sugars, for example lactulose and rhamnose, was expressed as a ratio to minimise the 
influence of extraneous factors such as gastric emptying and bowel transit time. The lactulose/
rhamnose ratio (LAC/RHA) was used as an index of intestinal integrity with a LAC/RHA ratio 
of 0.02 or less being considered normal while a higher LAC/RHA ratio represents perturbed 
gut integrity. Similarly, the L-rhamnose/3-O-methylglucose (RHA/OMG) and D-xylose/3-O-
methylglucose (XYL/OMG) ratios were used, respectively, as indices of absorptive capacity and 
mediated cellular transport with ratios of less than 0.28 [9] and 0.65 [10] respectively, representing 
diminished absorptive capacity. Normal volunteers tested in the same manner as our patients 
resulted in the following mean ratios: LAC/RHA 0.03±0.01[s.d.], RHA/OMG 0.26±0.004 [s.d.], 
XYL/OMG 0.71±0.12 [s.d.] (Numico Research BV, data on file).
Data analysis
The sugar ratios and corresponding mean DMS and DGS scores were calculated, using all 
available data for the analysis, which was undertaken with SPSS 10. Missing data were replaced 
with the values for the day before or after the sugar test was carried out. An analysis of variance 
was used to test differences between and within groups. The Mann-Whitney U test was used for 
significance calculations of differences in mean DMS and DGS between baseline and consecutive 
samples within a treatment group and between treatment groups. The sugar concentrations 
were transformed to logarithms in order to obtain a normal distribution. The urinary recovery 
was used to calculate the ratios and expressed as the mean with 95% confidence interval and 
a 2-sided unpaired student’s t-test was used to calculate significant differences with respect to 
baseline. A p-value < 0.05 was considered statistically significant. 
Results
Baseline data
The LAC/RHA ratios were not significantly different between the patients in the various treatment 
groups (LAC/RHA ratio; 0.04 - 0.06) but were higher than normal. The ratios of XYL/OMG (0.57 
- 0.69) and RHA/OMG (0,20 – 0,25) were also not significantly different between the patient 
groups but were lower than normal, except for the RHA/OMG ratios of patients treated with 
IDA-Bu-Cy 0,39 [0.09-0.70]. The sugar ratios were not significantly different between patients 
who had been previously received chemotherapy and those who had not, including patients with 
CML (data not shown). 
Differences in MBI 
Gut integrity measured by LAC/RHA ratio
The mean LAC/RHA ratios of patients given Cy-TBI, ATG-Cy-TBI, BEAM and HDM were 
significantly higher (p < 0.003) by week 2 than at baseline but 1 week later for those treated with 
idarubicin (p < 0.0001). (Figure 1) Furthermore, at week 2 the mean LAC/RHA ratios of patients 
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treated with idarubicin was significantly (p < 0.0001) lower than those for the other patients. The 
LAC/RHA ratios of patients treated with BEAM, HDM and ATG-Cy-TBI normalised earlier by week 
4, but were still significantly perturbed at week 5 for those given regimens containing idarubicin.
The mean RHA/OMG ratios of patients conditioned without idarubicin were significantly lower at 
weeks 2 and 3 with respect to baseline, and again occurred 1 week later for patients treated with 
idarubicin. Although the difference was less distinct than that found with the mean LAC/RHA 
ratio at week 2, the mean RHA/OMG ratio was significantly lower (p < 0.02) for the myeloablative 
regimens that did not contain idarubicin. The ratios for almost all patients were still abnormal 
before discharge, except for those treated with HDM. (Figure 2) The pattern of decreased 
absorptive capacity measured by XYL/OMG ratios was less obvious (Figure 3) and those ratios 
for patients treated with BEAM altered least of all. Nevertheless, the ratios for each patient group 
were still abnormal before discharge.
Figure 1  Pattern of weekly lactulose/rhamnose ratio. The lactulose/rhamnose (LAC/RHA) ratio for all 
groups was increased at baseline with respect to the values for normal volunteers. LAC/RHA 
ratios for Cyclo-TBI, ATG-Cyclo-TBI, BEAM and HDM were significantly increased by the second 
week after starting myeloablative therapy and were significantly higher than were the ratios for 
the idarubicin regimens. LAC/RHA ratios for IDA-Cyclo-TBI and IDA-Bu-Cyclo were significantly 
increased a week later. LAC/RHA ratios returned to normal for BEAM by week 4. There were no data 
for BEAM at week 5 and HDM at week 4 and 5 because patients had already been discharged.
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Figure 2 Pattern of weekly rhamnose/3-0-methylglucose ratio. The rhamnose/3-0-methylglucose ratio was 
significantly decreased for all except for IDA-Cyclo-TBI and IDA-Bu-Cyclo by week 3 after starting 
myeloablative therapy. None of the ratios had normalized before patients were discharged. There 
were no data for BEAM at week 5 and HDM at week 4 and 5 because patients had already been 
discharged. 
 
  
week
Figure 3 Pattern of weekly xylose/3-0-methylglucose ratio. The xylose/3-0-methylglucose ratios for all 
regimens were abnormally low at baseline. The pattern of these ratios was similar to that of the 
rhamnose/3-o-methylglucose ratio although the differences between them were less significant. 
The ratios were still abnormal before discharge. There were no data for BEAM at week 5 and HDM 
at week 4 and 5 because patients had already been discharged. 
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Oral mucositis (DMS) and gut toxicity (DGS)
The mean DMS of patients treated without idarubicin was already high (p < 0.01) by period 2 and 
reached a peak 1 week later, declining thereafter. Whereas the course of oral mucositis of those 
treated with idarubicin was delayed by a week (p < 0.001) but remained high after reaching grade 
II (p < 0.01). (Figure 4) Furthermore, the mean DMS of patients given idarubicin was significantly 
lower (p < 0.001) at week 2, and significantly higher (p < 0.001) at weeks 4 and 5 compared 
with the values for those patients not given idarubicin. The mean DGS did not reach grade II 
but followed a similar course irrespective of the myeloablative regimen given, but remained 
significantly higher (p < 0.001) at week 5 for patients treated with idarubicin. (Figure 5)
 
Figure 4 Pattern of weekly oral mucositis score (DMS). DMS was significantly higher for patients given 
myeloablative therapy that did not contain idarubicin by week 1 with respect to baseline and reached 
a peak one week later. The DMS for those who had received idarubicin was significantly lower than 
that for other regimens at week 2 but was significantly higher at weeks 4 and 5. There were no data 
for BEAM at week 5 and HDM at week 4 and 5 because patients had already been discharged. 
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Figure 5 Pattern of weekly gut mucositis score (DGS). DGS was significantly increased in all groups at the 
second week after starting myeloablative therapy and was still abnormal at discharge for those 
who had been given regimens containing idarubicin. There were no data for BEAM at week 5 and 
HDM at week 4 and 5 because patients had already been discharged.
Discussion
There was no real difference in the overall pattern of disturbed gut integrity and absorptive 
capacity of patients given the various myeloablative regimens though both were markedly 
abnormal for several weeks afterwards. Moreover, gut permeability was already disturbed before 
starting therapy as Keefe et al. have reported [11]. This might be the result of previous chemotherapy 
therapy or of active malignant disease [4]. Gut permeability was already significantly altered a week 
after starting myeloablative therapy with regimens that did not contain idarubicin. Surprisingly, 
HSCT recipients treated with idarubicin experienced similar changes in permeability a week later 
and these changes were more pronounced and prolonged. By contrast, permeability was least 
affected after BEAM and HDM treatment. This might be explained by cytotoxic therapy damaging 
intestinal clonogenic stem cells at different stages. Anthracyclines tend to preferentially kill the 
stem cells of a very early clonogenic lineage that are positioned at the base of the crypts of the 
intestine [12]. Hence, the tight junctions between intestinal cells that normally prevent passage 
of larger particles such as lactulose are profoundly disrupted, resulting in impaired gut integrity 
as has been shown by biopsy of the small intestine of patients given intensive chemotherapy, in 
which there was increased apoptosis located in crypts followed by hypoplastic villous atrophy and 
loss of enterocyte height [13].
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Alterations in gut integrity preceded the changes in absorptive capacity and tended to normalise 
earlier. This indicates that tight junctions are loosened before functional enterocytes are reduced 
in number and that gut integrity tends to be restored before absorptive capacity returns to 
normal. It is known that tight junctions between intestinal cells are already restored before 
they become fully matured enterocytes capable of normal absorption [14]. The different times to 
normalisation after the various myeloablative regimens suggest that not only is inhibition of 
intestinal clonogenic stem cell growth important but also that different myeloablative regimens 
affect the capacity for repairing the mucosa differently, which is mediated by the trefoil factor and 
other intestinal growth factors produced by goblet cells [15, 16].
Wardley et al. [2] showed that the myeloablative regimen and not the disease or stem cell 
source determined the severity of oral mucositis with the highest peak of mucositis occurring 
after HDM. However their analysis did not include patients treated with myeloablative regimens 
containing idarubicin [2]. In our study, gut toxicity preceded oral mucositis in all treatment groups 
probably because DGS measures direct cytotoxic effects like nausea and vomiting that occur 
soon after starting myeloablative therapy even with proper antiemetic therapy with 5-HT
3
 receptor 
antagonists. This suggests that DMS, DGS and sugar permeability tests do actually measure 
different features of MBI. As we noted earlier [4], diarrhoea or abnormal permeability might also 
be early manifestations of acute GVHD of the gut [17], although our follow up did not allow us to 
determine this. Only gut biopsy could confirm this, but these patients are considered too fragile 
to perform this invasive procedure. Our main interest was to look for differences in integrity and 
absorptive capacity shortly after starting myeloablative therapy to coincide with neutropenia, 
which usually resolves before clinically overt acute GVHD occurs. 
In conclusion, our study clearly showed that while sugar permeability tests could not 
distinguish between the MBI induced by different myeloablative regimens, they can determine 
the onset of disruption and dysfunction of the mucosal barrier of the small intestines and 
might therefore prove useful for testing interventions designed to ameliorate or prevent this 
complication.
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Summary
We noted a significant decline in the serum concentrations of citrulline of 32 haematopoietic stem 
cell transplant recipients following intensive myeloablative therapy during the first 3 weeks after 
transplant when patients have oral mucositis, a markedly disturbed gut integrity (L/R ratio) and 
are most at risk of infection and other severe complications. Closer inspection of the citrulline 
concentrations of 12 patients confirmed that the decline did indeed correspond with the onset of 
oral mucositis and altered gut integrity. Since serum citrulline is a reliable biochemical marker of 
small bowel enterocyte mass in humans with villous-atrophy associated diseases, it may prove a 
useful marker for intestinal mucosal damage induced by chemotherapy, allowing the relationship 
between gut mucosal damage and post-transplant complications including infections to be 
explored more readily. 
Introduction
Mucositis is a manifestation of mucosal barrier injury and is the most frequent cause of morbidity 
associated with the myeloablative conditioning treatment to prepare for an haematopoietic stem 
cell transplantation (HSCT) [1]. Oral mucositis is easy to recognise whereas detection of intestinal 
mucosal injury relies essentially on non-specific symptoms like nausea, vomiting, diarrhoea and 
abdominal cramps, which affect almost every HSCT recipient. An alternative means of recognising 
gut mucosal barrier injury is required if it is to be better understood and managed. Alterations in 
permeability and loss of epithelial surface are features of gut injury that can be detected by sugar 
permeability tests which are non-invasive and generally accepted as a surrogate marker of gut 
damage in patients treated for cancer [2]. However, sugar permeability tests are cumbersome and 
wholly dependent on patient compliance. A marker of intestinal injury that could be determined 
in blood would be ideal but none has been described so far. Citrulline might prove valuable in 
this regard since it is an end-product of glutamine metabolism of small intestinal enterocytes, 
cells which lack the necessary cytosolic enzymes to convert the amino acid to arginine [3]. Blood 
concentrations of citrulline directly reflect the cell mass of the small intestine since the small 
intestine is the principal source of the amino acid and it is not metabolised by the liver [4]. In 
mice, citrulline levels were used to quantify acute small bowel epithelial damage after single-
dose whole body irradiation [5]. The high-dose chemotherapy used to prepare patients to receive 
an HSCT injures the small intestine by inducing crypt apoptosis, hypoplastic villous atrophy 
and loss of enterocytes [6]. We determined the amino-acid profiles in the serum of a cohort of 
32 HSCT recipients who had participated in a prospective randomised placebo-controlled study 
approved by the local Ethics Committee, the aim of which was to investigate the possible benefits 
of parenteral nutrition (PN) supplemented with glutamine-dipeptide. As citrulline was included, 
we were able to relate the concentrations temporally with oral mucositis, gut toxicity and sugar 
permeability tests (SPT). 
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Patients and methods
Patients
32 patients (12 F; 20 M) with a mean age of 48 years (range 25-65) had given their informed 
consent to participate in the prospective study and all had received an HLA-matched T-cell 
depleted sibling HSCT to treat a haematological malignancy (AML (nine), ALL (seven), NHL 
(seven), MDS (three), CML (two), MPD (two), CLL (one), MF (one). The preparative regimen 
consisted of idarubicin to lower the risk of relapse [7, 8] given at a dose of 42 mg/m2 by continuous 
infusion over 48 hours starting 12 days before transplant (HSCT day –12), followed by 120 mg/kg 
cyclophosphamide (60 mg/kg per day on HSCT days – 6 & - 5) and 9 Gy of total body irradiation 
(4.5 Gy per day on HSCT days –2 & -1). Ciclosporin 3 mg/kg/day was given as prophylaxis against 
GVHD by continuous infusion from HSCT day –1 to +14 followed by 2 mg/kg/day until oral 
intake was possible. Haematopoietic growth factors were not used. Anti-infective prophylaxis 
consisted of ciprofloxacin and acyclovir or valaciclovir. Co-trimoxazole (sulphamethoxazole-
trimethoprim) was given as Pneumocystis carinii prophylaxis. No prophylactic systemic antifungal 
agents were given. Cefipime or ceftazidime was administered empirically at the onset of fever. 
All recipients were given PN supplemented by either glutamine-dipeptide or placebo on HSCT 
day –6. Glomerular filtration rate was determined on admission by measuring renal creatinine 
clearance (mL/min) and was estimated thereafter from the serum creatinine using the formula 
of Cockroft. & Gault [9].
Mucositis assessment
Patients were monitored daily for the presence of oral mucositis evidenced by lesions, erythema, 
oedema, pain, bleeding, dryness and the production of viscous mucous with each item being 
allocated a score of 0 or normal to 3 or severe. The separate values were summed to yield a 
daily oral mucositis score (DMS) with 3 grades: DMS grade I (1-7 points) mild mucositis, grade 
II (8-14 points) moderate mucositis and grade III (>14 points) severe mucositis [10]. Gut toxicity 
was scored likewise from 0 to 3 based on the frequency of vomiting and diarrhoea, as well as the 
occurrence of nausea, abdominal complaints, faecal incontinence and volume. Summation of 
the separate score yielded the daily gut score (DGS) grade I (1-6 points) represents mild toxicity, 
grade II (7-12 points) moderate toxicity and grade III (>12 points) severe toxicity. All gut toxicities 
following chemotherapy were ascribed to mucositis unless there was a more plausible alternative 
cause such as an adverse drug reaction or proven toxigenic infection.
Sugar permeability test (SPT)
An isotonic solution was prepared by dissolving 5 g lactulose (LAC), 1 g L-rhamnose (RHA), 0.2 
g 3-O-methylglucose (OMG), 0.5 g D-xylose (XYL) in 100 mL demineralised water, according to 
good manufacturing practice, by our own hospital pharmacy. After an overnight fast, the subjects 
emptied their bladders and then drank the solution. A light breakfast with a drink was allowed 
after 2 hours. Urine was collected for 5 hours after which the total volume passed was recorded, 
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and aliquots of approximately 5 mL were stored in -80°C until analysis was performed. The first 
SPT (baseline day) was performed before starting conditioning therapy and was repeated every 
Wednesday after baseline on HSCT days -6, 0, +7, +14 and +21.
Determination of the sugars in urine
The concentration of each sugar was determined using gas chromatography with flame ionisation 
detection with D-glucoheptose as an internal standard [11]. Data were collected on-line using Star 
Chromatography software (Varian, Tempe, Arizona, USA) and peak areas were measured and 
corrected to the internal standard. 
The concentration of each sugar was then estimated in µmol/L using standard calibration 
curves and urinary recovery of each sugar was calculated as a percentage of intake. The coefficient 
of variance for LAC, XYL, RHA and OMG were 2.3%, 3.7%, 3.1% and 2.3%. Urinary excretion of two 
sugars, for example lactulose and rhamnose, was expressed as a ratio to minimise the influence of 
extraneous factors such as gastric emptying and bowel transit time. The lactulose/rhamnose ratio 
(L/R) was used as an index of intestinal permeability or integrity with a L/R ratio of 0.02 or less being 
considered normal. Similarly, the L-rhamnose/3-O-methylglucose (RHA/OMG) D-and xylose/3-O-
methylglucose (XYL/OMG) ratios were used respectively as an index of absorptive capacity and 
mediated cellular transport with a ratio of 0.28 [12] and 0.65 [13] being considered normal. 
Citrulline analysis
The protocol prescribed serum to be obtained on HSCT days –12, -6, 0, +7, +14 and +21 for later 
amino acid analysis. In practice, this was not always done. Serum taken was stored at –80°C. 
Citrulline concentrations (µM) were measured by a standard procedure for determining amino 
acids using automated ion exchange column chromatography. 
Data analysis
The mean and 95% confidence interval [95% CI] of DMS and DGS scores on each of the days 
that the SPT was performed were calculated. If these were not recorded, they were classified as 
missing values. Sugar ratios were first transformed to logarithms and then expressed as the mean 
with 95% CI. A 2-sided unpaired student’s t-test was used to calculate significant differences with 
respect to baseline. One-way analysis of variance of citrulline concentrations (mean with 95% 
CI) between HSCT days was undertaken using SPSS v 11.0. ANOVA was also used to determine 
the role, if any, of glutamine supplementation. A p-value of < 0.05 was considered statistically 
significant. Correlations between groups were tested by Pearson’s r correlation. 
Results
All patients were profoundly neutropenic (granulocytes < 0.1 x 109/L) for the first 14 days after 
transplant. Five (16%) patients died during the first 3 weeks after transplant, two with sepsis 
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syndrome after Streptococcus mitis bacteraemia on HSCT day +9 and +12 respectively and one 
each from invasive candidiasis due to Candida albicans on HSCT day +13, ARDS on HSCT day 
+13 and VOD on HSCT day +21. Oral mucositis was present for the first 3 weeks after transplant 
but, unlike gut toxicity, showed a clear peak 1 week after transplant. The L/R ratio, increased 
significantly (p < 0.0001) on the day of transplant with respect to the baseline (i.e. 12 days after 
starting myeloablative therapy). The XYL/OMG and RHA/OMG ratios were also significantly 
decreased during the early post transplant period. (Table 1) Some patients were unable or 
unwilling to drink the solution because of severe mucositis, nausea or vomiting. Citrulline 
concentrations were significantly (p<0.0001) decreased on the day of transplant as compared to 
the baseline values with the nadir being observed 1 week later. 
Table 1 Mean [95% CI] of citrulline concentrations, oral mucositis, gut toxicity, L/R ratio, XYL/OMG ratio 
and RHA/OMG ratio of 32 HSCT recipients after myeloablative therapy
                      Citrulline        DMS       DGS
HSCT days N Mean [95%CI] N Mean [95%CI] Mean [95%CI]
-12 25 31.8 [28.2-35.3] 32 0.0 [0.0-0.1] 0.1 [0.0-0.2]
-6 27 25.7 [21.7-35.3] 25 0.4 [0.0-0.8] 0.9 [0.5-1.3]*
0 27 15.1 [12.8-17.4]* 30 4.5 [3.4-5.7]* 2.8 [2.0-3.7]*
+7 26  9.9 [7.9-11.8]* 31 9.1 [7.3-10.8]* 2.1 [0.9-3.3]*
+14 20 14.1 [11.2-16.9]* 26 4.3 [3.1-5.6]* 3.4 [2.1-4.6]*
+21 16 14.5 [12.2-16.8]* 18 2.9 [0.7-5.0]* 2.4 [1.3-3.5]*
Sugar Permeability Tests
HSCT days N        L/R ratio  XYL/OMG ratio RHA/OMG ratio
-12 31 0.04 [0.04-0.05] 0.64 [0.59-0.70] 0.25 [0.22-0.27]
-6 29 0.04 [0.03-0.06] 0.59 [0.54-0.65] 0.24 [0.21-0.27]
0 24 0.10 [0.06-0.14]* 0.57 [0.50-0.63]* 0.25 [0.15-0.36]
+7 14 0.18 [0.14-0.22]* 0.40 [0.31-0.49]* 0.11 [0.05-0.18]*
+14 16 0.20 [0.11-0.30]* 0.44 [0.38-0.49]* 0.11 [0.07-0.14]*
+21 10 0.26 [0.01-0.51]* 0.45 [0.34-0.57]* 0.11 [0.07-0.15]*
* Significantly different with respect to baseline
To examine the relationship of citrulline and transplant related complications in more detail, we 
selected the 12 patients from whom blood had been obtained on each of the HSCT days –12, -
6, 0, +7 and +14 for the citrulline assay. Figure 1 illustrates a clear downward trend for citrulline 
concentrations in all but one case (patient # 12). There was no obvious difference seen between 
the mucositis and SPT observed in this patient and that found for the other 11 patients (data not 
shown). 
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Figure 1 Citrulline concentrations and their relation to the extent of villous atrophy. 
     Quartile 1: > 30 µM – no villous atrophy; 
      Quartile 2: 20-30 µM – partial villous atrophy;
       Quartile 3: 10-20 µM – proximal total villous atrophy;     
   Quartile 4: < 10 µM – diffuse total villous atrophy. 
  Adapted from Crenn et al.[4]  -     -  - -  patient # 4; -     -  - -  patient # 12 




The demographics and transplant-related complications that occurred in these patients are 
shown in table 2. 
There is no common pattern in terms of infectious complications or acute GVHD apparent. 
Serum creatinine rose significantly for one patient (# 4) but citrulline levels remained low. Six 
patients had received glutamine. The mean citrulline levels were not influenced by the use of 
glutamine supplementation (ANOVA, p=0.08, data not shown). 
Citrulline concentrations correlated significantly with DMS r = -0.36, DGS r = -0.25; L/R ratio 
r = -0.41; XYL/OMG ratio r = 0.24 and RHA/OMG ratio r = 0.41.
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Discussion
This was a reasonably homogeneous group with respect to myeloablative regimen, prophylaxis 
and transplant procedure and citrulline concentrations declined after HSCT at the same time, 
as oral mucositis and gut toxicity were apparent. Gut integrity, measured by L/R ratio and the 
absorptive capacity of rhamnose, xylose and 3-O-methylgluscose were also severely perturbed. A 
mean nadir of <10 µM citrulline was reached about 3 weeks after starting myeloablative therapy 
that is during the first week after transplant. This level is considered predictive of severe and 
extensive villous atrophy in patients with coeliac disease [4] (Figure 1). Furthermore, applying the 
thresholds that indicate the severity of villous atrophy documented in patients with coeliac disease 
helps illustrate the potential clinical value of declining citrulline levels after intense myeloablative 
therapy in HSCT recipients [4]. We could not confirm the presence of small bowel villous atrophy 
or intestinal mucosal damage by endoscopy, as the procedure carries a high risk especially shortly 
after transplant. Nevertheless, when taken together, the changes in DGS (signs and symptoms), 
SPT (functionality) and citrulline levels (enterocyte mass) indicate that the mucosal epithelium of 
the small intestines is severely damaged for a prolonged period after HSC transplant though each 
measure seems to reflect a different manifestation of damage to the small intestine. 
Interestingly, citrulline levels on admission were lower than those found for healthy individuals 
(40±10 µM) [4] and the L/R ratio was also higher. This might reflect residual damage to the small 
intestine after previous intensive chemotherapy given to induce remission of haematological 
malignancy or consolidate it. 
Several factors are known to influence citrulline kinetics though none seem to apply to this 
patient population. The kidneys extract most of the citrulline released by the intestines and convert 
it to arginine. Citrulline levels may therefore be “falsely” increased when creatinine clearance is 
below 50 mL/min. We only measured creatinine clearance once and estimated it further from 
serum creatinine but only one patient showed a significant increase. Enteral feeding can induce a 
slight decrease in citrulline but the patients in this study were only able to imbibe water and were 
being given their nutrition parenterally during the observation period. Taking blood samples for 
amino acids whilst continuing parenteral nutrition can also confound but this is unlikely to be 
important for this patient population since levels continued to decline nonetheless. 
These results show that low serum citrulline concentrations do coincide with and appear to 
correspond to severe and extensive mucosal barrier injury of the small intestine. If so, this simple 
test may provide another potentially useful tool for studying the relationship between mucosal 
barrier injury and other post-transplant complications such as malnutrition, infection and graft-
versus-host disease.
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Summary
Intestinal mucositis is an important cause of cancer treatment related morbidity and mortality, 
carrying a serious economic burden. Currently, objective parameters are lacking that would enable 
the monitoring of gut damage in routine clinical practice, thus hindering the development of 
clinical studies designed to investigate potential new strategies aimed at reducing or preventing 
this side effect. The authors investigated the characteristics of serum citrulline concentration 
compared with sugar permeability tests with respect to its use as a marker for cancer treatment-
induced small bowel injury.  
In this prospective study, 10 patients with haematological malignancies who were receiving 
myeloablative therapy had gut toxicity assessed with sugar permeability tests. Serum citrulline 
concentration also were determined using archival serum samples. The association between 
both parameters and their respective characteristics were analyzed and compared with data from 
the literature. 
Sensitivity and specificity were better for the citrulline assay compared with sugar permeability 
tests. Maximum gut damage assessed with the citrulline assay was observed 1-2 weeks earlier 
compared with the sugar permeability test. Similarly, citrulline indicated recovery of gut damage 
at 3 weeks after transplantation, whereas most sugar permeability tests remained abnormal. 
The simplicity of the method, the low costs and the lack of drawbacks to the method make the 
citrulline assay the first choice for measuring and monitoring treatment-related gut damage and 
provides an objective parameter for cancer treatment-related gut toxicity.
Introduction
An increased use of multiple treatment modalities is characteristic for current developments 
in curative cancer treatment. This strategy has yielded superior treatment results in a variety 
of solid tumors, although treatment related acute toxicity is increased as well [1-5]. In patients 
with haematological malignancies, epithelial gut damage has been suggested as a causal 
factor in the life-threatening graft-versus-host disease that occurs after myeloablative therapy 
[6]. In general, severe mucositis has a detrimental effect on treatment outcome due to necessary 
reductions in treatment intensity and/or treatment interruption. In addition to these detrimental 
acute effects, epithelial gut damage has also been suggested as one of several mechanisms 
that contribute to late treatment-related sequellae [7]. Taking into account mucositis-associated 
complications, such as a longer hospital stay, an increased number of infectious events and 
nutritional support, Elting et al. [8] recently estimated an incremental cost of $ 2725 and $ 5565 per 
chemotherapy cycle associated grade 1-2 mucositis and grade 3-4 mucositis, respectively. Hence, 
it is expected that preventing and/or reducing epithelial gut damage will have significant clinical 
and socioeconomic impact. However, clinical studies addressing treatment-induced gut damage 
have been hampered by the fact that objective parameters are lacking to enable monitoring of 
damage in routine clinical practice. 
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Previously, clinical symptoms were used most frequently as surrogate endpoint for gut damage. 
In addition to the fact that toxicity grading systems are not used uniformly by investigators [9] 
they are undergoing adjustment on a regular basis. More important, however, is that clinical 
symptoms correlate poorly with objective parameters of gut damage such as sugar permeability 
tests (SPT) [10-12], altered histomorphology [13] or treatment-related parameters [9], illustrating the 
complexicity of the pathophysiology of clinical symptoms related to cytotoxic treatment-induced 
small bowel damage [14-16]. 
Currently, morphologic parameters and SPT’s are the objective endpoints used in pre-
clinical and clinical studies. However, both methods are unsuited for monitoring purposes in 
routine clinical practice. In a preclinical study, we recently demonstrated that plasma citrulline 
concentration is a radiation dose-dependent parameter that correlates with radiation-induced 
small bowel morphologic endpoints, such as mucosal surface or crypt regeneration [17]. In a 
subsequent clinical study, we demonstrated that plasma citrulline concentration is correlated 
with small bowel radiation dose and volume parameters [9]. Similarly, we observed decreased 
citrulline levels in response to myelo-ablative therapy [18]. In addition to surgery [19], celiac and non-
celiac disease [20] and acute cellular rejection following small bowel transplantation [21, 22], cytotoxic 
treatment was identified as another event associated with small bowel epithelial cell loss that can 
be monitored by plasma citrulline. 
The objective of the current study was to compare the citrulline assay with a currently used 
method for measuring small bowel damage, that is, the SPT. For this purpose, we analyzed a 
group of 10 patients who were uniformly treated in a prospective pharmacokinetic study for a 
haematological malignancy. We hypothesized that changes in citrullinaemia are correlated with 
changes in absorption of sugar probes associated with the loss of mucosal surface and with 
changes in gut permeation as assessed with multiple sugar probes. 
Materials and methods
Subjects
Patient characteristics are summarized in Table 1. Between June 1999 and December 2000, 10 
patients with a mean age of 43 years (age range 22 – 59 years) underwent haematopoietic stem 
cell transplantation (HSCT) for a haematological malignancy at the department of Haematology, 
University Medical Centre St. Radboud, Nijmegen. All patients provided informed consent to 
participate in a prospective study investigating the pharmacokinetics and safety of 14 days of 
intravenous itraconazole nanocrystals in patients who were undergoing a HLA-matched partial 
T-cell depleted sibling bone marrow transplantation. The conditioning regimen consisted of 
idarubicin given at a dose of 42 mg/m2 by continuous infusion over 48 hours starting 12 days 
before transplantation (HSCT day –12), followed by 120 mg/kg cyclophosphamide (60 mg/kg 
per day on HSCT day –6 and –5) and 9 Gy of total body irradiation (TBI) in 2 fractions (4.5 Gy 
per fraction on HSCT day –2 and –1). The total duration of the study period was 34 days, from 
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HSCT day –12 until HSCT day +21. For prophylaxis against graft-versus-host disease, patients were 
administered cyclosporine at 3 mg/kg per day by continuous infusion from HSCT day –1 to HSCT 
day +14 followed by 2 mg/kg per day until oral intake was possible. Parenteral nutritional support 
was started on HSCT day –7 and was sustained until the daily oral intake was sufficient. No 
agents were applied that are believed to ameliorate alimentary tract mucositis (that is, amifostine, 
glutamine, keratinocyte growth factor). Anti-infective prophylaxis consisted of ciprofloxacin, 
acyclovir and sulphamethoxazole-trimethoprim. Antifungal prophylaxis started on HSCT day –6 
consisting of intravenous itraconazole 200 mg twice daily for 2 days followed by 200 mg once daily 
for 10 days. All patients were treated with meropenem pre-emptively from the day after transplant 
until neutrophil recovery (> 0.5x109/L). The glomerular filtration rate was determined on admission 
by measuring renal creatinine clearance (in mL per minute) and was estimated thereafter from the 
serum creatinine level using the formula from Cockroft & Gault [23]. 
Clinical toxicity assessment
Gut toxicity was scored daily using six items, that is, frequency of emesis and diarrhea, occurrence 
of nausea, abdominal complaints, fecal incontinence and fecal volume [12]. Each of these items 
was allocated a score between 0 (normal) and 3 (severe). Summation of the scores yielded a daily 
gut score (DGS) with 3 grades: mild toxicity (DGS grade I; 1-6 points), moderate toxicity (DGS II; 
7 – 12 points) and severe toxicity (DGS grade III; 13 – 18 points). All gut toxicities after cytotoxic 
treatment were ascribed to mucositis, unless there was a more plausible alternative cause, such 
as an adverse drug reaction or proven toxigenic infection. 
Sugar permeability test (SPT)
An isotonic solution was prepared by dissolving 5 g lactulose (LAC), 1 g L-rhamnose (RHA), 0.5 
gram D-xylose (XYL) and 0.2 gram 3-O-methyl-glucose (OMG) in 100 mL demineralised water, 
according to good manufacturing practice by the pharmacy of the University Medical Centre St. 
Radboud. After an overnight fast, the subjects emptied their bladders and then drank the test 
solution. A light breakfast with a drink was allowed after 2 hours. Urine was collected for 5 hours. 
The total volume was recorded and aliquots of 5 mL were stored in -80°C until analysis. The first 
(baseline) SPT was performed on HSCT day –12 before starting conditioning therapy and was 
repeated on HSCT day –7, 0, +7, +14 and +21, yielding 6 time points in 5 weeks per patient.
Urinary excretion ratios of differential sugar permeability tests
Urinary excretion was determined using gas chromatography with flame ionization detection with 
D-glucoheptose as an internal standard [24]. Data were collected online using Star Chromatography 
software (Varian, Tempe, Arizona, USA) and peak areas were measured and corrected for the 
internal standard. Urinary recovery of each sugar was expressed as a percentage of the intake and 
the lactulose/rhamnose ratio (L/R), the D-xylose/3-O-methyl-glucose ratio (XYL/OMG) and the 
rhamnose/3-O-methyl-glucose ratio (RHA/OMG) were calculated. The L/R ratio is considered 
a measure of intestinal permeability, whereas the XYL/OMG and RHA/OMG ratios are used as 
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indices of epithelial absorptive capacity and mediated cellular transport, respectively. L/R ratios, 
XYL/OMG ratios and RHA/OMG ratios of ≤0.02 [25, 26], ≥ 0.28 [27] and ≥0.65 [28], respectively, are 
considered normal. 
Determination of serum citrulline concentration
The protocol required obtaining serum daily from HSCT day –6 until HSCT day +1, every other 
day thereafter until HSCT day +7, again daily thereafter until HSCT day +12 and finally on HSCT 
day +21 yielding 17 time points over 4 weeks per patient. The serum was stored at -80°C until 
analysis. For determination of amino acids, 250 µL serum was deproteinized by adding it to 22 
mg dry 5-sulfosalicylic acid. The serum citrulline concentration (µmol/L) was measured by using 
high-performance liquid chromatography [29]. 
Statistical analysis
SPSS software for Windows (Release 11.0; SPSS Inc., Chicago, IL) was used for statistical analyses. 
All results are expressed as the mean with 95% confidence interval [95% CI]. One-way analyses 
of variance (ANOVAs) were used to analyze changes in citrulline concentration and dual sugar 
test ratios, respectively. A Student t test for paired data was used to investigate differences with 
respect to baseline values. A Pearson correlation procedure was performed using the raw data on 
citrulline concentration, urinary recovery and dual sugar test ratios to determine the correlations 
between these parameters. A p-value <0.05 was considered statistically significant. 
Results
Clinical parameters
No treatment-related lethal sequellae occurred. Patient demographics are summarized in Table 1. 
Throughout the study period, mild (DGS grade I) and moderate (DGS grade II) intestinal toxicity 
were observed in 6 and 4 patients, respectively. All but one patient (#5) had microbiologically 
and/or clinically defined infectious events during the study period. Fever (body temperature 
≥38°C) was present on ≥1 day in all patients who experienced infectious events. A fever index was 
calculated as the ratio between the number of days with a body temperature ≥ 38°C and the total 
number of days on which the body temperature was registered. The mean fever index was 0.21 
(range 0.00 - 0.56) (Table 1). Micrococcus sendentarius and Staphylococcus epidermidis bacteraemia 
were identified in one and five patients, respectively. No association was observed between any 
of these clinical parameters and bacteraemia (data not shown). 
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Table 1 Patient characteristics and clinical parameters
Pt n Gender Age (yrs) Diagnosis Max DGS Bacteraemia LOS Fever Index
1 Male 32 ALL 2 Yes 33 0.39
2 Female 48 NHL 1 - 33 NA
3 Female 47 AML 1 Yes 30 0.06
4 Male 52 NHL 1 Yes 42 0.24
5 Female 59 MF 1 - 39 0.00
6 Male 32 AML 1 - 42 0.06
7 Male 30 ALL 2 Yes 107 0.29
8 Female 59 CML 2 Yes 44 0.56
9 Male 22 ALL 1 Yes 35 0.06
10 Female 52 CML 2 - 38 0.28
Abbreviations: Max DGS: maximum daily gut score. FI: fever index indicating the ratio between the 
number of days at which a body temperature ≥ 38°C was registered and the total number of days during 
the study period on which the body temperature was registered. LOS: length of hospital stay in days, 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, CML: chronic myeloid leukemia, 
NHL: Non-Hodgkin’s lymphoma, MF: myelofibrosis, NA: not available
Citrulline concentration
The mean citrulline concentration in 10 patients at HSCT day –6 was 25.7 (95% CI: 17.1 – 34.4 µmol/
L) (Table 2). During the complete study period, a significant decline in citrulline concentration was 
observed (One-way ANOVA: p<0.001. Figure 1) with the lowest concentration measured at HSCT 
day +5 (mean 8.9 µmol/L; 95% CI: 4.4 – 13.4 µmol/L). Compared with the first sample at HSCT day 
–6, the citrulline concentration decreased significantly between HSCT day –2 and +12. At HSCT day 
+21, the citrulline concentration no longer differed from the value measured at HSCT day –6.
Table 2 Time-course of serum citrulline concentration for all study time points (µmol/L)
Day Mean    95%CI  n Test
–6 25.7 17.1 – 34.4 10
–5 21.5 14.4 – 28.6 10 0.177 
–4 18.1 10.2 – 26.1 10 0.057 
–3 18.6 9.5 – 27.8 10 0.075 
–2 15.6 9.9 – 21.2 10 0.004 
–1 14.5 8.4  – 20.7 10 0.006 
0 12.3 8.0 – 16.5 10 0.001 
1 11.6 6.6 – 16.6 10 0.000 
3 9.7 5.3 – 14.1 10 0.000 
5 8.9 4.4 – 13.4 10 0.000 
7 9.9 5.5 – 14.2 10 0.000 
8 11.3 6.3 – 16.3 10 0.001 
9 11.5 6.1 – 17.0 10 0.001 
10 12.4 10.5 – 14.2 8 0.016 
11 15.7 8.6 – 22.9 8 0.009 
12 13.8 6.1 – 21.4 9 0.002 
21 20.1 11.1 – 29.1 9 0.109 
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Day: number of days to haematopoietic stem cell transplantation, 95% CI: 95% confidence interval, 
N: the number of individuals tested.The two-sided, Student t test for paired data test was used. 
Comparison with baseline levels were assessed at HSCT day –6 (these data correspond to Figure 1).
Figure 1 Time-course of serum citrulline concentration (µmol/L) between HSCT day –6 and +21.
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HSCT = haematopoietic stem cell transplantation. Symbols: ◊ 60 mg /kg cyclophosphamide. ∆ 4.5 Gray 
of Total Body Irradiation. Trendline: polynomial, 2nd order. Dotted lines represent the upper and lower 
bounds of 95% CI, respectively (one-way ANOVA; p<0.001). The mean citrulline concentrations measured 
between HSCT day +1 and HSCT day +9 differed significantly compared with the concentrations measured 
at HSCT day –6 (Tukey’s post-hoc testing: p=0.035, p=0.007, p=0.003, p=0.008, p=0.029 and p=0.035 for 
HSCT day +1, +3, +5, +7, +8 and +9, respectively).
Urinary sugar recovery and sugar permeability test
The results of urinary sugar excretion (% intake) and SPT ratios determined at HSCT day –12 
(baseline), –7, 0, +7, +14 and +21 are summarized in Table 3 and 4. Comparison with baseline 
values yielded significantly increased LAC excretion on HSCT day +7 (p=0.029) and significantly 
decreased RHA excretion on HSCT day +14. In a one-way ANOVA, only alterations in RHA 
excretion were significant (p=0.025). 
Compared with baseline values, the L/R ratio was significantly increased on HSCT day +7 and 
+21 (p=0.020 and p=0.012, respectively). The RHA/OMG ratio was significantly decreased on 
HSCT day +7, +14 and +21 (p=0.027, p=0.033 and p=0.036, respectively). In a one-way ANOVA, 
only alterations in the XYL/OMG ratio and the RHA/OMG ratio were significant (p=0.032 and 
p<0.001, respectively). 
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Table 3 Time course of urinary sugar excretion (% intake)
Lactulose Rhamnose D-Xylose 3-O-methylglucose
day N Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
–12 10 0.2 0.1 – 0.3 4.4 2.5 – 6.3 13.2 7.2 – 19.3 19.5 12.0 – 27.0
–7 10 0.4 0.1 – 0.7 8.1 3.4 – 12.9 17.5 7.6 – 27.4 27.4 13.4 – 41.4
0 8 0.7 –0.2 – 0.2 6.2 1.5 – 10.8 17.8 2.7 – 33.0 28.3 5.3 – 51.3
+7 8 0.3 0.2 – 0.4* 2.6 1.3 – 4.0 10.4 5.6 – 15.2 20.4 11.0 – 27.9
+14 7 0.3 –0.0 – 0.7 2.5 0.3 – 4.8** 9.6 3.7 – 15.5* 19.2 7.2 – 31.2
+21 5 0.2 0.1 – 0.6 1.7 –0.2 – 3.5 11.3 –1.0 – 23.7 26.0 –5.1 – 57.0
Day: the number of days to haematopoietic stem cell transplant, N: the number of individuals tested. 
Statistics were determined with 2-sided, Student t tests for paired data to investigate changes relative 
to the baseline value at HSCT day –12. * p < 0.05; ** p < 0.01. One-way ANOVA: Rhamnose p=0.025. 
Lactulose, D-xylose and 3-O-methyl-glucose: p value not significant
Table 4 Time course of serum citrulline concentration (µmol/L) and sugar permeability test ratios
Citrulline L/R ratio X/O ratio R/O ratio
day  N Mean 95% CI N Mean 95% CI N Mean 95% CI N Mean 95% CI
–12  - _____ __________ 10 0.04 0.03 – 0.06 10 0.68 0.56 – 0.80 10 0.23 0.17 – 0.26
– 7 10 25.7 17.1 – 34.4 10 0.05 0.03 – 0.07 10 0.65 0.52 – 0.79 10 0.29 0.22 – 0.35
0 10 12.3 2.3 – 16.5** 8 0.13 0.00 – 0.27 8 0.61 0.45 – 0.77 8 0.21  0.15 – 0.28 
+ 7 10 9.9 5.5 – 14.2*** 8 0.12 0.06 – 0.17* 8 0.51 0.47 – 0.57 8 0.13 0.10 – 0.16*
+14 9 13.8 6.1 – 21.4** 7 0.18 0.02 – 0.34 7 0.51 0.43 – 0.58 7 0.13 0.07 – 0.20*
+21 9 20.1 11.1 – 29.1 5 0.13 0.06 – 0.20* 5 0.45 0.33 – 0.58 5 0.09 0.07 – 0.20*
Day: the number of days to haematopoietic stem cell transplant (HSCT), N: the number of individuals 
tested; L/R = lactulose / rhamnose; X/O = D-xylose / 3O-methylglucose; R/O = rhamnose / O-methyl-
glucose. Statistics were determined with 2-sided, Student t tests for paired data to investigate changes 
relative to the baseline value (that is, HSCT day –12 for sugar permeability tests and HSCT day –7 
for citrulline). Citrulline data that were obtained at HSCT day –6 and +12 were used to calculate of 
correlations with SPT data obtained at HSCT day –7 and +14, respectively. * p < 0.05; ** p < 0.01 and 
*** p < 0.001
Correlation between citrulline concentration, clinical parameters, urinary sugar 
excretion and dual-sugar test ratios
Because no serum was available before the start of treatment, the value assessed at HSCT day 
–6 is referred to as the baseline in this analysis. The citrulline nadir, calculated as percentage of 
the baseline, but not the absolute value (µmol/L), was significantly correlated with the maximum 
DGS (p=0.033). The maximum DGS was significantly correlated with the urinary RHA and XYL 
recovery (p=0.047 and p=0.050, respectively). No correlation was observed between these 
parameters and dual-sugar test ratios (data not shown). 
The citrulline data obtained at HSCT day –6 and +12 were used for the calculation of 
correlations with SPT data obtained at HSCT day –7 and +14, respectively. Thus, citrulline and 
SPT data were available for comparison at 5 time points during 4 weeks, that is, on HSCT day –7, 
0, +7, +14 and +21. The time-course of the respective parameters is shown in Figure 2a-c. The 
time-course of citrulline indicates a maximum damage at HSCT day +7 as compared to HSCT 
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day +14 for the urinary recovery of the individual sugar probes and, to some extent, for the L/R 
ratio and compared with HSCT day +21 for the XYL/OMG and RHA/OMG ratios. A recovery of 
intestinal damage during the study period is indicated by the citrulline, RHA, XYL and OMG 
urinary recovery data and the L/R ratio in contrast to LAC recovery and the XYL/OMG ratio 
and the RHA/OMG ratio. It is interesting to note that urinary recovery of all sugar probes was 
increased 1 week after initiation of the conditioning regimen. (Figure 2a-c) 
The L/R ratio and the urinary recovery of all four sugars were significantly correlated with 
each other, although they were not correlated with the citrulline concentration. The citrulline 
concentration (µmol/L) was correlated with the RHA/OMG ratio (p=0.025). No correlation was 
observed with the L/R and XYL/OMG ratios.
Figure 2 
Tim
e course of serum
 citrulline concentration (A
), urinary sugar excretion (B
) and dual-sugar test ratios (C
) detem
ined on H
SC
T day –12, -7, 
0
, +7, +14 and +21.
104
_____ Chapter 7 _______________________________________________________________________________________________________________ _____________________________________________ Monitoring small bowel toxicity by serum citrulline concentration _____ 
105
Sym
bols: 
C
itrulline (O
             ); LA
C
 (
 _ - _ - _); R
H
A
 (
             ); X
YL (
              ); O
M
G
 (*              ),; L/R
 (
); X
YL/O
M
G
 (o
); R
H
A
/O
M
G
 (
).
Trendline: 3
rd order polynom
ial. For presentation purposes, the urinary sugar recovery data presented in figure a w
ere m
ultiplied by a factor 10
3 (LA
C
) or 
by a factor 10
2 (R
H
A
, X
YL and O
M
G
). D
ata points in figure a and b represent m
ean values. N
ote that citrulline values show
n starts on H
SC
T 
day –7.
Figure 2 
Tim
e course of serum
 citrulline concentration (A
), urinary sugar excretion (B
) and dual-sugar test ratios (C
) detem
ined on H
SC
T day –12, -7, 
0
, +7, +14 and +21.
A
B
C
106
_____ Chapter 7 _______________________________________________________________________________________________________________ _____________________________________________ Monitoring small bowel toxicity by serum citrulline concentration _____ 
107
Discussion
In the current study, further support was provided for the use of serum citrulline concentration as 
a marker for cytotoxic treatment-induced gut damage [9, 17, 18]. We observed a discrepancy between 
the time course of two objective endpoints for epithelial gut damage (that is, the serum citrulline 
concentration and the sugar permeability test). Compared with the sugar probe results, the time-
course for citrulline is in agreement with known kinetics of epithelial cell loss after radiotherapy 
[30] and chemotherapy [13]. 
Gut permeability testing is a noninvasive method for the assessment of altered gut barrier 
function as an endpoint for intestinal damage [25, 26]. Currently, the SPT is the objective endpoint 
used in clinical studies to quantify gut damage [12, 31] and to assess treatment effects aimed at 
mucoprotection [32]. By simultaneously using multiple sugar probes, which are chosen on behalf 
of different permeation pathways, information about intestinal absorptive capacity is obtained 
in addition to information about intestinal permeability. It is generally accepted that alterations 
in the L/R ratio provide an index for the intestinal permeability, whereas the recovery of RHA, 
XYL and OMG and their ratios provide an index for the intestinal absorptive capacity [26, 33]. 
Following myeloablative therapy, increased gut permeability (L/R ratio) and decreased absorptive 
capacity (RHA/OMG ratio) was observed (Table 4) in agreement with previous results [12, 18] and 
with reports from the literature [10, 13]. Remarkably, the decrease of the XYL/OMG ratio was not 
statistically significant compared with previous findings from a group of 56 similarly treated 
patients in our department [12]. Similarly, urinary recovery data did not display major changes 
(Table 3). The small number of patients in the present series and the relatively large standard 
variations may explain this finding. 
We performed a series of preclinical and clinical experiments to develop an objective 
parameter that would enable us to monitor gut damage in routine clinical practice [9, 17]. Cytotoxic 
treatment induces intestinal epithelial cell loss [13, 30]. Plasma citrulline concentration is a surrogate 
endpoint for the small intestinal epithelial cell mass, irrespective of the underlying cause of cell 
loss, such as surgical resection [19, 34, 35], celiac and non-celiac disease [20] or cellular rejection after 
small bowel transplantation [21, 22]. We identified plasma citrulline concentration as a simple and 
sensitive marker enabling quantitation of cytotoxic treatment-induced small bowel epithelial cell 
loss [9, 17]. This was confirmed in patients subjected to myeloablative therapy [18]. In the current 
study, the citrulline concentration was determined in archival serum samples obtained during an 
observation period of 5 weeks in a series of 10 patients who were uniformly treated with intensive 
myeloablative therapy. The results were in complete agreement with previous data obtained in 
similarly treated patients [18] and clearly demonstrated the reproducibility and simplicity of the 
assay and its ability to enable close monitoring of this type of treatment-induced gut damage, as 
illustrated in Figure 1. 
In contrast to Crenn et al. [20] we were not able to correlate the citrulline level with the degree of 
mucosal atrophy. Instead, clinical symptoms [12] associated with mucosal atrophy were used as a 
surrogate endpoint, in addition to sugar permeability tests. The absolute citrulline concentration 
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(µmol/L) did not correlate with these endpoints whereas the normalized citrulline level (% 
baseline) correlated with the maximal gut toxicity observed during the observation period. 
A similar correlation was observed between the urinary recovery of RHA and XYL (% intake) 
and maximal gut toxicity. However, there were several limitations to the use of these surrogate 
endpoints in the current study. First, compared with the serum citrulline concentration, which is 
considered to be highly dependent upon the small intestinal cell mass [36, 37], the gut toxicity score 
we used does not specifically address small intestinal toxicity but merely gastrointestinal toxicity 
in general. Second, mucosal denudation is merely one of several events underlying clinical 
symptoms related to cytotoxic treatment [13-16]. 
Comparison of the citrulline assay results with the SPT results yielded some striking differences 
between both endpoints. The citrulline level (µmol/L or % baseline) did not correlate with gut 
permeability (L/R ratio). Except for a correlation with the RHA/OMG ratio, no other correlation 
was observed with parameters indicative for the absorptive capacity used in this study (that is, 
XYL/OMG ratio or the urinary recovery of RHA, XYL and OMG, respectively). Furthermore, the 
time course of both endpoints was essentially different (Figure 2). The maximum damage and 
recovery were recorded between 1-2 weeks earlier using the citrulline assay compared with the 
sugar probe test results. In contrast to the time course of urinary sugar probe recovery, the time 
course observed for citrulline was in complete agreement with the time course observed for 
other function tests related to a reduced number of epithelial cells [17] and with known kinetics of 
injured gut epithelium after radiotherapy [30] or chemotherapy [13]. Remarkably, the RHA recovery, 
which was considered the most appropriate estimate of the mucosal surface available for 
absorption [33] and citrulline concentration during the initial study period, yielded contradictory 
results concerning the relations with mucosal atrophy and known kinetics of this mucosal event 
[13, 30]. The initial increase in the sugar probe recovery (and in RHA recovery in particular) may be 
explained by alterations in the permeation pathway or by altered pre-absorptive factors, such as 
gastric emptying or small bowel transit time, and both factors are frequently affected by this type 
of treatment. 
Unfortunately, no serum was available for citrulline analysis at HSCT day –12. However, 
the citrulline concentrations measured at HSCT day –6, (that is, 1 week after initiation of the 
conditioning regimen) were comparable to baseline citrulline concentrations in a previous study 
(mean: 30.9 µmol/L; 95% CI: 26.6 – 35.2 µmol/L) [9]. Hence, it is reasonable to assume that a 
change, if any, occurring in the citrulline level during the first week of the conditioning regimen 
would be a minor decline. Finally, the average 95% CI was significantly greater for LAC, RHA, 
XYL and OMG compared with citrulline (p=0.001) (Table 2-3). Although the sugar tests showed 
remarkable changes during the study period (Figure 2), statistical significance was moderate 
(Table 2-3) compared with citrulline. 
Gastrointestinal mucositis is a common side effect of cancer treatment that, not infrequently, 
is persistent [38], which may cause a major economic burden [8]. In addition to tumor control, data 
on normal tissue damage are required to assess the therapeutic value of treatment regimens. In 
patients with small bowel damage, clinical signs and symptoms expressed in toxicity scores are 
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the current standard. For the reasons described above, there is an urgent need for an objective 
parameter. Ideally, such a marker should be easily accessed and should be independent of 
medication and metabolic events, such as diet and nutritional status. Previous attempts have 
been made to develop simple blood tests for measuring gut damage [39, 40]. However, to date, 
none are used in clinical practice. We suggest that serum citrulline fulfils most, if not all, of these 
requirements. In addition to yielding highly reproducible results and functioning as a sensitive 
and specific marker for epithelial cell loss, the citrulline assay can be applied as a simple blood 
test and is relatively inexpensive. 
The results of the current study, in which serum citrulline concentration was used as a marker 
for cytotoxic treatment-induced intestinal damage are highly reproducible. Overall, the citrulline 
concentration appears to be a quantitative parameter that is independent of the underlying cause 
for epithelial cell loss [9, 17-21]. Compared to sugar permeability tests, the citrulline assay is more 
sensitive and more specific for measuring small bowel epithelial cell loss. In addition, this assay 
enables more accurate assessment of induction and repair kinetics of damage. The simplicity 
of the method, the low costs and the lack of methodological drawbacks, as discussed earlier, 
make this assay the first choice for measuring and monitoring treatment-related gut damage. 
In addition, the citrulline assay provides an objective parameter to the clinician that enables 
standardized assessment of treatment-related morbidity. 
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Summary
We conducted a prospective, randomised, double-blinded, placebo-controlled pilot study of 
parenteral nutrition (PN) supplemented with 0.57 g/kg glutamine-dipeptide in a homogeneous 
group of 32 allogeneic stem cell transplant (HSCT) recipients to determine its effect on mucosal 
barrier injury (MBI). All patients had been prepared with idarubicin, cyclophosphamide and 
total body irradiation. PN (by continuous infusion) started on HSCT day –6 for a median of 
19 days. MBI measured by sugar permeability tests, daily mucositis score, daily gut score, and 
citrulline concentrations was not reduced by glutamine-dipeptide. However, the daily gut score 
was significantly lower for the glutamine group on HSCT +7 (p = 0.001) whilst citrulline was 
lower (p = 0.03) for the placebo group on HSCT day +21. Albumin was significantly lower in the 
placebo group on HSCT day +21 (32±4 versus 37±3, p = 0.001) whilst CRP was higher (74±48 
versus 34±38, p = 0.003). Other transplant-related complications (infections, acute graft-versus-
host disease) were less common although this did not reach statistical significance nor translate 
into a reduced length of hospital stay or lower mortality. These results indicate that it would be 
worthwhile conducting a larger trial to see whether or not giving glutamine-dipeptide reduces the 
100-day allogeneic transplant-related complications.
Introduction
Glutamine can behave as an essential amino acid in clinical settings where there is marked 
metabolic stress such as occurs after haematopoeitic stem cell transplant (HSCT). The amino acid 
is a key substrate involved in many metabolic processes including inter-organ nitrogen transfer, 
protein synthesis, gluconeogenesis, acid-base homeostasis and nucleic acid biosynthesis. 
Glutamine is also a substrate for glutathione synthesis thereby playing a role as an antioxidant 
and scavenger and is the major fuel of intestinal mucosal cells and immune cells, including those 
located in the gut-associated lymphoid tissue [1]. Glutamine supplementation in animals reduced 
bacterial translocation and mucosal damage after chemotherapy or radiotherapy, making 
supplementation an attractive option for reducing post-transplant complications [2]. However, the 
results of clinical studies amongst recipients of autologous or allogeneic HSCT given glutamine-
dipeptide orally or parenterally are contradictory. Some indicate a trend towards reduced 
mortality, shorter length of hospital stay (LOS), lower rejection and infection rate, and less use 
of parenteral nutrition (PN) [3]. Autologous HSCT recipients reported that oral administration of 
glutamine leads to less severe oral mucositis and a shorter duration as they had less oral pain 
and required less opioid medication [4]. However, interpretation of the results is hampered by 
the heterogeneity of the patient populations. There has also been a lack of an objective tool for 
measuring mucosal barrier injury (MBI) not only of the mouth but also of the digestive tract 
as a whole [5], despite the fact that MBI is the most frequent cause of morbidity associated with 
the myeloablative conditioning treatment to prepare for an HSCT [6;7] and increases the costs of 
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health care resources [8]. Oral mucositis is relatively easy to recognise [9] whereas the detection 
of intestinal mucosal injury has relied essentially on non-specific symptoms such as nausea, 
vomiting, diarrhoea and abdominal cramps, which affect almost every HSCT recipient and do not 
necessary reflect MBI. Sugar permeability tests provide an objective assessment of gut integrity 
and absorptive capacity, reflecting alterations in permeability and loss of epithelial surface that 
are features of gut MBI [10]. We recently reported that serum citrulline concentrations of HSCT 
recipients who participated in a pilot study of glutamine-dipeptide supplementation could also 
be used to monitor intestinal mucosal damage after myeloablative therapy [11]. We now report in 
full the results of the prospective, randomised, double-blinded, placebo-controlled pilot study 
to determine whether glutamine-dipeptide supplementation reduces mucosal barrier injury as 
measured by a daily mucositis score (DMS), daily gut score (DGS), sugar permeability tests 
(SPT) and serum citrulline. 
Patients and methods
Patients
From July 1999 to July 2002, patients admitted to receive an HLA-matched T-cell depleted sibling 
graft were asked to participate in the study provided they were between 18-65 years of age and 
were to receive myeloablative therapy with idarubicin to lower the risk of relapse given at a dose 
of 42 mg/m2 by continuous infusion over 48 hours starting 12 days before transplant (HSCT day 
–12), 120 mg/kg cyclophosphamide (60 mg/kg per day on HSCT days –6 & - 5) and 9 Gray of 
total body irradiation (4.5 Gy per day on HSCT days –2 & -1) [12]. In addition, patients had to be 
free of an inborn-error of amino acid metabolism, insulin-dependent diabetes and inflammatory 
bowel disease. All patients had to give their informed consent in writing before randomisation. 
The local ethics committee approved the protocol. 
Treatment
Patients were randomly allocated to receive either standard Aminomix (Fresenius-Kabi, Nederland 
BV, ‘s-Hertogenbosch, The Netherlands) parenterally or Aminomix in which a portion of the 
amino acids were replaced by 200 ml glutamine-dipeptide, L-alanyl-L-glutamine (Dipeptiven, 
Fresenius-Kabi) to obtain an isonitrogenous and isocaloric solution equivalent to 0.57 g/kg/d 
glutamine-dipeptide. Randomisation was performed by the hospital pharmacy and, except for the 
hospital pharmacist, all other personnel involved in the trial were blinded, as were the patients. 
Parenteral nutrition was administered from HSCT day –6 onwards until bone marrow recovery 
(granulocyte count above 0.5 x 109/L), removal of central venous catheter for any reason or 
because of intolerance.
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Supportive care
Cyclosporin 3 mg/kg/day was given as prophylaxis against graft-versus-host disease (GVHD) 
by continuous infusion from HSCT day –1 to +14 followed by 2 mg/kg/day until oral intake was 
possible. Patients received continuously intravenous morphine on demand to control mucositis-
related pain. Erythrocyte transfusions were given when the haemoglobin concentration was less 
than 6 mmol/L and platelets were transfused for bleeding or when platelet counts fell below 15 
x 109/L. Haematopoietic growth factors were not used. Anti-infective prophylaxis consisted of 
ciprofloxacin and acyclovir or valaciclovir. Co-trimoxazole (sulphamethoxazole-trimethoprim) 
was given for prophylaxis against Pneumocystis carinii. Fluconazole was only given to patients 
colonised with Candida albicans and no other systemic antifungal agents were given for 
prophylaxis. Cefipime or ceftazidime was administered empirically at the onset of fever. Full blood 
counts together with renal and liver function tests and C-reactive protein (CRP) were performed 
daily. The glomerular filtration rate was determined on admission by measuring renal creatinine 
clearance (millilitres per minute) and was estimated thereafter from the serum creatinine using 
the formula of Cockroft & Gault [13]. Baseline body mass index (BMI) was calculated and albumin 
was measured weekly. 
Citrulline assay
The protocol-prescribed serum was obtained on HSCT days –12, -6, 0, +7, +14 and +21 for later 
amino acid analysis. In practice, this was not always done. Serum taken was stored at –80°C. 
Citrulline concentrations (micromolar) were measured by a standard procedure for determining 
amino acids using automated ion-exchange column chromatography after completion of the 
study. The citrulline concentrations of the population have been recently published [11]. 
Mucositis assessment
Patients were monitored daily for the presence of oral mucositis evidenced by lesions, erythema, 
oedema, pain, bleeding, dryness and the production of viscous mucous with each item being 
allocated a score of 0 (normal) to 3 (severe). The separate values were summed to yield a daily 
oral mucositis score (DMS) with 3 grades: 1-7 for DMS grade I or mild mucositis, 8-14 for grade 
II or moderate mucositis and ≥ 15 for grade III or severe mucositis. DMS grade II is comparable 
with WHO grade III [14]. Gut toxicity was scored likewise from 0 to 3 based on the frequency 
of vomiting and diarrhoea, as well as the occurrence of nausea, abdominal complaints, faecal 
incontinence and volume. Summation of the separate score yielded the daily gut score (DGS) 
with 1-6 for grade I or mild toxicity, 7-12 for grade II or moderate toxicity and ≥ 13 for grade III 
or severe toxicity. All gut toxicities following chemotherapy were ascribed to mucositis unless 
there was a more plausible alternative explanation, such as an adverse drug reaction or proven 
Clostridium difficile infection.
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Sugar permeability test (SPT)
An isotonic solution was prepared by dissolving 5 g lactulose (LAC), 1 g L-rhamnose (RHA), 0.2 
g 3-O-methylglucose (OMG), 0.5 g D-xylose (XYL) in 100 mL demineralised water according to 
good manufacturing practice by our own hospital pharmacy. After overnight fasting, subjects 
emptied their bladders and then drank the solution. A light breakfast with a drink was allowed 
after 2 hours. Urine was collected for 5 hours after which the total volume passed was recorded, 
and aliquots of approximately 5 mL were stored in -80°C until assayed. The first SPT (baseline 
day) was performed before starting conditioning therapy and others were determined every 
Wednesday after baseline on HSCT days –12, -6, 0, +7, +14 and +21.
Determination of the sugars in urine
The concentration of each sugar was determined using gas chromatography with flame 
ionisation detection with D-glucoheptose as an internal standard [15]. Data were collected on-
line using Star Chromatography software (Varian, Tempe, Arizona, USA) and peak areas were 
measured and corrected to the internal standard. The concentration of each sugar was then 
estimated in micromoles per litre using standard calibration curves and urinary recovery of each 
sugar was calculated as a percentage of intake. The coefficient of variance for LAC, XYL, RHA and 
OMG were 2.3%, 3.7%, 3.1% and 2.3%, respectively. Urinary excretion of two sugars, for example 
lactulose and rhamnose, was expressed as a ratio to minimise the influence of extraneous 
factors such as gastric emptying and bowel transit time. The lactulose/rhamnose ratio (L/R) 
was used as an index of intestinal permeability or integrity with a L/R ratio of 0.02 or less being 
considered normal. Similarly, the L-rhamnose/3-O-methylglucose (RHA/OMG) and D-xylose/3-
O-methylglucose (XYL/OMG) ratios were used, respectively, as indices of absorptive capacity 
and mediated cellular transport, with a ratio of 0.28 [16] and 0.65 [17] being considered normal. 
Transplant related complications
Every event that occurred during the study until 3 months post-transplant was recorded and 
classified as either an infectious event (IE) or non-infectious event (NIE), irrespective of its 
relation to study treatment. The infectious events were sub-divided into microbiologically defined 
infections (MDI) with or without bacteraemia, clinically defined infections (CDI) or unexplained 
fever. Non-infectious events were rated as mild, moderate or severe. Acute GVHD was scored 
using the Glucksberg criteria. Any event resulting in admission to the ICU or having a significant 
mortality risk despite optimal therapy or resulting in death was considered a serious adverse 
event. 
Data analysis
The primary end point of the study was to investigate the effect of glutamine-dipeptide 
supplementation on gut MBI measured by SPT. Secondary endpoints were differences in 
DMS, DGS, citrulline and morphine use (mean daily dose), time to granulocyte recovery (> 0.5 
x 109/L (days), length of hospital stay (LOS in days), and the frequency of transplant-related 
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complications estimated by the number of events per patient divided by LOS. The mean and 
standard deviation (SD) of DMS, DGS scores and citrulline concentrations on each of the days 
that the SPT was performed were calculated. If these items were not recorded on the specified day, 
the scores obtained on the day before or after were used. The sugar ratios were first transformed 
to logarithms and then expressed as the mean with SD. ANOVA was used to determine the 
impact, if any, of glutamine supplementation. Comparison of variables between the two groups 
was done using the Student’s t-test or Mann-Whitney U test. All analyses were done using SPSS 
v 11.0 with a p-value of < 0.05 being considered statistically significant. 
Results
Patient characteristics
Thirty-five patients were recruited but three failed to meet the inclusion criteria and were not 
entered into the study: one patient was not transplanted because of relapsed disease, another 
developed a cerebral lesion whilst the third was given another myeloablative regimen. Twenty 
of the 32 patients were men, and the mean age of the population was 48 (range 25-65) years. 
All patients had been treated for a haematological malignancy – acute myeloid leukaemia (9), 
acute lymphoblastic leukaemia (7), non-Hodgkin’s lymphoma (7), myelodysplastic syndrome 
(3), chronic myelogenous leukaemia (2), myeloproliferative disorder (2), chronic lymphocytic 
leukaemia (1), chronic myelofibrosis (1). (Table 1)
Table 1 Characteristics of patients at baseline
Glutamine-dipeptide   Placebo     P value
Number of patients  16  16  ns
Age (mean + range in years)  49  (25-64)  48 (28-57)  ns
Women (n)  5  7  ns
BMI (mean)  26  27  ns
BMI > 25 (n)  10  11  ns
Acute leukaemia (n)  7  9  ns
Albumin (mean ± SD)  45  (± 2)  44  (± 3)  ns
C-reactive protein (mean ± SD)  11  (± 14)  18  (± 18)  ns
Creatinine clearance (ml/min) (mean ± SD)  99  (± 54)  79  (± 30)  p = 0.2
BMI Body Mass Index, ns not significant
There was no difference between the treatment and placebo groups in terms of baseline BMI, the 
proportion considered overweight (BMI > 25), creatinine clearance (ml/min), CRP or albumin 
concentrations. Also DMS, DGS, citrulline and the ratios of L/R, XYL/OMG and RHA/OMG were 
similar (Table 2).
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Table 2 Duration of parenteral nutrition (PN) and reasons for stopping
Glutamine-dipeptide Placebo
Number of patients  16  16
Days of PN (mean)  18.8  17.9
CVC removal (n)  8  9
ANC > 500/mm3 (n)  6  4
Intolerance (n)  1  2
Doctor’s decision (n)  1  1
CVC central venous catheter ANC absolute neutrophil count
Clinical results
The duration of PN administration was comparable in both groups as were the reasons for 
stopping PN (Table 2).
Table 3 Results of mucosal barrier injury (MBI) assessments at baseline, peak and at end of parenteral 
nutrition (PN) administration
Glutamine-dipeptide          Placebo P value
Baseline
DMS  0  0.2 (± 0.4)  ns
DGS  0  1.3 (± 2.2)  ns
L/R ratio  0.04 (± 0.02)  0.04 (± 0.02)  ns
XYL/OMG ratio  0.58 (± 0.2)  0.62 (± 0.09)  ns
RHA/OMG ratio  0.24 (± 0.06)  0.24 (± 0.05)  ns
citrulline  34 (± 8)  30 (±7)  ns
HSCT +7
DMS   8.1 (± 3.5)  9.3 (± 3.1)  ns
DGS   1.5 (± 1.7)  3.6 (± 2.5)  p = 0.001
L/R ratio   0.15 (± 0.07)  0.19 (± 0.08)  ns
XYL/OMG ratio   0.44 (± 0.16)  0.34 (± 0.12)  ns
RHA/OMG ratio   0.15 (± 0.11)  0.07 (± 0.05)  ns
Citrulline   11 (± 5)  10 (± 10)  ns
HSCT +21
DMS   2.2 (± 2.3)  2.4 (± 2.0)  ns
DGS   2.6  (± 2.0)  2.8 (± 2.0)  ns
L/R ratio   0.11 (± 0.14)  0.17 (± 0.13)  ns
XYL/OMG ratio   0.47 (± 0.22)   0.44 (± 0.09)  ns
RHA/OMG ratio   0.13 (± 0.07)   0.09 (± 0.05)  ns
Citrulline  18 (± 6)   12 (± 3)  p = 0.03
DMS Daily Mucositis Score, DGS Daily Gut Score, L/R ratio Lactulose/Rhamnose ratio, XYL/OMG ratio Xylose/
3-O-Methylglucose ratio, RHA/OMG ratio Rhamnose/3- O -Methylglucose ratio, HSCT Haemato-poeitic stem 
cell transplantation, ns not significant. Results are depicted as means ± standard deviation
118
_____  Chapter 8  _______________________________________________________________________________________________________________ _____________________________________________________________________________  A pilot study of parenteral glutamine  _____ 
119
Mucosal barrier injury
Glutamine supplementation had no significant beneficial effect upon MBI as measured by SPT, 
DMS, DGS or citrulline concentrations on the consecutive sampling days. DGS was significantly 
lower for the glutamine group only on HSCT +7 (p = 0.001) whilst citrulline was lower (p = 0.03) 
for the placebo group on HSCT day +21 (Table 3). In both arms, the L/R ratio was significantly 
higher from HSCT day 0 till +21 with respect to baseline and both XYL/OMG and RHA/OMG 
ratios were significantly lower during the same period (results not shown). Furthermore, there 
was no difference in the mean daily dose of morphine used to alleviate mucositis-related pain 
(40 mg/d glutamine versus 38 mg/d placebo), and nine patients in the glutamine group needed 
morphine versus 12 patients in the placebo group where patients also used tramadol and 
transdermal fentanyl. 
Transplant-related complications 
There were four serious adverse events in each group resulting in death. In the glutamine 
group, two patients died because of an IE (one on HSCT day +12 because of sepsis syndrome 
after Streptococcus mitis bacteraemia and the other on HSCT +13 due to invasive Candida 
infection) and two because of an NIE (both due to multi-organ failure on HSCT days +13 and 
+43 respectively). In the placebo group, two patients died because of an IE (one on HSCT day 
+9 because of sepsis syndrome and the other on HSCT day +21 because of invasive pulmonary 
aspergillosis) and two died due to an NIE (one because of grade IV acute GVHD on HSCT day +55 
and the other due to cerebral haemorrhage after primary graft rejection on HSCT day +56). LOS 
was not significantly different (days 36 versus 41, p = 0.2). In general, fewer events occurred in the 
glutamine group. This difference was not statistically significant and is predominantly explained 
by fewer non-severe NIE such as those related to cyclosporin use, namely, hypertension, tremors, 
CNS symptoms, fluid retention and abnormal liver function tests (Figure 1). The cyclosporine 
dose was not significantly different on HSCT days +7 or +21 (mean daily dose respectively 252 and 
245 mg in the glutamine group versus 243 and 239 mg in the placebo group). The trend of fewer 
events was seen across all categories in favour of glutamine use. 
In addition, albumin was significantly lower in the placebo group on HSCT day +21 (32±4 versus 
37±3, p = 0.001) whilst CRP was higher (74±48 versus 34±38, p = 0.003). Furthermore, fewer 
patients in the glutamine arm (three versus seven) developed acute GVHD overall grade ≥ II 
necessitating immunosuppressive therapy with systemic corticosteroid therapy shortly after 
transplant, and also experienced fewer clinically or microbiologically defined infections (Table 4). 
The mean duration of neutropenia (< 0.5 x 109/L) for the glutamine and placebo group was 20 
versus 21 days, respectively, and 35 versus 40 days for thrombocytopenia (< 50 x 109/L). 
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Figure 1 Categories of events
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Table 4  Infectious complications
Events (total counts) Glutamine-dipeptide 
(n=16)
Placebo 
(n=16)
P value
Clinically Defined Infection - total
 Exit site infection
 Abscess right buttock
 Pulmonary infiltrate
 Acute Respiratory Distress Syndrome
 Meningitis
 Phlebitis
 Folliculitis
 Influenza-like illness
 Oesophagitis
 Sinusitis
 Probable pulmonary aspergillosis
7
1
1
3
1
1
-
-
-
-
-
-
11
2
–
2
1
–
1
1
1
1
1
1
ns
Microbiological Defined Infection - total
• Blood cultures - total
  Coagulase negative staphylococci
  Oral viridans streptococci
  Staphylococcus haemolyticus
  Coryneforms
  Escherichia coli
  Acinetobacter baumanii + Staphyloccus haemolyticus
  Bacillus species + Staphylococcus epidermidis
  Streptococcus mitis + Candida albicans
  Candida glabrata
• others - total
  Enterocolitis
  Herpes stomatitis
  Pulmonary Cytomegalovirus (early antigen positive BAL)
  Cutaneous fungal infection
  Exit site supra-pubic catheter
  Proven pulmonary aspergillosis
  Herpes simplex oesophagitis
  Oral candidiasis
18
13
6
5
–
-
–
–
1
1
-
5
1
2
1
1
-
-
-
-
31
22
10
5
3
1
1
1
–
-
1
9
1
2
–
2
1
1
1
1
ns
ns
ns
BAL Broncho-alveolar lavage, ns not significant
Discussion
Supplementing parenteral nutrition with glutamine-dipeptide had no beneficial effect upon the 
onset or severity of MBI of the alimentary tract primarily measured by SPT in this homogeneous 
group of allogeneic HSCT recipients. This is in line with the results of a similar study in which 
glutamine given parenterally failed to prevent small bowel malabsorption of D-xylose among 
autologous HSCT recipients prepared for transplant by various different conditioning regimens 
[18]. Patients in this study were given glutamine-dipeptide for a very short time that is, a mean 
122
_____  Chapter 8  _______________________________________________________________________________________________________________ _____________________________________________________________________________  A pilot study of parenteral glutamine  _____ 
123
of 3 days compared with those in our study. Only DGS was significantly lower for the patients 
given glutamine on HSCT day +7 but DGS measured other symptoms than those strictly related 
to MBI and therefore does not give a true reflection of MBI [10]. In the current study, there were 
significant differences in citrulline, albumin and CRP apparent on HSCT day +21 favouring 
glutamine-dipeptide supplementation. This suggests that glutamine might have a beneficial 
effect upon repair of damaged tissues, such as those of the small intestines since citrulline 
concentrations start to return to normal levels around this time after HSCT, indicating recovery of 
small intestinal cells [19]. In the allogeneic setting, acute GVHD also tends to occur then, though 
citrulline concentrations were not different between recipients with or without acute GVHD (data 
not shown). Strikingly, fewer patients given glutamine-dipeptide developed severe acute GVHD 
during the first 3 months post-transplant. Lymphocyte recovery tends to be significantly quicker 
after glutamine supplementation because glutamine is the major fuel of immunoreactive cells, 
but neither in our study nor in the autologous HSCT recipients was the duration of neutropenia 
influenced by glutamine-dipeptide [20;21].
In general, the patients receiving glutamine faired better (Figure 1). The number of non-
infectious and infectious events was higher in the placebo group but not significantly, probably 
because of the small size of the group of patients. Two older randomised placebo-controlled 
studies done predominantly in allogeneic HSCT recipients prepared with various regimens also 
indicated a reduction in infections and LOS after glutamine-dipeptide (0.57 g/kg/day) [22;23]. All 
these data taken together would justify a larger multicentre study to assess whether glutamine 
reduces post-transplant-related complications. 
The lack of impact on MBI measured objectively and the apparent reduction in post-transplant 
complications at first appears inconsistent. However, glutamine is an essential component 
of glutathione (GSH) production that, in turn, is hampered by the conditioning regimen 
resulting in depletion of GSH [3]. Glutamine is the rate-limiting factor in hepatic and intestinal 
GSH production, and GSH is one of the main antioxidant protecting tissues in general and 
hepatocytes and endothelial cells in particular from the free radicals generated by conditioning 
therapy [24]. Glutamine given parenterally was shown to preserve the protein C and albumin levels 
of HSCT recipients [25]. We found fewer liver function abnormalities, higher albumin levels and less 
toxicities related to cyclosporin among patients receiving glutamine-dipeptide just as Brown et 
al. had reported suggesting that glutamine preserves hepatic function and has a role in reducing 
tissue damage [25]. This effect can also be mediated by the inflammatory response which, is able to 
down-regulate the kinetics of drugs that are metabolised by the cytochrome P450 system [26]. So, 
differences in inflammation could account for alterations in cyclosporine pharmacokinetics [27]. 
In conclusion, glutamine exerts a possible beneficial effect by preventing oxidative tissue 
damage and improving the restoration of damaged tissue. It therefore seems warranted 
to conduct a large multicentre trial to determine whether glutamine is capable of reducing 
transplant-related complications 3 months after allogeneic HSCT. 
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Summary
We noted a significant increase of IL-8, LBP and CRP mirroring the pattern of mucosal barrier 
injury as measured by gut integrity (Lactulose/Rhamnose ratio), daily mucositis score (DMS) 
and serum citrulline concentrations of 32 haematopoietic stem cell transplant recipients 
following intensive myeloablative therapy. Concentrations of IL-8, LBP and CRP were already 
significantly elevated before the onset of fever or bacteraemia due to oral viridans streptococci 
in the first week after transplant during profound neutropenia. These markers reached their peak 
when citrulline concentrations reached their nadir, the highest scores of DMS were attained and 
when there was significantly decreased gut integrity. This suggests that the degree of mucosal 
barrier injury rather than bacteraemia due to oral viridans streptococci determines the intensity 
of the inflammatory response.
Introduction
Mucosal Barrier Injury (MBI) of the digestive tract induced by intensive cytotoxic therapy is a 
complex pathobiological process [1]. It begins immediately after starting anticancer therapy with 
the activation of the nuclear transcription factor NF-κB resulting in the production and release 
of pro-inflammatory cytokines by various cells including lymphocytes, macrophages, endothelial 
cells and gut epithelial cells [2;3]. Gut epithelial cells produce not only pro-inflammatory cytokines 
like TNF-α, IL-1α, IL-6 but also the chemokines Monocyte Chemoattractant Protein-1 (MCP-1) and 
IL-8, antimicrobial peptides (defensins, cathelicidins, lactoferrin) and the acute phase protein, 
LPS-Binding Protein (LBP) [3;4, 5]. The release of pro-inflammatory cytokines and the blocking of 
clonogenic epithelial stem cells renewal results in apoptosis and necrosis, which manifests itself 
as epithelial atrophy and ulcerative lesions [6]. The latter are a potential portal of entry for oral 
viridans (alpha-haemolytic) streptococci (OVS), which are universal commensals of the oral cavity 
placing haematopoietic stem cell transplant (HSCT) recipients at risk of developing bacteraemia 
due to these bacteria [7]. Our standard myeloablative regimen of idarubicin, cyclophosphamide 
and TBI to prepare patients for a T-cell depleted HSCT [8] is known to induce prolonged and 
severe MBI of the oral cavity and digestive tract [9]. This is invariably accompanied by fever and 
bacteraemia due to viridans streptococci occurs frequently [10] as well as the continued release of 
C-reactive protein (CRP) (unpublished observation). We had prospectively routinely determined 
CRP concentrations throughout admission of 32 HSCT recipients participating in a prospective 
randomised placebo-controlled study of glutamine-dipeptide enriched parenteral nutrition and 
had collected serum and plasma samples for measuring IL-8 and LBP later. We were particularly 
interested in investigating the production of IL-8 and LBP together with CRP to determine the 
pro-inflammatory response of the gut during the process of MBI using oral mucositis, sugar 
permeability tests (SPT) and serum citrulline concentrations [11]. 
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Patients and methods
Patients
32 patients (12 F; 20 M) with a mean age of 48 years (range 25-65) had given their informed 
consent to participate in the prospective study of glutamine-enriched total parenteral nutrition. All 
had received an HLA-matched T-cell depleted sibling HSCT to treat a haematological malignancy 
– acute myeloid leukaemia (9), acute lymphoblastic leukaemia (7), non-Hodgkin’s lymphoma 
(7), myelodysplastic syndrome (3), chronic myelogenous leukaemia (2), myeloproliferative 
disorder (2), chronic lymphocytic leukaemia (1), chronic myelofibrosis (1). On admission, a triple 
lumen intravascular catheter (IVC) was inserted into the subclavian vein. The myeloablative 
regimen started on HSCT day –12. Idarubicin was given at a dose of 42 mg/m2 by continuous 
infusion over 48 hours, followed by 120 mg/kg cyclophosphamide (60 mg/kg/d) on HSCT days 
– 6 & - 5 and TBI (4.5 Gy/d) on HSCT days –2 & -1. All recipients were given parenteral nutrition 
on HSCT day –6 supplemented with either glutamine-dipeptide or placebo. Cyclosporin 3 mg/
kg/day was given by continuous infusion as prophylaxis against GVHD for the first 2 weeks after 
transplant followed by 2 mg/kg/d until oral intake was possible. Haematopoietic growth factors 
were not used. Anti-infective prophylaxis was administered orally and consisted of ciprofloxacin, 
acyclovir or valaciclovir and co-trimoxazole (sulphamethoxazole-trimethoprim). Fluconazole was 
only given orally to patients colonised with Candida albicans. No other systemic antifungal agents 
were given for prophylaxis. Full blood counts with absolute neutrophil count (ANC) together with 
renal and liver function tests were performed daily. Oral gargle samples and faeces was obtained 
twice weekly for culture to detect the presence of Gram-negative bacilli and yeasts. Cefepime or 
ceftazidime was administered empirically at the onset of fever (≥38.5 °C once or >38 °C sustained 
for > 6 hours during neutropenia (ANC < 0.5x109/L).
Blood cultures
Ten millilitres of blood was obtained from each lumen of the IVC for aerobic culture at 
approximately 9:00 every Monday and Thursday on HSCT days -12, -6, -2, +1, +5, +8, +12, +15, 
+19, + 22. At the onset of fever, two additional blood cultures were obtained from each lumen of 
the IVC together with two 20 mL samples drawn through two separate peripheral veins within 30 
minutes of each other. Bacteraemia due to viridans streptococci was considered present when 
the organism was recovered from a single blood culture from any source. Isolates were identified 
as oral viridans streptococci on the basis of cultural appearance, Gram stain and morphology, 
resistance to optochin and the identification of Streptococcus mitis, Streptococcus oralis or 
Streptococcus sanguis using the API 20S STREP kit (bioMérieux sa, Marcy l’Etoile, France)
Inflammatory response
C-reactive protein
CRP was measured on HSCT –12 and daily from HSCT –7 to HSCT +22 using a nephelometric 
assay (Turbidtimer®, DADE-BEHRING). Values below 10 mg/L were considered normal.
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Interleukin-8 and lipopolysaccharide binding protein
Plasma was obtained on HSCT days –12, -6, 0, +7, +14 and +21 and stored at –80°C for later 
analysis. IL-8 and LBP concentrations were determined by a chemiluminescence immunoassay 
according to the manufacturer’s instructions (Immotile, Diagnostic Products Corporation, Los 
Angeles, USA). The cut-off value for IL-8 and LBP were 40 ng/L and 2 mg/L, respectively.
Mucosal barrier injury
Citrulline 
The protocol prescribed serum to be obtained on HSCT days –12, -6, 0, +7, +14 and +21 for later 
amino acid analysis. In practice, this was not always done. Serum taken was stored at –80°C. 
Citrulline concentrations (µM) were measured by a standard procedure for determining amino 
acids using automated ion exchange column chromatography after closing of the study [12]. 
Oral mucositis assessment 
Patients were monitored daily by trained nurses for the presence of oral mucositis evidenced 
by lesions, erythema, oedema, pain, bleeding, dryness and the production of viscous mucous 
with each item being allocated a score of 0 or normal to 3 or severe. The separate values were 
summed to yield a daily oral mucositis score (DMS) with 3 grades: DMS grade I (1-7 points) mild 
mucositis, grade II (8-14 points) moderate mucositis and grade III (>14 points) severe mucositis. 
The DMS grade is comparable with the WHO scale [13]. 
Sugar permeability test (SPT) 
The SPT was performed as previously described [9]. Briefly, after an overnight fast, the subjects 
emptied their bladders and then drank an isotonic solution containing 5 g lactulose, 1 g L-
rhamnose, 0.2 g 3-O-methylglucose (OMG), 0.5 g D-xylose in 100 mL demineralised water. Urine 
was then collected for 5 hours after which the total volume passed was recorded, and aliquots of 
approximately 5 mL were stored in -80°C until analysis was performed. The first SPT (baseline 
day) was performed before starting conditioning therapy and was repeated every Wednesday 
after baseline on HSCT days –12, -6, 0, +7, +14 and +21. Urinary excretion was determined using 
gas chromatography and urinary recovery of each sugar was expressed as a percentage of the 
intake. The lactulose/rhamnose ratio (L/R) was used as an index of intestinal permeability or 
integrity with a L/R ratio of 0.02 or less being considered normal. 
Statistical analysis
SPSS for windows software (Release 12.1) was used for statistical analysis. All results are expressed 
as the mean with 95% CI. One-way analysis of variance (ANOVA) was used to analyse changes 
in the concentrations of CRP, IL-8, LBP and citrulline, sugar test recoveries, L/R ratio, ANC and 
maximum daily temperature, respectively. CRP was measured daily but only those samples taken 
on or within a day of SPT being performed were used. Student’s t test was done to investigate 
differences with respect to baseline values. The correlation between the citrulline concentration, 
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urinary recovery of sugars and the L/R ratio was estimated using Pearson’s procedure. A p-value 
<0.05 was considered statistically significant. 
Results
Mucosal barrier injury
Oral mucositis (DMS) was present for the first 3 weeks after transplant and showed a clear peak 
1 week after transplant (Figure 1) coinciding with the nadir of citrulline concentrations. (Figure 2) 
Citrulline concentrations and the recovery of D-xylose, L-rhamnose and 3-O-methylglucose but 
not lactulose, were significantly decreased on the day of transplant as compared to the baseline 
values that is, 12 days after starting myeloablative therapy (p<0.0001). (Table 1) The L/R ratio at 
baseline was lower than found in normal persons but was significantly increased on the day of 
transplant (p < 0.0001) with respect to that baseline. (Figure 3)
Table 1 Mean [95% CI] of oral mucositis (DMS), citrulline concentrations, urinary sugar recovery of D-
xylose, L-rhamnose, 3-O-methylglucose and lactulose in percentage and lactulose/rhamnose 
(L/R) ratio of 32 HSCT recipients after myeloablative therapy
HSCT days N DMS N Citrulline N D-xylose
-12 32 0.0 [0.0-0.1] 25 31.8 [28.2-35.3] 31 20.8 [17.0-24.6]
-6 25 0.4 [0.0-0.8] 27 25.7 [21.7-35.3] 29 20.0 [16.3-23.8]
0 30 4.5 [3.4-5.7]* 27 15.1 [12.8-17.4]* 24 12.6 [9.3-16.0] *
+7 31 9.1 [7.3-10.8]* 26 9.9 [7.9-11.8]* 14 9.8 [6.0-13.6] *
+14 26 4.3 [3.1-5.6]* 20 14.1 [11.2-16.9]* 16 5.6 [2.4-8.9] *
+21 18 2.9 [0.7-5.0]* 16 14.5 [12.2-16.8]* 10 7.5 [2.8-12.2] *
HSCT days L-rhamnose 3-OMG Lactulose L/R ratio
-12 7.8 [6.1-9.4] 33.0 [26.8-39.3] 0.3 [0.2-0.4] 0.04 [0.04-0.05]
-6 8.1 [6.5-9.8] 32.9 [27.0-38.7] 0.3 [0.2-0.4] 0.04 [0.03-0.06]
0 4.3 [3.3-5.2] * 22.0 [16.1-27.8] * 0.3 [0.3-0.4] 0.10 [0.06-0.14]*
+7 2.6 [1.0-4.2] * 26.2 [17.8-34.6] 0.4 [0.2-0.6] 0.18 [0.14-0.22]*
+14 1.1 [0.5-1.7] * 14.8 [4.4-25.2] * 0.2 [0.1-0.2] * 0.20 [0.11-0.30]*
+21 1.7 [0.8-2.6] * 18.1 [5.3-30.9] * 0.2 [0.1-0.4] 0.26 [0.01-0.51]*
* Significantly different with respect to baseline
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Figure 1 Pattern of daily oral mucositis score 
after myeloablative therapy. DMS was 
significantly higher for patients given 
myeloablative therapy at transplant day 
and reached their peak 1 week later.
Figure 2 Pattern of citrullline after myeloablative 
therapy. Citrulline concentrations 
gradually declined after 1 week of 
starting myeloablative therapy and were 
significantly lower at transplant day but 
reached their nadir 1 week later.
Figure 3 Pattern of lactulose/rhamnose ratio after myeloablative therapy. The lactulose/rhamnose ratio 
was increased at baseline with respect to the values for normal volunteers and was significantly 
increased by the second week after starting myeloablative therapy. The ratios were still 
abnormal before discharge.
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Inflammatory response
CRP, IL-8 and LBP concentrations were significantly increased by the day of transplant and their 
peak occurred 1 week later (Table 2 and Figure 4) when patients were profoundly neutropenic. 
The maximum temperature followed the same pattern with the highest mean value (38.2 °C) 
occurring 1 week after transplant. The administration of glutamine-dipeptide had no influence 
on IL-8 or LBP concentrations (data not shown). However CRP concentrations were significantly 
lower on HSCT day +21 for those patients receiving glutamine (34 versus 74, p = 0.003). CRP 
concentrations were significantly correlated respectively with those of LBP, r = 0.85, IL-8, r = 0.62, 
L/R ratio, r = 0.46 and citrulline, r = -0.43.
Table 2 Mean [95% CI] of C-reactive protein (CRP), interleukin-8 (Il-8), LPS-binding protein (LBP) in 32 
HSCT recipients after myeloablative therapy
HSCT days N CRP N IL-8 N LBP
-12 32 14.8 [8.9-20.6] 27 12.8 [1.2-24.3] 20 18.1 [14.1-22.1]
-6 72 14.0 [10.1-17.9] 29 14.5 [3.7-25.2] 24 16.9 [14.0-19.9]
0 48 47.9 [36.8-59.1]* 28 49.0 [30.5-67.4]* 21 27.1 [23.2-31.0]*
+7 46 154.1 [126.8-181.4]* 27 211.2 [86.0-336.3]* 18 53.8 [43.0-64.7]*
+14 39 87.8 [60.2-115.4]* 23 44.2 [12.3-76.1]* 16 36.4 [25.1-47.6]*
+21 44 53.3 [39.0-67.7]* 15 19.7 [13.0-26.4] 10 27.0 [17.6-36.4]
* Significantly different with respect to baseline
OVS bacteraemia
All except one patient developed fever during neutropenia and were treated empirically with a 
cephalosporin. Eleven patients had bacteraemia due to OVS occurring on HSCT days +1 till +8. 
Mean concentrations of CRP, IL-8 and LBP measured on HSCT day 0 were already significantly 
increased before the onset of OVS bacteraemia and MBI was manifest as measured by low 
citrulline concentrations, perturbed gut integrity and increased DMS. There were no significantly 
different results on HSCT day 0 or at baseline for patients who developed OVS bacteraemia. 
(data not shown) 
Gram-negative bacilli
Acinetobacter baumanii was recovered from a single aerobic blood culture from one patient on 
day +1 after transplant but no other Gram-negative bacilli were recovered from blood cultures or 
surveillance specimens of any other patient during the study period.
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Figure 4 Pattern of C-reactive protein, interleukin-8, LPS-binding protein after myeloablative therapy
Concentrations of CRP, IL-8 and LBP showed the similar pattern and were significantly 
increased at transplant day and reached their peak 1 week later.
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Discussion
MBI measured by DMS, citrulline and SPT followed a clear pattern beginning 13 days after starting 
myeloablative therapy and reached a peak 1 week later as did the levels of CRP, IL-8 and LBP. 
These markers of inflammation therefore appear to reflect the burden of gut mucosal damage. 
A similar pattern of elevated markers of inflammation has been noted before in the first 2 weeks 
after transplant. The CRP, IL-8 and LBP concentrations reached a peak 20 days after therapy 
that is, 1 week after transplant. This might be a result of endothelial cells or surviving immune 
effector cells responding to invading bacteria [14]. However, only eleven patients developed OVS 
bacteraemia and though CRP, IL-8 and LBP concentrations were already increased before the 
onset of OVS bacteraemia they were not different from those of patients who did not develop 
bacteraemia. Markedly elevated LBP and CRP levels were also found 1 week after transplant 
among paediatric HSCT recipients and endotoxaemia, though not bacteraemia, occurred in four 
out of the 14 patients on the day of transplant [15]. The authors postulated that LBP and CRP were 
predominantly produced by the liver in response to LPS. Although we did not test for endotoxin 
in our patients, it seems unlikely that any occurred since all patients had received ciprofloxacin 
as prophylaxis, Gram-negative bacilli were only recovered once from the blood cultures of one 
patients but not from any surveillance samples. These results suggest that bacteria do not trigger 
the inflammatory response but rather that MBI initiates the process. Indeed the release of pro-
inflammatory cytokines has been shown in rats given 5-FU to be associated with evolving MBI 
and to precede microbial translocation [16]. Moreover, translocation of microorganisms from the 
lumen of the gut is thought to be promoted when the integrity of the mucosal barrier is impaired 
by anticancer therapy [17]. Similar bacteria as those recovered from blood also have been shown 
to be already present in the gut lumen at start of chemotherapy well before bacteraemia occurs 
signifying that their is necessary but not sufficient to lead to bacteraemia but that perturbations 
of the mucosal barrier are a necessary prerequisite [18]. 
It therefore seems that MBI triggers directly an inflammatory response that precedes the 
occurrence of bacteraemia and that bacteria play little, if any, role. Consequently, preventing 
or restoring damage to the mucosal barrier may provide a more effective means of preventing 
bacteraemia after transplant than antimicrobial prophylaxis. 
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Summary
This review explores the role, if any, of the microbial commensal flora in the pathophysiology 
of the “mucosal barrier injury” induced by chemotherapy. Mucosal barrier injury (MBI) extends 
beyond oral mucositis to involve the entire digestive tract and is more than just a risk factor for 
severe infectious complications; it is a manifestation of the collapse of the relationship between 
the host and the endogenous microbial flora. Epithelial cells are an integral component of the 
anatomical and immunological mucosal barrier functioning as the front line of host defence 
against microorganisms. Clarification of how these cells recognise and interact with the microbial 
flora is critical for understanding the process of mucosal barrier injury and necessary for managing 
those patients at the greatest risk of developing MBI and the related infectious complications. 
Introduction
Historically, the stomatotoxicity or oral mucositis induced by anticancer therapy was simply attributed 
to direct impairment of the proliferation of epithelial cells resulting in ulceration. Colonisation of the 
affected area by bacteria then exacerbated the mucositis. The subsequent disruption of the mucosal 
surfaces together with evolving neutropenia then opened the door to opportunistic infection which 
was often life-threatening [1]. A new model was proposed by Sonis describing four successive phases 
of oral mucositis (Figure 1) – an inflammatory (connective tissue) phase followed by an epithelial 
phase, an ulcerative/infective phase and finally a healing phase [2]. 
It was also postulated that bacterial colonisation of ulcerated surfaces up-regulated the pro-
inflammatory cytokine response and lead directly to systemic infection. Since infection was 
thought to play an important role in the pathophysiology of mucositis it seemed reasonable to 
employ antimicrobial agents for prevention and treatment of oral mucositis but this proved futile 
[3]. The model of Sonis restricts itself to the oral cavity and microorganisms are not involved in 
the first phase of pro-inflammatory cytokine release. To better understand the role, if any, of the 
microflora in causing mucosal damage, it is necessary to postulate that “mucosal barrier injury” 
(MBI) affects the entire digestive tract. Particularly at the level of epithelial cells, as they are an 
integral component of the anatomical and immunological mucosal barrier. This barrier functions 
as the front line of host defence against microorganisms [4]. Intestinal epithelial cells are the key 
players in the innate immune response (Figure 2) and therefore, it is important to clarify how 
epithelial cells recognise and interact with the microflora as this is critical for understanding the 
process of MBI. 
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Figure 1 The four phases of mucosal barrier injury. Mucosal barrier injury occurs in four phases. The 
first phase is the inflammatory phase and is characterised by the induction of pro-inflammatory 
cytokines by anti-cancer therapy while the epithelial cells are still intact. The second phase is 
the epithelial phase when cells cease dividing and go into apoptosis. This phase coincides with 
neutropenia. The third phase is when necrosis and ulcerations occur and when the endogenous 
microbial flora and their products might translocate. The final phase is when healing takes place. 
 
 
Figure 2 Cross-talk between epithelial cells and microflora. The mucosal surface is the frontier where 
the commensal microbial flora and their products first encounter the innate immune response. 
Epithelial cells play an active role in protecting the host against invaders either by secretion of 
defensins (Paneth cells), mucins (Goblet cells) or by upregulating HLA-class II molecules and 
Toll-like receptors. Microbial products are sensed by NOD proteins after internalisation and then 
NF-κB is activated resulting in the secretion of various immunomodulating cytokines in the 
submucosal tissue. 
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Clinical features of MBI
Oral MBI
Each regimen used for anti-cancer treatment is associated with varying degrees of mucosal damage 
though oral mucositis is reported to affect predominantly haematopoietic stem cell transplant 
(HSCT) recipients who have received myeloablative regimens [5]. In general, oral mucositis is 
characterised by functional complaints such as pain and difficulty in swallowing (dysphagia) 
and anatomic changes such as oedema, erythema, ulceration, pseudomembrane formation, and 
alterations in mucus consistency with changes in saliva production (xerostomia). When severe 
or protracted, oral mucositis prevents the patient from eating and drinking normally, which is 
frequently managed by giving parenteral nutrition. Irrespective of the scoring system used, oral 
mucositis is known to begin around a week after starting conditioning and to worsen until a 
peak is reached after which resolution takes place. Risk factors for oral mucositis have not been 
systematically explored but salivary function and the status of oral health and hygiene are thought 
to be important. The composition of the oral microflora has also been highlighted though neither 
antiseptic mouth rinses, including chlorhexidine nor oral decontamination were more effective 
in reducing mucositis, pain or oral infection than good systematic oral hygiene [6]. A multivariate 
analysis to identify risk factors found that the conditioning regimen was the only independent risk 
factor for oral mucositis [7]. Moreover, certain chemotherapeutic agents such as etoposide and 
methotrexate may also be secreted in the saliva thereby intensifying oral mucositis [8].
Gut MBI 
There are no reliable data on the incidence of gut MBI although symptoms of bowel upset including 
nausea, vomiting, diarrhoea and abdominal complaints affect almost every patient immediately 
following treatment with high-dose chemotherapy. These symptoms are often difficult to ascertain 
because many patients receive anti-emetics to manage nausea and vomiting and narcotic 
analgesics to relieve the pain associated with oral mucositis. Alterations in permeability and loss 
of epithelial surface are the principle features of gut MBI but symptoms of gut toxicity correlate 
poorly [9]. Permeability tests involve ingesting sugars and detecting their presence either in blood 
or urine. In general, permeability increases within a week after initiating myeloablative therapy 
and continues to increase for another 10 days or so when it reaches a plateau which persists for 
a further 3 weeks [9]. Although permeability tests are non-specific in measuring differences in 
integrity and absorptive capacity, they can determine the onset of disruption and dysfunction of 
the mucosal barrier of the small intestines [10]. The lactulose/rhamnose ratio will be higher after 
high-dose chemotherapy due to an increase in lactulose absorption reflecting opening of the 
tight junctions, which are the dynamic structures between epithelial cells that exert control over 
the paracellular flow of solutes and a decrease in rhamnose absorption which reflects a loss of 
surface area of the gut epithelium [11]. Serum citrulline concentrations can also be used to explore 
the relationship between gut MBI and post-transplant complications since citrulline is a reliable 
biochemical marker of small bowel enterocyte mass in humans [12].
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Pathophysiology of MBI – current thinking     
Activation of a number of transcription factors mostly by reactive oxygen species is the hallmark 
of the initiation phase of MBI in response to chemotherapy and irradiation [13]. The activation of 
the transcription factor, nuclear factor-kappa B (NF-κB) leads to the up-regulation of many genes 
resulting in the production of the pro-inflammatory cytokines, TNF-α, IL-1 and IL-6. Most NF-κB 
activation takes place in epithelial cells together with resident intra-epithelial lymphocytes and 
macrophages, located in the extensive gastrointestinal–associated lymphoid tissue (GALT) [14]. 
Gut epithelial cells subsequently secrete pro-inflammatory cytokines and chemokines and up-
regulate MHC class II molecules and adhesion molecules [15]. Local matrix metalloproteinases are 
then activated by the pro-inflammatory cytokines and cleave extracellular-matrix substrates such 
as collagen and fibronectin [16]. 
At the same time, clonogenic stem cells in the crypts die according to the hierarchical 
distribution of mitotic activity [17]. Epithelial cellular apoptosis results in crypt hypoplasia and 
villous atrophy [18]. The apoptosis rate is higher in the small intestine than in the large intestine 
probably because of the higher ratio of pro-apoptotic genes to anti-apoptotic genes of the bcl-2 
family reflecting the role of the small intestine in neutralising potential toxins [17]. The evolving 
breaches in the physical barrier enable microorganisms to translocate more easily [19]. Bacteria 
and their cell wall products peptidoglycan and lipopolysacharide (LPS) can subsequently activate 
tissue macrophages to produce more pro-inflammatory cytokines to amplify local tissue damage 
[13].
The interaction between damaged epithelial cells and colonising microflora is clearly complex 
and will be discussed in detail below. The functional capacities of intestinal epithelial cells with 
respect to local defences are affected differently by chemotherapy with goblet and Paneth cells 
being spared relative to enterocytes [20]. mRNA expression of the goblet cell markers mucin 
(MUC2) and trefoil factor-3 (TFF3) is decreased following methotrexate treatment though the 
protein levels are maintained. TFF3 improves epithelial cell viability and promotes cell migration 
and wound repair after damage. Consequently it plays an important role in restoring the mucosal 
barrier and in remodelling the extracellular-matrix by diverse metalloproteinases that degrade 
inflammation and repair the tissues [16]. 
Paneth cells located throughout the intestines normally produce crypt defensins and peptides 
such as lysozyme to enhance innate mucosal immunity. It has been shown that production of 
lysozyme was increased after treatment with methotrexate [20]. The functional capacities of 
enterocytes located in the epithelium covering the area of Peyer’s patches are preserved [21]. 
However, goblet cell number and TFF3 promotor activity are markedly decreased after increasing 
the dose of methotrexate or after irradiation therapy [22]. Various other cytokines such as glucagon-
like peptide-2 (GLP-2), transforming growth factor-β (TGF-β) and keratinocyte growth factor 
contribute to the healing process and down regulate inflammation with KGF probably playing a 
key role as it exhibits a clear cytoprotective effect possibly via induction of TFF3 [4].
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The role of the microbial flora in the normal host
The development of a stable microbial ecosystem, comprising some 400 different species, in 
the adult gut, is a slow process that takes several years from birth to evolve. Once this microbial 
ecosystem is established, it remains remarkably constant throughout life [23]. The number of 
viable bacteria normally increases from 103 colony forming units/gram food mass (cfu/g) in 
the stomach and duodenum to 107 cfu/g in the ileum and 1012 cfu/g in the large bowel content. 
However, the composition of the microflora within the lumen differs from that found on the 
mucosal surfaces. The interaction between the microorganisms and host takes place along 
the large mucosal surface of the gut, which is estimated to be 400 M2. The microflora provide 
regulatory signals that are necessary for the development and function of epithelial cells and 
subepithelial structures [24]. In addition, colonisation with bacterial flora is critical for the immune 
system in fine-tuning the T-cell repertoire and cytokine profiles. The normal commensal bacteria 
are even considered crucial for building the architecture of the intestine [25]. Bacterial adhesion 
occurs first at the sites of mucin production in a mucous layer covering the entrance of the 
villi but not inside the crypts themselves. Contact between bacteria and the epithelial-binding 
sites creates a state of controlled physiological inflammation [26]. The purpose of a controlled 
physiological inflammation, is to contain the commensal flora and eliminate pathogens that could 
cause infection. The induction of this response may be dependent of the morphological state of 
the microorganisms. For example, Candida albicans transformation into true hyphae promotes 
its interaction with the epithelium and elicits a strong response [27]. The discrimination between 
microorganisms is in part mediated by the Toll-like pattern recognition receptors expressed 
on the apical surfaces of intestinal epithelial cells with TLR2 recognising and triggering a host 
response to the lipoproteins and peptidoglycans of Gram-positive bacteria and the zymosan of 
yeast, and TLR4 mediating the response to the LPS emanating from Gram-negative bacteria [28]. 
The enterocytes can also transport soluble microbial antigens thereby functioning as sensors of 
the luminal environment [29]. The microbial sensing proteins NOD1 and NOD2 (nucleotide-binding 
oligomerization domain 2) detect intracellular microbial products though NOD2 recognises the 
specific peptidoglycan motif muramyldipeptide (MDP) [30]. Activation of epithelial NF-κB after 
TLR signalling or activated NOD2 is probably a central regulator of the evolving innate immune 
response against pathogens resulting in secretion of the chemokines IL-8, IL-6 and LBP [31]. The 
commensal flora normally attenuates the pro-inflammatory response and induces a distinctive 
form of tolerance by blocking degradation of IκB the inhibitor of the NF-κB [31]. This results in 
continuous low grade inflammation with an almost complete absence of inflammatory effector 
cells [32]. Hence, the “no NF-KB activation” state of the gut epithelial cells that is maintained by 
commensal bacteria needs to be overridden for an immune response against pathogenic bacteria 
to be mounted. This network of interactions in the line of host defences includes activated 
mucosal T- and B-cells, M cells in Peyer’s patches, intraepithelial lymphocytes and dendritic 
cells, which together with the neutrophils make up GALT under normal circumstances [24]. The 
administration of anticancer therapy changes this. 
144
_____  Chapter 10  ____________________________________________________________________________________________________________ _____________________________________________________________  Mucosal Barrier Injury paradigm of dysregulation  _____ 
145
The role of the microbial flora in MBI – a hypothesis
When treatment of patients with haematological malignancies was intensified some 20 years 
ago, bacteraemia during neutropenia was predominantly due to the Gram-negative facultative 
anaerobes of the enteric bacteria especially Escherichia coli and Klebsiella pneumonia and the 
strict aerobe Pseudomonas aeruginosa [33]. Prophylaxis at the start of anticancer treatment with 
the nonabsorbable antibiotic regimens such as neomycin and polymyxin or the absorbable 
regimens of co-trimoxazole (trimethoprim-sulfamethoxazole) and colistin or a fluoroquinolone 
resulted in fewer episodes of Gram-negative bacteraemia [34]. Their use also lead to a shift towards 
infections due to the more resistant Gram-positive bacteria mainly viridans streptococci and 
coagulase negative staphylococci [35] which now account for 3 of every 4 bacteraemic episodes 
among patients with haematological malignancies (SCOPE project) [36]. The use of H
2
-receptor 
antagonists and proton-pump inhibitors to manage the dyspepsia associated with MBI, 
further encourages colonisation of the upper digestive tract with these Gram-positive bacteria 
[37]. Bacterial overgrowth is then enhanced by gastroparesis and delayed bowel emptying due 
impairment of the autonomic nerves induced by the anticancer treatment [38]. Under stress, 
epithelial cells perceive innocuous bacteria as a threat and up-regulate IL-8 production [39]. 
Barrier function is subsequently altered after bacterial exposure and permeability is increased 
by opening of the tight-junctions via a zonulin (ZO-1)-driven pathway in an attempt to flush out 
the intruders [40]. Recently it has been shown that TLR2 signalling, via protein kinase C activation, 
relocates ZO-1 in such a way that tight junction modelling is increased resulting in improved 
integrity [41]. Lactobacilli and bifidobacteria normally stimulate epithelial cells to produce mucin to 
prevent foreign bacteria from adhering but this process is abrogated following chemotherapy [42]. 
Indeed, bacterial adherence is increased after the administration of anticancer therapy, possibly 
because receptor sites in the mucous layer or the apical membranes of epithelial cells have been 
altered [43,44]. Consequently the state of controlled physiological inflammation is deregulated 
and tolerance to luminal commensals is lost. The deregulation or inability to block the pro-
inflammatory response through the degradation of IκB by epithelial cells is probably crucial since 
NF-κB activation by MBI is protracted. The resultant pro-inflammatory response is therefore 
stimulated by exposure to both cytotoxic therapy and to microorganisms. (Figure 3) 
Mucosal integrity is then dramatically diminished by the overwhelming inflammatory response. 
Ultimately, epithelial cells undergo apoptosis and are shed into the gut lumen. Under normal 
circumstances translocation of indigenous bacteria from the lumen to the tissues occurs low rate 
but is increased when the mucosal barrier is disrupted [45]. Obligate anaerobes and Gram-positive 
bacteria appear to be less efficient translocators than Gram-negative bacteria but in theory, any 
member of the normal commensals can translocate when conditions allow. The remnants of the 
adaptive and innate immune system will attempt to respond to the invading microorganisms to 
prevent them from entering the submucosal connective tissue and blood or lymph circulation. 
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Figure 3 Model for inducing mucosal barrier injury. Both cytoreductive therapy and the microbial flora 
activate the transcription factor, NF-κB in epithelial cells resulting in an ongoing inflammatory 
response aggravating MBI.
Infectious complications of MBI
Damaged mucosa increases the risk of infections and mortality especially among transplant 
recipients [46]. The duration of fever, parenteral narcotic use, total parenteral nutrition, antibiotic 
therapy and the total number of days in hospital correlate directly with the extent and severity 
of MBI. Gram-positive bacteraemia due to oral viridans streptococci (OVS) is related to MBI of 
the upper part of the digestive tract, whilst neutropenic enterocolitis is related to the lower part 
of the digestive tract. Gram-negative bacillary infections and those due to coagulase-negative 
staphylococci (CoNS) can be related to MBI at any site. Recipients of autologous HSCT with 
oral ulcerative mucositis were found to be 3 times more likely to develop OVS bacteraemia than 
those without mucositis [47]. The viridans species S. mitis and S. oralis are associated with more 
serious complications such as sepsis and adult respiratory distress syndrome which carries 
a high mortality (80%) [48]. Coagulase-negative staphylococci (CoNS) were the most frequent 
isolates in the SCOPE project [36] and though bacteraemia is frequently related to the use of 
central venous catheters, mucosal sites are also an important source of these bacteria [49]. MBI is 
clearly a risk factor for bacteraemia due to Acinetobacter species, Stenotrophomonas maltophilia 
and Capnocytophaga species [50,51]. Despite adequate empirical antibiotic therapy, Gram-negative 
bacillary bacteraemia due to Escherichia coli, Klebsiella species and Pseudomonas aeruginosa are 
still associated with the highest mortality amongst HSCT recipients [52]. Anaerobic bacteria are 
rarely involved though MBI is an independent predictor of bacteraemia due to Fusobacterium 
nucleatum [53]. Bacteraemia with different species including Staphylococcus aureus, Pseudomonas 
aeruginosa, Clostridium species and Candida species is associated with neutropenic enterocolitis 
  
  
  
 
  
  
146
_____  Chapter 10  ____________________________________________________________________________________________________________ _____________________________________________________________  Mucosal Barrier Injury paradigm of dysregulation  _____ 
147
(typhlitis), which is considered to be an extreme manifestation of MBI. This appears to be the 
result of the delicate balance between host and microflora being totally disturbed in the setting 
of prolonged exposure to antibiotics resulting in selection of particularly Clostridium species 
[54]. Indeed the occurrence of bacteraemia due to one of these species, Clostridium tertium, is 
considered pathognomonic for neutropenic enterocolitis [55]. This phenomenon is also illustrated 
by Candida species that normally colonise the mucosal surfaces without harming the host but 
which can be invasive when MBI is apparent [56]. These observations support the contention that 
MBI provides a portal of entry to the systemic circulation by commensal flora of the oral cavity 
and gastrointestinal tract. 
Summarising discussion
MBI is more than a risk factor for severe infectious complications after anti-cancer treatment; 
it is a manifestation of a collapse of the relationship between the host and the endogenous 
microflora. Epithelial cells are the first to encounter the microorganisms and play a crucial 
role in the regulation of the barrier between host and lumen content. After the administration 
of chemotherapy or irradiation not only is the anatomic barrier disrupted providing a portal 
of entry to microorganisms but the state of controlled inflammation is also abrogated. The 
endogenous flora plays a role throughout the whole process of MBI by determining the pre-MBI 
inflammation state and accelerating the MBI induced pro-inflammatory response and apoptosis. 
After translocation, microorganisms trigger the systemic inflammatory response and can cause 
an infectious disease. The microflora probably also has a role in repairing the barrier. Probiotics 
(lactobacilli and bifidobacteria) and prebiotics (non-digestible food ingredients such as fructo-
oligosaccharides) appear to exert anti-inflammatory effects [24]. The role of the endogenous flora 
shifts from being of benefit to the host to causing disease to that host especially when that host 
has damaged mucous membranes. (Figure 4) 
The delicate balance between microbes and a damaged host has been termed the “damage-
response” framework in which microbial pathogenesis is the outcome. The inflammatory 
response of the host itself partially explains the degree of damaged caused [57]. MBI therefore 
represents the loss of regulation of the interaction between the host and microorganisms, which 
would explain why almost all attempts thus far to prevent or ameliorate MBI with antimicrobial 
therapy have failed. It may be more fruitful to aim at either down regulating the inflammatory 
response or at restoring the barrier by stimulating epithelial cell functioning using growth factors 
such as recombinant human keratinocyte growth factor (KGF) [58], IL-11 [59], glucagon-like peptide 
or intestinal trefoil factor to manage those patients at the greatest risk of developing MBI. Clinical 
trials with one of these agents, KGF, are currently in progress and the results are awaited with 
interest.
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Figure 4 Model for invasive infections. Cytoreductive chemotherapy induces injury to the mucosal barrier 
and antimicrobial agents alter the ecology of the commensal microbial flora leading to selection 
of opportunistic pathogens. These microorganisms adhere to the epithelial surface of the 
damaged mucosa and either translocate or establish a local infection eliciting an inflammatory 
response and hence an infectious disease process.
References 
1. Berger AM, Kilroy TJ. Adverse effects of treatment; oral complications. In: DeVita VT, Hellman S, Rosenberg SA, eds. 
Cancer; principles and practice of oncology. Philadelphia: Lippincott - Raven Publishers; 1997:2714-2725.
2. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced 
stomatotoxicity. Oral Oncol. 1998; 34:39-43.
3. Donnelly J.P., Bellm L.A., Epstein JB, Sonis S.T., Symonds RP. Antimicrobial therapy to prevent or treat oral 
mucositis. Lancet Infect Dis. 2003; 3:405-412.
4. Blijlevens NMA., Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and 
consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant. 2000; 
25:1269-1278.
5. Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK. Clinical assessment scale for the rating of oral 
mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer. 
1992; 69:2469-2477.
6. Cheng K.K, Molassiotis, A., Chang A.M., Cheung S.S. Evaluation of an oral care protocol intervention in the 
prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. Eur J Cancer. 2001; 37:2056-
2063.
7. Wardley AM, Jayson GC, Swindell R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative 
conditioning regimens and haematopoietic progenitor rescue. Br J Haematol. 2000; 110:292-299.
8. Albertioni F, Rask C, Schroeder H, Peterson C. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva 
from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral 
mucositis. Anticancer Drugs. 1997; 8:119-124.
9. Blijlevens N.M.A., van’t Land B., Donnelly JP, M’Rabet L., DePauw BE. Measuring mucosal damage induced by 
cytotoxic therapy. Support Care Cancer. 2004; 12:227-233.
148
_____  Chapter 10  ____________________________________________________________________________________________________________ _____________________________________________________________  Mucosal Barrier Injury paradigm of dysregulation  _____ 
149
10. Blijlevens N.M.A., Donnelly J.P., dePauw B.E. Prospective evaluation of gut mucosal barrier injury following various 
myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplant. 2005; 35:707-711
11. Keefe DM, Cummins AG, Dale BM et al. Effect of high-dose chemotherapy on intestinal permeability in humans. 
Clin Sci Colch. 1997; 92:385-389.
12. Blijlevens N.M.A., Lutgens L.C.H.W., Schattenberg A.V.M.B.., De Pauw B.E. Citrulline: a potentially simple 
quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant. 2004; 
34:193-196.
13. Sonis S.T., Elting L.S., Keefe DM et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, 
measurement, epidemiology, and consequences for patients. Cancer. 2004; 100:1995-2025.
14. van’t Land B., Blijlevens N.M.A., \marteijn J et al. Role of curcumin and the inhibition of NF-kappaB in the onset of 
chemotherapy induced mucosal barrier injury. Leukemia. 2004; 18:276-284.
15. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-
cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute 
and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood. 1994; 83:2360-2367.
16. Parks W.C., Wilson C.L., Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate 
immunity. Nature Reviews Immunolgy. 2004; 4:617-629.
17. Potten C.S., Wilson J.W., Booth C. Regulation and significance of apoptosis in the stem cells of the gastrointestinal 
epithelium. Stem Cells. 1997; 15:82-93.
18. Keefe DMK, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes 
hypoplasia in crypts of the small intestine in humans. Gut. 2000; 47:632-637.
19. Berg R.D. Bacterial Translocation from the Gastrointestinal Tracts of Mice Receiving Immunosuppressive 
Chemotherapeutic Agents. Current Microbiology. 1983; 8:285-292.
20. Verburg M., Renes I.B., van Nispen D.J.P.M. et al. Specific responses in rat small intestinal epithelial mRNA 
expression and protein levels during chemotherapeutic damage and regeneration. J Histochem Cytochem. 2002; 50:
1525-1536.
21. Renes I.B., Verburg M., Bulsing N.P. et al. Protection of the Peyer’s patch-associated crypt and villus epithelium 
against methotrexate-induced damage is based on its distinct regulation of proliferation. J Pathol. 2002; 198:60-
68.
22. Beck P.L., Wong J.F., Li Y. et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by 
intestinal trefoil factor. Gastroenterology. 2004; 126:796-808.
23. Hart A.L., Stagg A.J., Frame M. et al. Review article: the role of the gut flora in health and disease and its modification 
as therapy. Aliment Pharmacol Ther. 2002; 16:1383-1303.
24. Shanahan F. The host-microbe interface within the gut. Best Practice & Research Clinical Gastroenterology. 2002; 16:
915-931.
25. Madara J. Building an intestine--architectural contributions of commensal bacteria. N Engl J Med. 2004; 351:1685-
1686.
26. Xavier R.J., Podolsky DK. How to get along--friendly microbes in a hostile world. Science. 2000; 289:1483-1484.
27. Villar CC, Kashleva H, Dongari-Bagtzoglou A. Role of Candida albicans polymorphism in interactions with oral 
epithelial cells. Oral Microbiol Immunol. 2004; 19:262-269.
28. Akira S., Takeda K. Toll-like receptor signalling. Nature Reviews Immunolgy. 2004; 4:499-511.
29. Kagnoff MF, Eckmann L. Epithelial cells as sensors for microbial infection. J Clin Invest. 1997; 100:6-10.
30. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol. 
2003; 3:371-382.
31. Neish A.S., Gewirtz A.T., Zeng H. et al. Prokaryotic regulation of epithelial responses by inhibition of IkB-a 
ubiquitination. Science. 2000; 289:1560-1563.
32. Xavier RJ, Podolsky DK. Microbiology. How to get along--friendly microbes in a hostile world. Science. 2000; 289:
1483-1484.
33. Tancrede CH, Andremont AO. Bacterial translocation and gram-negative bacteremia in patients with hematological 
malignancies. J Infect Dis. 1985; 152:99-103.
34. Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic 
patients: a meta-analysis. Clin Infect Dis. 1996; 23:795-805.
148
_____  Chapter 10  ____________________________________________________________________________________________________________ _____________________________________________________________  Mucosal Barrier Injury paradigm of dysregulation  _____ 
149
35. Sepkowitz K.A. Antibiotic prophylaxis in patients receiving hematopoietic stem cell transplant. Bone Marrow 
Transplant. 2002; 29:367-371.
36. Wisplinghoff H., seifert H., Wenzel RP, Edmond M.B. Current trends in the epidemiology of nosocomial 
bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United 
States. Clin Infect Dis. 2003; 36:1103-1110.
37. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study 
of predisposing factors. Clin Infect Dis. 1992; 14:1201-1207.
38. Hecht JR, Lembo T, Chap L. Prolonged nausea and vomiting after high dose chemotherapy and autologous 
peripheral stem cell transplantation in the treatment of high risk breast carcinoma. Cancer. 1997; 79:1698-1702.
39. Nazli A., Yang P-C., Jury J. et al. Epithelia under metabolic stress perceive commensal bacteria as a threat. Am J 
Pathol. 2004; 164:947-957.
40. El Asmar R., Panigrahi P., Bamford P. et al. Host-dependent zonulin secretion causes the impairment of the small 
intestine barrier function after bacterial exposure. Gastroenterology. 2002; 123:1607-1615.
41. Cario E., Gerken G., Podolsky DK. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity 
via protein kinase C. Gastroenterology. 2004; 127:224-238.
42. Mack D.R., Ahrne S., Hyde L., Wei S., Hollingsworth M.A. Extracellular MUC3 mucin secretion follows adherence of 
Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003; 52:827-833.
43. Sandovsky-Losica H, Segal E. Interaction of Candida albicans with murine gastrointestinal mucosa: effect of 
irradiation on adherence in vitro. Journal of medical and Veterinary Mycology. 1989; 27:345-352.
44. Sandovsky-Losica H, Segal E. Interaction of Candida albicans with murine gastrointestinal mucosa from 
methotrexate and 5-fluorouracil treated animals: in vitro adhesion and prevention. Journal of medical and Veterinary 
Mycology. 1990; 28:279-287.
45. Ellis M. Preventing microbial translocation in haematological malignancy. British Journal of Haematology. 2004; 125:
282-293.
46. Sonis ST, Oster G, Fuchs H et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-
cell transplantation. J Clin Oncol. 2001; 19:2201-2205.
47. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal 
infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 
1998; 82:2275-2281.
48. Marron A, Carratala J, Gonzalez-Barca E et al. Serious complications of bacteremia caused by Viridans Streptococci 
in neutropenic patients with cancer. Clin Infect Dis. 2000; 31:1126-1130.
49. Costa S.F., Miceli M.H., Anaissie EJ. Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia? 
Lancet Infect Dis. 2004; 4:278-86.
50. Labarca J.A., Leber A.L., Kern V.L. et al. Outbreak of stenotrophomonas maltophilia bacteremia in allogenic bone 
marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis. 2000; 30:195-197.
51. Martino R., Ramila E., Capdevilla J.A. et al. Bacteremia caused by Capnocytophaga species in patients with 
neutropenia and cancer: results of a multicenter study. Clin Infect Dis. 2001; 33:e20-e22.
52. Collin B.A., Leather H.L., Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream 
isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001; 33:947-953.
53. Lark R.L., McNeil S.A., VanderHyde K. et al. Risk factors for anaerobic bloodstream infections in bone marrow 
transplant recipients. Clin Infect Dis. 2001; 33:338-343.
54. Gomez L, Martino R, Rolston KV. Neutropenic Enterocolitis: Spectrum of the Disease and Comparison of Definite 
and Possible Cases. Clin Infect Dis. 1998; 27:695-699.
55. Miller DL, Brazer S, Murdoch D, Reller LB, Corey GR. Significance of Clostridium tertium bacteremia in neutropenic 
and nonneutropenic patients: review of 32 cases. Clin Infect Dis. 2001; 32:975-978.
56. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis. 2001; 33:1959-1967.
57. Casadevall A., Pirofski L-A. The damage-response framework of microbial pathogenesis. Nature Reviews 
Microbiology. 2003; 1:17-24.
58. Meropol N.J., Somer R.A.Gutheil J., Pelley R.J. et al. Randomized phase 1 trial of recombinant human keratinocyte 
growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 2003; 21:1452-1458.
59. Ellis M., Zwaan F., Hedstrom U. et al. Recombinant human interleukin 11 and bacterial infection in patients with 
haemological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. 
Lancet. 2003; 361:275-280.

Summarising conclusions and recommendations
Chapter 11 
152
_____  Chapter 11  ____________________________________________________________________________________________________________ ________________________________________________________________  Summarising conclusions and recommendations  _____ 
153
152
_____  Chapter 11  ____________________________________________________________________________________________________________ ________________________________________________________________  Summarising conclusions and recommendations  _____ 
153
Summarising conclusions and recommendations
Worldwide there are more than 10 million patients being treated for cancer and this number is 
expected to continue to rise as people are living longer. Treatment with intensive chemotherapy 
alone or in combination with radiation therapy is available for a variety of different cancers. 
Unfortunately, it is often complicated by damage to the integument of the mouth and, to a 
larger extent, of the gastrointestinal (GI) tract, which results in significant morbidity and a 
lower quality of life [1]. While the severe pain of oral mucositis is often the most obvious and 
troublesome symptom of patients undergoing intensive cytotoxic therapy, gastrointestinal injury 
is more life threatening [2]. Mucosal barrier injury (MBI) as manifest in the mouth and GI tract 
of haematopoietic stem cell transplant recipients is the focus of this thesis, and a pathological 
model is presented to explain MBI, the role of activated nuclear factor-kappa B is explored, and 
the resultant release of pro-inflammatory cytokines in initiating MBI is considered. In addition, 
measuring MBI by using oral mucositis, gut toxicity, sugar permeability testing and citrulline 
levels is investigated, the role of glutamine-dipeptide in treating MBI is discussed and the 
relationship between MBI and the inflammatory response is analysed in relation to bacteraemia 
that develops after stem cell transplantation. 
In chapter 2 we concluded that mucosal barrier injury is a dynamic and complex pathobiological 
process and not solely the direct toxicological effect of blocking clonogenic cell turnover by 
cytotoxic therapy. We applied the model proposed by Sonis [3] describing four successive phases of 
oral mucositis – an inflammatory (vascular) phase followed by an epithelial phase, an ulcerative/
infective phase and finally a healing phase to the entire gastrointestinal tract which integrated 
for the first time the role of the pro-inflammatory cytokines, interleukin-1 and tumour necrosis 
factor-α released in response to cytotoxic therapy, the effects of local immunity and the role of the 
oral microbial flora. We discussed the special features of MBI to the other parts of the digestive 
tract, as there are major differences in architecture of the mucosal tissue layer functioning as the 
barrier between inner domain and outer surface of the human body. The gut associated lymphoid 
tissue (GALT) forms an integral part of lining of epithelial cells and distinguishes the gut from 
the mouth. Moreover, GALT has specific implications for transplant-related complications such 
as infections and acute Graft-versus-Host Disease. The value or otherwise of relying on the 
common manifestations of MBI of the mouth (ulcerations, redness, oedema, and pain) and gut 
(nausea, vomiting, cramping, diarrhoea and pain) were discussed. As a result, a different means 
of measuring MBI by using sugar permeability tests was proposed. MBI of HSCT recipients 
treated with myeloablative therapy normally prevents them from eating necessitating admission 
to hospital for hydration, narcotic pain medication and total parental nutrition. Insight into the 
mechanism of MBI is of paramount importance for developing approaches for preventing or 
treating MBI. Until very recently there were no pharmaceutical agents available to prevent or treat 
MBI various growth factors are becoming available for testing their possible benefit managing 
MBI effectively [4;5].
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Mucosal Barrier Injury; the initiation phase
We hypothesised that pro-inflammatory cytokines play an essential role in initiating and amplifying 
MBI after cytotoxic therapy. Gut epithelial cells secrete pro-inflammatory cytokines TNF-α, IL-1 
and IL-6 and various chemokines (IL-8 and LBP) and up-regulate MHC class II molecules and 
adhesion molecules after cytotoxic treatment [6]. The release of these pro-inflammatory cytokines 
by cytotoxic therapy is mediated by the activation of the transcription factor, nuclear factor-kappa 
B (NF-κB). Cellular apoptosis is the net result depending of magnitude of damaged cellular 
DNA. Inhibiting NF-κB activation therefore could limit the initiation and amplification of MBI 
though NF-κB activation also seems essential for epithelial cell proliferation and survival. In 
chapter 3, we showed that NF-κB was activated in IEC-6 cells exposed to cytarabine (Ara-C) 
and methotrexate (MTX) resulting in induction of TNF-α and Monocyte Chemoattractant 
Protein-1 (MCP-1). Similar findings were noted after treating rats with methotrexate. Although 
NF-κB inhibition increased the susceptibility of IEC-6 cells to Ara-C and enhanced MTX induced 
apoptosis despite the addition of CAPE, Inhibition of NF-κB by curcumin after MTX treatment 
resulted only in partial amelioration of villous atrophy in the small intestine. This might provide 
a new approach to preventing MBI while maintaining the anti-tumour effect of cytotoxic therapy.
Mucosal Barrier Injury measured after cytotoxic therapy
Oral mucositis is easy to recognise whereas detection of intestinal mucosal injury relies essentially 
on non-specific symptoms such as nausea, vomiting, diarrhoea and abdominal cramps which 
affect almost every HSCT recipient. An alternative means of recognising gut mucosal barrier 
injury is required if it is to be better understood and managed. The small intestine is responsible 
for the digestion and absorption of nutrients and can be divided into three segments: the 
duodenum nearest to the stomach, the jejunum further along and the ileum at the lower part 
adjacent to the large intestine. The functional absorption surface of the intestinal epithelium 
consists of microvilli at the surface of the intestinal cells. The integrity of the epithelial barrier 
is maintained by a tightly regulated system of occluding tight junctions providing an important 
physical barrier that ensures selective absorption by the enterocytes. The absorption surface is 
diminished after cytotoxic therapy resulting in villous and crypt atrophy, crypt loss and loosening 
of the tight junctions resulting in disruption of the barrier. Mucosal barrier function of the gut 
can be measured by sugar permeability tests as these are generally accepted as a surrogate 
marker of gut damage in patients treated for cancer [7]. In chapter 4 we used a multi-sugar probe 
consisting of four different sugars each measuring different aspects of intestinal transport 
and permeability. D-xylose permeates by means of a passive carrier whereas 3-O-methyl-D-
glucose is actively transported across the epithelial layer. Non-mediated absorption capacity is 
measured using L-rhamnose while lactulose is not normally transported when tight junctions are 
functioning normally. The advantage of using different probes simultaneously is that extraneous 
factors will affect the individual probes equally allowing the urinary excretion ratios to function 
as an index of intestinal permeability and transport capacity. In particular, the ratio of lactulose/
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rhamnose (L/R) can be used as an index of gut integrity. We measured MBI of 18 patients treated 
with chemotherapy for the first time for AML/MDS and 56 HSCT recipients who had received 
myeloablative therapy with idarubicin, cyclophosphamide and total body irradiation using the 
sugar permeability test (SPT), daily mucositis score and gut toxicity. Oral mucositis and, to a 
lesser extent, gut toxicity were significantly correlated with abnormal permeability testing and 
each measured different features of MBI thereby complementing one another. Gut integrity 
was already disturbed in the patients with AML/MDS before starting treatment and so might 
be related to untreated disease. The L/R ratio was abnormal in HSCT recipients before starting 
myeloablative therapy and remained markedly perturbed for a month after transplant. 
Mucosal Barrier Injury following various myeloablative regimens for stem cell 
transplant
We applied the same approach in chapter 5 to measuring MBI among 129 recipients of an 
allogeneic or autologous HSCT who had been given different myeloablative regimens. We scored 
oral mucositis, gut toxicity and measured gut integrity using the lactulose/rhamnose ratio and 
gut absorption using the ratios of rhamnose/3-O-methylglucose and xylose/3-O-methylglucose. 
Regimens that did not contain idarubicin induced oral mucositis and perturbed gut integrity and 
absorption earlier than did those containing the anthracycline. By contrast, regimens containing 
idarubicin induced more severe and prolonged oral and gut MBI. The gut integrity and absorption 
of most patients were still abnormal at discharge around 3 to 4 weeks after the transplant. These 
results confirm that the integrity and absorptive capacity of the gut is affected adversely by 
myeloablative regimens in general although only two patterns of mucosal injury were apparent 
depending on whether or not idarubicin was used.
Mucosal Barrier Injury measured by citrulline
Sugar permeability tests are non-invasive tests detecting alterations in permeability and loss 
of epithelial surface that are features of gut MBI. However, they are cumbersome and wholly 
dependent on patient compliance. A marker of intestinal injury that could be determined in blood 
would be ideal but none has been described so far. Citrulline might prove valuable in this regard 
since serum concentrations have been shown to be a reliable biochemical marker of small bowel 
enterocyte mass in humans with villous-atrophy associated diseases [8] and a similar picture of 
villus atrophy and loss of enterocytes is seen after high-dose chemotherapy used to prepare 
patients to receive an HSCT [9]. We had determined the amino-acid profiles in the serum of a 
cohort of 32 HSCT recipients and were able to relate the concentrations of each one temporally 
with oral mucositis, gut toxicity and sugar permeability tests (SPT). In chapter 6 we noted a 
significant decline in the serum concentrations of citrulline during the first three weeks after 
transplant when patients had oral mucositis, a markedly disturbed gut integrity (L/R ratio) and 
were most at risk of infection and other severe complications. A complete consecutive series of 
samples of 12 patients confirmed that the decline did indeed correspond with the onset of oral 
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mucositis and altered gut integrity. Therefore, citrulline may prove a useful marker of intestinal 
mucosal damage induced by chemotherapy allowing the relationship between gut mucosal 
damage and post-transplant complications, including infections, to be explored more readily.
Mucosal Barrier Injury: comparison of sugar permeability testing and citrulline
To confirm the characteristics of serum citrulline concentration we analysed serum citrulline 
concentration using archival serum samples of 10 recipients of an allogeneic HSCT who 
participated in a pharmacokinetic study of itraconazole and for whom the daily mucositis 
score, gut toxicity and sugar permeability had been determined. (Chapter 7) The sensitivity and 
specificity of the citrulline assay was better than those for the other tools. Maximum gut damage 
as determined by serum citrulline concentrations was observed 1-2 weeks earlier than was 
the case for sugar permeability test. Similarly, rising serum citrulline concentrations indicated 
recovery of gut damage 3 weeks after transplant whereas most sugar permeability tests were still 
abnormal. Serum citrulline assay might be the first choice for objectively and simply measuring 
and monitoring gut damage in routine clinical practice.
Mucosal Barrier Injury: a randomised study of parenteral given glutamine-dipeptide  
Glutamine has attracted a lot of attention because it is the primary fuel for intestinal epithelia 
and the cornerstone of protein and nucleic acid synthesis. However mucosal cells cannot 
synthesise enough glutamine themselves making the amino acid conditionally essential during 
stress such as that induced by myeloablative therapy for preparing for an HSCT. In chapter 
8 we describe the results of a conducted prospective, randomised, double-blinded, placebo-
controlled pilot study of parenteral nutrition (PN) supplemented with 0.57 g/kg glutamine-
dipeptide in a homogeneous group of 32 allogeneic HSCT recipients prepared with idarubicin, 
cyclophosphamide and TBI. The goal was to reduce post-transplant complications in general and 
MBI specifically [10]. Unfortunately, MBI measured by daily mucositis score, daily gut score, sugar 
permeability tests and serum citrulline concentrations were not reduced by glutamine-dipeptide. 
Transplant related complications such as infections and acute graft-versus-host disease were less 
common but not statistically significantly less than those seen for the placebo group, nor was 
length of hospital stay reduced or transplant related mortality lower. Only the daily gut score was 
significantly lower for the glutamine group on HSCT +7. The placebo group had a significantly 
higher CRP concentration and significantly lower citrulline and albumen on HSCT day +21. 
These results indicate that glutamine could have a possible beneficial effect when gut epithelial 
cells are beginning to recover from MBI by preventing oxidative tissue damage and improving 
the restoration of damaged tissue. So, it would still be worthwhile conducting a larger trial to 
see whether or not giving glutamine-dipeptide over a longer period might reduce the 100-day 
allogeneic transplant related complications.
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Mucosal Barrier Injury and inflammatory response in relation to bacteraemia
Anticancer therapy activates nuclear transcription factor NF-κB resulting in the production and 
release of pro-inflammatory cytokines (TNF-α, IL-1α, IL-6, IL-8 and LPS-Binding Protein) but 
also blocks clonogenic epithelial stem cell renewal resulting in apoptosis and necrosis which 
manifests itself as epithelial atrophy and ulcerative lesions [11-14]. The latter potentially offer a portal 
of entry for oral viridans (alpha-haemolytic) streptococci (OVS) which are universal commensal 
residents of the oral cavity placing HSCT recipients at risk of developing OVS bacteraemia [15]. In 
chapter 9 we noted a significant increase in the markers of an inflammatory response of 32 HSCT 
recipients after myeloablative therapy namely, IL-8, LBP and CRP, mirroring the pattern of MBI as 
measured by gut integrity (L/R ratio), daily mucositis score and serum citrulline concentrations. 
The concentrations of IL-8, LBP and CRP were also already significantly elevated by the first week 
after transplant during profound neutropenia before the onset of fever or bacteraemia. These 
inflammatory response markers reached their peak when serum citrulline concentrations reached 
their nadir, the highest scores of DMS were attained and when there was significantly decreased 
gut integrity. This suggested that the degree of MBI rather than bacteraemia determines the 
intensity of the inflammatory response.
Mucosal Barrier Injury: paradigm for dysregulation of mucosal barrier and microbial 
flora
Under normal circumstances there is a continuous controlled cross talk between the microbial 
flora and the epithelial cells lining the lumen of the gut. Epithelial cells are an integral component 
of the anatomical and immunological mucosal barrier and from the front line of host defences 
against microorganisms. These cells are also the key players in the innate immune response and, 
when under stress, they up regulate the innate host response by producing IL-8 and LBP [16]. In 
chapter 10 we discussed the disturbance of the delicate balance between the damaged mucosal 
barrier and the endogenous microbial flora. We concluded that MBI is far more than just a risk 
factor for severe infectious complications after anti-cancer treatment. Indeed, the endogenous 
microbial flora determines the inflammation state before MBI ensues, accelerates the pro-
inflammatory response induced by MBI and apoptosis and might even trigger the systemic 
inflammatory response eventually leading to an infectious disease. The endogenous microbial 
flora also has a role in repairing the same barrier [17]. This delicate balance between microbes and 
the damaged host has been termed the “damage-response” framework [18] in which microbial 
pathogenesis is the outcome of the interaction between a damaged host and his microbial flora. 
This model seems appropriate for explaining MBI and infectious complications that occur after 
exposure to cytotoxic therapy. 
Recommendations
It is clear that MBI is a complex and dynamic pathobiological process manifested not only in 
the mouth but throughout the entire digestive tract. Moreover MBI diminishes the quality of life 
and can predispose the patient to more serious clinical complications including disseminated 
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infections and even death. Therefore it is important to assess different features of MBI by using a 
variety of instruments including a mucositis score for MBI that affects the mouth and both sugar 
permeability tests and serum citrulline for MBI of the gut. 
The inflammatory response of the host is the result of a dysregulated interaction with the 
endogenous microorganisms and plays a crucial role in the process of MBI contributing to the 
degree of damage to the mucosa caused by cytotoxic therapy. The role, if any, of microorganisms 
in augmenting the inflammatory response during MBI remains intriguing. The oral viridans 
streptococci (OVS) are a common cause of bacteraemia associated with MBI but are they 
actually pathogens or simply passengers? In other words, is OVS bacteraemia a useful marker of 
markedly disturbed mucosal barrier? Whichever is the case it may provide a useful tool for further 
exploring the relationship between the endogenous flora, MBI and the inflammatory response. 
Given the complex nature of MBI it seems an exercise in futility to attempt to circumvent MBI 
by tackling only one facet of the process. Indeed up to now, virtually all attempts to prevent or 
ameliorate MBI with antimicrobial therapy or other therapies have failed. Instead, it may be more 
fruitful to aim either at down-regulating the inflammatory response or at restoring the barrier 
by stimulating epithelial cell functioning using a growth factor such as recombinant human 
keratinocyte growth factor (KGF) [19], interleukin-11 (IL-11) [20], glucagon-like peptide or intestinal 
trefoil factor.. 
References
1.  Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al. Oral mucositis and the clinical and economic 
outcomes of hematopoietic stem-cell transplantation. J.Clin.Oncol. 2001; 19:2201-5.
2.  Rapoport AP, Miller Watelet LF, Linder T, Eberly S, Raubertas RF, Lipp J et al. Analysis of factors that correlate with 
mucositis in recipients of autologous and allogeneic stem-cell transplants. J.Clin.Oncol. 1999; 17:2446-53.
3.  Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced 
stomatotoxicity. Oral Oncol. 1998; 34:39-43.
4.  Ellis M, Zwaan F, Hedstrom U, Poynton C, Kristensen J, Jumaa P et al. Recombinant human interleukin 11 and 
bacterial infection in patients with [correction of ] haematological malignant disease undergoing chemotherapy: a 
double-blind placebo-controlled randomised trial. Lancet 2003; 361:275-80.
5.  Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al. Randomized phase I trial of recombinant 
human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J.Clin.Oncol. 2003; 
21:1452-8.
6.  Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-
cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute 
and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83:2360-7.
7.  Blijlevens NMA., Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and 
consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant. 2000; 
25:1269-78.
8.  Crenn P, Vahedi K, Lavergne-Slove A, Cynober L, Matuchansky C, Messing B. Plasma citrulline: A marker of 
enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology 2003; 124:1210-9.
9.  Keefe DMK, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes 
hypoplasia in crypts of the small intestine in humans. Gut 2000; 47:632-7.
10.  Klimberg VS,.McClellan JL. Claude H. Organ, Jr. Honorary Lectureship. Glutamine, cancer, and its therapy. 
Am.J.Surg. 1996; 172:418-24.
158
_____  Chapter 11  ____________________________________________________________________________________________________________ ________________________________________________________________  Summarising conclusions and recommendations  _____ 
159
11.  Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia 
in crypts of the small intestine in humans. Gut 2000; 47:632-7.
12.  van’t Land B, Blijlevens NM, Marteijn J, Timal S, Donnelly JP, de Witte TJ et al. Role of curcumin and the inhibition 
of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia 2004; 18:276-84.
13.  Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-
cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute 
and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83:2360-7.
14.  Otte JM,.Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. 
Am.J.Physiol Gastrointest.Liver Physiol 2004; 286:G613-G626.
15.  Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal 
infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 
1998; 82:2275-81.
16.  Nazli A, Yang PC, Jury J, Howe K, Watson JL, Soderholm JD et al. Epithelia under metabolic stress perceive 
commensal bacteria as a threat. Am.J.Pathol. 2004; 164:947-57.
17.  Madara J. Building an intestine--architectural contributions of commensal bacteria. N.Engl.J.Med. 2004; 351:1685-
6.
18.  Casadevall A,.Pirofski LA. The damage-response framework of microbial pathogenesis. Nat.Rev.Microbiol. 2003; 
1:17-24.
19.  Meropol N.J., Somer R.A.Gutheil J., Pelley R.J., Modiano M.R., Rowinsky E.K., Rothenberg M.L. et al. Randomized 
phase 1 trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal 
protectant. J Clin Oncol 2003; 21:1452-8.
20.  Ellis M., Zwaan F., Hedstrom U., Poynton CH, Kristensen J., Jumaa P. et al. Recombinant human interleukin 11 
and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: a double-blind 
placebo-controlled randomised trial. Lancet 2003; 361:275-80.

Nederlandse samenvatting voor niet-ingewijden
Chapter 12 
162
_____  Chapter 12  ____________________________________________________________________________________________________________ _________________________________________________________________  Nederlandse samenvatting voor niet-ingewijden  _____ 
163
162
_____  Chapter 12  ____________________________________________________________________________________________________________ _________________________________________________________________  Nederlandse samenvatting voor niet-ingewijden  _____ 
163
Nederlandse samenvatting voor niet-ingewijden
De behandeling van mensen met een kwaadaardige ziekte door middel van chemotherapie of 
bestraling heeft bijwerkingen waarvan een aantal nadelig tot zelfs schadelijk kunnen zijn. Gelukkig 
zijn de meeste bijwerkingen zoals misselijkheid en braken van voorbijgaande aard maar ze kunnen 
wel ernstige hinder opleveren en aanleiding zijn tot levensbedreigende complicaties. Dit boekje gaat 
over één van die bijwerkingen van voorbijgaande aard namelijk mucositis of te wel slijmvliesschade. 
De slijmvliezen in het menselijk lichaam vormen een natuurlijke barrière die ons lichaam beschermt 
tegen het binnendringen van zowel schadelijke stoffen als de meeste bacteriën en schimmels. 
Dezelfde slijmvliezen nemen overigens drank en voedsel op in ons lichaam. De slijmvliesschade 
veroorzaakt door chemotherapie of bestraling is alleen zichtbaar in de mond van patiënten, maar 
reikt van mond tot anus. Roodheid, zwelling en pijn zijn de eerste verschijnselen van de toegebrachte 
schade. Uiteindelijk kunnen er zelfs zweren ontstaan, plekken waar het slijmvlies helemaal kapot 
is gegaan. Dit leidt er toe dat patiënten hun mond niet goed meer kunnen openen en slecht 
kunnen slikken zodat zij weinig tot niets eten en zelfs water met moeite binnen kunnen houden. 
Tegelijkertijd zijn de meeste patiënten misselijk, hebben braakneigingen en waterdunne diarree met 
heftige buikkrampen. Met name patiënten die een stamceltransplantatie ondergaan hebben veel 
last van deze slijmvliesschade, omdat zij ter voorbereiding op een stamceltransplantatie behandeld 
worden met zeer intensieve chemotherapie, soms in combinatie met bestraling van het gehele 
lichaam. Als regel is de slijmvliesschade bij deze patiënten zo uitgesproken dat zij via een infuus 
in de bloedbaan kunstmatig gevoed moeten worden. Bovendien hebben de patiënten meestal 
morfine nodig tegen de pijn. Het slijmvlies kan zo ernstig beschadigd raken dat bacteriën en 
schimmels niet langer kunnen worden tegengehouden, hetgeen kan leiden tot levensbedreigende 
infecties. Of de slijmvliesschade veroorzaakt door chemotherapie of bestraling is te voorkomen of 
te verhelpen, hangt af van een aantal factoren. Zo is het belangrijk om te weten hoe deze schade nu 
precies ontstaat. Ondanks dat dit nogal voor de hand lijkt te liggen, bestond er tot voor kort maar 
weinig aandacht voor dit probleem in de medische literatuur. Dit gebrek aan belangstelling zou 
kunnen samenhangen met de beperkte therapeutische mogelijkheden en het feit dat de schade zich 
na verloop van tijd spontaan herstelt. 
In hoofdstuk 2 is de literatuur over de schade aan het slijmvlies van het spijsverteringskanaal 
zoals die optreedt na chemotherapie en bestraling samengevat. De engelse term “mucosal 
barrier injury” wordt geïntroduceerd omdat die benaming beter dan de term “mucositis” aangeeft 
wat er met de slijmvliezen gebeurt. Vervolgens wordt aan de hand van een model dat uitgaat van 
een viertal opeenvolgende fases een mogelijke verklaring gegeven voor het mechanisme dat 
verantwoordelijk zou kunnen zijn voor het ontstaan van “mucosal barrier injury“. In de eerste fase 
worden onder meer door de slijmvliescellen eiwitten geproduceerd die ontstekingsbevorderend 
werken. In de tweede fase wordt de celgroei geremd hetgeen weer leidt tot het ontstaan van 
zweren in de derde fase. In de laatste en vierde fase volgt dan uiteindelijk herstel op van het 
slijmvlies. Verder wordt uitvoerig ingegaan op de methodiek om de mate van slijmvliesschade 
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van mond en darmen zo goed mogelijk vast te stellen. Ook de gevolgen van de slijmvliesschade, 
zoals infecties bij stamcel transplantatie patiënten, worden uitvoerig besproken. Daarnaast 
wordt een kort overzicht gegeven van de therapeutische mogelijkheden om de slijmvliesschade 
te voorkomen dan wel te behandelen. De twee belangrijkste boodschappen van dat eerste 
hoofdstuk zijn dat niet alleen het slijmvlies van de mond wordt beschadigd maar ook in de rest 
van het spijsverteringskanaal en dat de slijmvliesschade niet louter een gevolg is van remming 
van snel delende slijmvlies cellen. Een en ander is het gevolg van een complexe cascade van 
gebeurtenissen die uiteindelijk leiden tot ontsteking en het kapot gaan van het slijmvlies. 
De slijmvliesschade begint met een ontstekingsfase zoals eerder in hoofdstuk 2 is beschreven. 
Chemotherapie activeert een belangrijke factor: nuclear factor-kappaB (NF-κB). Deze factor 
regelt het opstarten en overschrijven van bepaalde erfelijke informatie uit de celkern hetgeen leidt 
tot de productie van ontstekingsbevorderende stoffen. Deze zogenaamde pro-inflammatoire 
cytokines en chemokines zijn eiwitten die meestal op afstand hun effect sorteren. Uit het 
onderzoek beschreven in hoofdstuk 3 wordt duidelijk dat deze ontstekingsbevorderende stoffen 
in de slijmvliezen van de darmen van bepaalde proefdieren een ontstekingsreactie veroorzaken. 
NF-κB regelt echter niet alleen de productie van deze ontstekingsbevorderende stoffen, maar 
speelt ook een belangrijke rol bij het aflezen van informatie uit de celkern voor de productie van 
factoren die de cel juist in leven houden. Recent is ontdekt dat kwaadaardige cellen zich kunnen 
beschermen tegen de door chemotherapie en bestraling veroorzaakte celdood door de productie 
van het NF-κB te activeren. Remming van NF-κB is dan ook een efficiënte manier gebleken om 
chemotherapie, althans in celkweken en in proefdieren, beter te laten werken. Als het remmen 
van NF-κB enerzijds de schade aan de slijmvliescellen vergroot en anderzijds de ontstekings-
verschijnselen kan doen afnemen, komt de vraag op wat nu eigenlijk het uiteindelijke resultaat 
is van een verminderde productie van deze factor. In dit kader werden zowel een farmaceutische 
NF-κB remmer, CAPE als een kruid, curcumin, getest in proefdieren die chemotherapie in de 
vorm van methotrexaat hadden gekregen. Noch het gebruik van curcumin, noch dat van CAPE 
resulteerde in een toename van slijmvliesschade die na het toedienen van methotrexaat berucht 
is. Dat lijkt gunstig, maar men dient zich ervan bewust te zijn dat hiermee ook geen duidelijkheid 
is verkregen over het mogelijk positieve effect van de remming van NF-κB. 
Hoofdstuk 4 is gewijd aan pogingen om de ernst van schade aan het slijmvlies van de darmen bij 
patiënten beter in kaart te brengen met behulp van de zogeheten suikertesten. Bij de voorbereiding 
op een stamceltransplantatie worden de slijmvliezen in het gehele spijsverteringskanaal van de 
patiënt ernstig beschadigd. Deze beschadiging veroorzaakt veel pijn, waarvoor in veel gevallen 
morfine moet worden toegediend, dat echter de peristaltiek van de darmen vermindert. Voor 
de patiënt is dat gunstig omdat daardoor zowel de pijn als diarree minder wordt maar voor de 
behandelend arts wordt het moeilijker een goed beeld te krijgen van de ernst van de schade 
aan de darm omdat diarree immers een klinische parameter is. In een poging een objectieve 
maat voor de schade te krijgen dronken de patiënten iedere week een drankje waarin een viertal 
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suikers: lactulose, rhamnose, xylose and 3-O-methylglucose – waren opgelost. Het is hierbij van 
belang te weten dat lactulose normaal gesproken door de darmen niet wordt opgenomen en 
de andere suikers daarentegen wel. Lactulose wordt merkwaardigerwijs juist wel opgenomen 
door een beschadigd darmslijmvlies terwijl opname van de andere suikers terugloopt. Zijn de 
suikers eenmaal opgenomen in de bloedbaan worden ze in de urine uitgescheiden en kunnen 
dan eenvoudig worden gemeten. De hoeveelheid suiker die in de urine wordt teruggevonden is 
uiteraard afhankelijk van opgenomen hoeveelheid. Op basis hiervan krijgt men dus een objectieve 
maat voor de doorlaatbaarheid en integriteit van de beschadigde darm. Om vergelijkingsmateriaal 
te krijgen werden deze suikertesten ook uitgevoerd bij patiënten bij wie kort tevoren een acute 
bloedziekte was vastgesteld en die nooit eerder behandeling met chemotherapie of bestraling 
hadden gehad. Het blijkt echter dat patiënten met een acute bloedziekte bij diagnose al een 
gestoorde doorlaatbaarheid van de darm hebben, maar dat de integriteit van de darm pas zeer 
ernstig gestoord raakt na de stamceltransplantatie. De integriteit blijft na de transplantatie 
wekenlang gestoord en is zelfs nog niet hersteld op het moment dat de patiënten weer naar huis 
gaan. De resultaten van de suikertesten zijn vergeleken met die waardes welke werden verkregen 
met behulp van het zogenaamde scoringssysteem dat is gebaseerd is op zichtbare afwijkingen 
en subjectieve klachten veroorzaakt door slijmvliesschade aan mond en darmen. Het blijkt dat 
de schade die in de mond te zien is een patroon laat zien dat sterk overeenkomt met wat wordt 
gevonden met de suikertesten maar dat met mondscore, darmscore en suikertesten een ander 
aspect van de ontstane slijmvliesschade wordt gemeten.  
Vervolgens is bekeken of een stoornis in de doorlaatbaarheid en integriteit van de darmen 
samenhangt met het soort chemotherapie en wat de invloed is van een aanvullende bestraling 
als voorbereiding op een stamceltransplantatie. In hoofdstuk 5 is beschreven dat gemiddeld één 
week na de start van deze zogenaamde conditionering de suikertesten fors gestoord zijn ten 
opzichte van de uitgangswaarden maar dat de grootste schade aan de darmen een week later 
ontstaat. Patiënten die in de voorbereiding idarubicine als extra chemotherapeuticum toegediend 
hadden gekregen, ontwikkelen deze schade pas gemiddeld 14 dagen na het starten van de 
behandeling. Deze slijmvliesschade blijkt echter veel ernstiger en houdt ook langer aan dan bij 
patiënten die niet met idarubicine werden geconditioneerd.
De suikertesten zijn een bewerkelijke en voor de patiënt hinderlijke manier om de schade aan het 
darmslijmvlies te meten. Door de kapotte mond of pijnlijke keel kan het nagenoeg onmogelijk 
zijn om de testdrank in te nemen. Bovendien hebben verpleegkundigen vaak onvoldoende tijd 
voor het verzamelen van de benodigde urine. Het kunnen beschikken over een simpele bloedtest 
waarmee de schade van het slijmvlies kan worden gemeten is dus zeer aantrekkelijk. Uit de 
gegevens gepresenteerd in hoofdstuk 6 blijkt dat het bepalen van het aminozuur citrulline in het 
bloed wellicht deze rol zal kunnen vervullen. Gezonde cellen in het darmslijmvlies gebruiken een 
ander aminozuur, glutamine, als brandstof. Bij het verbruiken van glutamine wordt uiteindelijk 
citrulline gevormd, hetgeen door de cellen aan het bloed wordt afgegeven. De cellen in het 
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darmslijmvlies zijn hierin heel bijzonder want alle andere cellen in het lichaam zetten citrulline 
eerst om in arginine, weer een ander aminozuur, om vervolgens dat arginine af aan de bloedbaan. 
In recent gepubliceerd onderzoek heeft men aangetoond dat de hoeveelheid citrulline in het 
bloed een heel goede maat is voor het aantal functionerende darmcellen. Om dit te testen bij 
een groep stamceltransplantatie patiënten is citrulline gemeten in het bloed voor start van de 
conditionering en vervolgens iedere week. De citrulline spiegel zakt vrij snel na aanvang van de 
conditionering met een laagste waarde op het moment waarop ook de mond het meest kapot is 
en de darmdoorlaatbaarheid en integriteit gemeten met behulp van de suikertesten zeer ernstig 
gestoord. Bovendien traden er in diezelfde periode van maximale slijmvliesschade ook allerlei 
infectieuze complicaties op.
In hoofdstuk 7 is een andere groep stamceltransplantatie patiënten beschreven, waarbij opnieuw 
naar citrulline concentraties in relatie tot de suikertesten is gekeken. Het verschil met het eerdere 
onderzoek was het frequenter bepalen van citrulline. Met dit groter aantal metingen werd opnieuw 
hetzelfde patroon gevonden van dalende citrulline waardes in combinatie met een toenemende 
schade aan cellen in het darmslijmvlies gemeten met behulp van mondscore, darmscore en 
suikertesten. Tevens bleek dat de citrulline concentraties al dalen voordat de suikertesten 
gestoord raken of dat er tekenen van slijmvliesschade in de mond te zien zijn. Anderzijds is 
het opvallend dat bij het stijgen van de citrulline concentraties 4 weken na transplantatie de 
darmdoorlaatbaarheid en integriteit nog duidelijk gestoord zijn. 
In hoofdstuk 8 is beschreven of het toevoegen van glutamine aan de kunstmatige voeding het 
darmslijmvlies beschermt tegen de schadelijke effecten van chemotherapie en de bestraling. 
Dit onderzoek is gedaan in de vorm van een gerandomiseerde studie bij patiënten die een 
stamceltransplantatie moesten ondergaan en toestemming hadden gegeven voor deelname aan 
deze studie. Door het lot werd bepaald welke patiënt normale kunstmatige voeding zou krijgen 
en voor welke patient glutamine in maximale dosering zou worden toegevoegd. Het onderzoek 
werd gedaan volgens de regels voor een dubbelblinde trial, dat wil zeggen dat noch de patiënt 
noch het behandelend team van dokters en verpleegkundigen wisten wie welk type voeding zou 
krijgen. Deze opzet voorkomt dat de onderzoekers zich zouden kunnen laten beïnvloeden door 
de wetenschap of iemand nu wel of niet glutamine in de kunstmatige voeding toegevoegd krijgt. 
De hypothese achter dit onderzoek was dat de schade aan de darmen wellicht minder zou zijn 
indien voldoende glutamine zou worden gegeven omdat glutamine immers de brandstof is voor 
de cellen in het darmslijmvlies. De schade werd gemeten met mondscore, darmscore, citrulline 
en suikertesten. De gemeten schade bleek echter niet minder bij patiënten die glutamine 
toegediend hadden gekregen. Wel was het zo dat bij de patiënten die kunstmatige voeding met 
glutamine hadden gekregen minder complicaties, met name infecties, werden gezien na de 
stamceltransplantatie. Ook waren er aanwijzingen dat leverschade minder uitgesproken was bij 
deze patiënten. De verschillen in het voordeel van de met glutamine behandelde patiënten waren 
echter niet significant; dat wil zeggen dat de gevonden verschillen op toeval kunnen berusten. 
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Een studie met meer patiënten kan wellicht duidelijk maken of toediening van glutamine aan 
kunstmatige voeding nu wel of niet zin heeft.
Tijdens de bovengenoemde studie in hoofdstuk 8 was ook regelmatig bloed afgenomen van 
de patiënten om de spiegels van een aantal bekende ontstekingsbevorderende eiwitten te 
kunnen bepalen. In hoofdstuk 9 worden de resultaten van het meten van een drietal van deze 
ontstekingsbevorderende eiwitten, interleukine-8 (IL-8), LPS-bindend protein (LBP) en C-reactive 
protein (CRP), beschreven. Daarbij is nagegaan of er een relatie was met het ontstaan en beloop 
van de slijmvliesschade en met het kweken van bacteriën uit het bloed. Het bestaan van een 
dergelijke relatie is namelijk beschreven. IL-8 wordt onder andere geproduceerd door cellen in het 
darmslijmvlies als een reactie op micro-organismen, bijvoorbeeld bacteriën in de darmen. Dit eiwit 
helpt het lichaam om zich teweer te stellen tegen deze bacteriën. Hetzelfde geldt min of meer voor 
LBP dat in staat is om zich te binden aan een celwandbestanddeel, het zogeheten lipopolysaccharide 
(LPS), van bepaalde soorten bacteriën dat ook een rol speelt in de afweermechanismen van de 
cellen uit het darmslijmvlies. CRP is een eiwit wat door heel veel cellen in het lichaam kan worden 
geproduceerd; in deze studie wordt het gebruikt als algemene maat voor ontsteking. Omdat de 
slijmvliesschade bij deze stamceltransplantatie patiënten al eerder was gemeten met behulp van 
de mondscore, darmscore, citrulline en suikertesten kon worden nagegaan of er een samenhang 
bestaat tussen het verloop van de spiegels van deze ontstekingseiwitten en de ernst van de 
schade aan het slijmvlies. Een significante stijging van IL-8, LBP en CRP werd gemeten op het 
moment van stamceltransplantatie. Alledrie eiwitten bereikten hun piek na 1 week, in dezelfde 
periode van maximale slijmvliesschade. Verder bleek dat de bacteriën pas uit het bloed worden 
gekweekt na het oplopen van de waardes van IL-8, LBP en CRP. Dit doet vermoeden dat deze 
ontstekingsbevorderende eiwitten waarschijnlijk een uiting zijn van aanwezige slijmvliesschade en 
dat de verhoogde spiegels niet primair worden veroorzaakt door bacteriën uit het bloed. 
De bevindingen uit voorgaande hoofdstukken waren aanleiding om de rol van micro-organismen 
in het proces van slijmvliesschade opnieuw onder de loep te nemen. Theorieën omtrent het 
samenspel van micro-organismen en hun gastheer, de patiënt die intensieve chemotherapie 
ontvangt, in relatie tot de slijmvliesschade zijn weergegeven in hoofdstuk 10. De slijmvliesschade 
is niet alleen een risico-factor voor het ontwikkelen van infectieuze complicaties na intensieve 
chemotherapie maar ook en vooral het resultaat van een verstoord evenwicht tussen de patiënt 
en zijn micro-organismen. De mate van uiteindelijke slijmvlies schade na intensieve therapie 
wordt voornamelijk bepaald door de ontstekingsreactie van de patiënt in het algemeen en die van 
cellen in het darmslijmvlies in het bijzonder. Het eindresultaat wordt mede beïnvloed door de 
reactie van de cellen in het darmslijmvlies op micro-organismen die deze barrière passeren. Op 
basis van de boven beschreven bevindingen komt men tot de conclusie dat het dus aanbeveling 
verdient om meer geld en mankracht te investeren in pogingen om de normale slijmvliesbarrière 
te herstellen dan patiënten waarvan de verwachting is dat zij ernstige slijmvliesschade zullen 
ontwikkelen te beschermen met antibiotica.  
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List of abbreviations
3-OMG 3-O-Methylglucose
AML Acute Myeloid Leukemia
Ara-C Arabinoside Cytosine
ATG Anti-Thymocyte Globulines
Bu Busulphan
CAPE Caffeic Acid Phenethyl Ester
Cy Cyclophosphamide
CRP C-Reactive Protein
DGS Daily Gut Score
DMS Daily Mucositis Score
GALT Gut Associated Lymfoid Tissue
GI Gastro-intestinal
GVHD Graft-versus-Host Disease
HPLC High-Pressure-Liquid Chromatography
HSCT Haematopoietic Stem Cell Transplantation 
IDA Idarubicin
IEC-6 Intestinal Epithelial Cell line
IκB Inhibitor κB
IL-1 Interleukin-1
IL-8 Interleukin-8
L or LAC Lactulose
L/R Lactulose/Rhamnose ratio
LAC/RHA Lactulose/Rhamnose ratio
LBP LPS-Binding Protein
LOS Length Of Stay in hospital
LPS Lipopolysaccharide
MBI Mucosal Barrier Injury
MCP Monocyte Chemoattractant Protein
MDS Myelodysplastic Syndrome
MHC Major Histo-Compatibility
MSTFA N-Methyl-N-9trimethylsilyl trifluoroacetamide
MTX Methotrexate
NF-κB Nuclear Factor-kappa B
OVS Oral Viridans Streptococci
PN Parenteral Nutrition
R or RHA L-Rhamnose
SAT Sugar Absorption Test
SPT Sugar Permeability Test
TBI Total Body Irradiation
TNF-α Tumour Necrosis Factor-alpha
XYL D-xylose
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Dr. I.H. Go en Dr. R.W. de Koning). Vanaf 1997 vervolgde zij de opleiding in het Universitair 
Medisch Centrum St Radboud te Nijmegen (opleider Prof. dr. J.W.M. van der Meer) en op 1 
januari 1998 werd zij geregistreerd als internist. Sindsdien werkt zij op de afdeling Hematologie 
waar ook de opleiding tot internist-hematoloog plaatsvond (Hoofd Prof. dr.T.J.M. de Witte). In 
1999 begon zij met het onderzoek dat vermeld is in dit proefschrift. Sinds 1 oktober 2001 “werkt” 
zij als staflid op de afdeling Hematologie van het UMC St Radboud. Haar aandachtsveld is de 
supportieve zorg in de intensieve hemato-oncologie, inclusief de stamceltransplantatie. 
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Een groot aantal mensen heeft bijgedragen aan het tot stand komen van dit proefschrift. Om 
recht te doen aan éénieders bijdrage, ben ik verheugd dat velen zich hebben laten fotograferen 
op vrijdag 29 april 2005. Diegenen onder jullie die helaas niet aanwezig konden zijn, 
verpleegkundigen, voedingsassistenten, diëtisten, secretaresses, analisten en artsen, wil ik bij 
deze bedanken voor hun bijdrage. 
1 Bea van’t Land met foto van Laura M’Rabet
2 Reinier Raymakers
3 Peter Donnelly 
4 Nicole Blijlevens
5 Ben de Pauw 
6 Leo Kruissen
7 Elly Bouman
8 Michel Schaap
9 Toine Smiet 
10 Theo de Witte
11 Paul Verweij 
12 Nori van Wijngaarden 
13 Wjera Novotna
14 Margot van den Akker
15 Helen Lamers
16 Marije Niehof
17 Marie-José Jorna 
18 Sabire Arslan
19 Roland van der Loos
20 Noud Hendriks
21 Martin Strohmaier
22 Huib de Jong
23 Sander Kropman
24 Marc Schreurs 
25 Maartje Knoops
26 Ank van de Laak
27 Loes de Ponti
28 Lucia Kregting
29 Maarten van Vliet
30 Marianne Wilders
31 Léon Kant
32 Gerard Vogel
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Maar mijn grootste dank gaat uit naar al die patiënten die geparticipeerd hebben in de supportive 
care studies van de afdeling Hematologie, zonder hun inzet en enthousiasme zou ik niet zulke 
mooie resultaten hebben gekregen.
Verder wil ik graag een aantal personen nog speciaal bedanken die een bijzondere rol in mijn 
promotie traject hebben gespeeld. 
Ten eerste, mijn promoter, Ben de Pauw, voor het simpele feit dat hij geloofde in mijn capaciteiten 
als klinisch onderzoekster en de weg vrij maakte om mijn onderzoek in huis op poten en 
internationaal op de kaart te zetten. Jouw scherpe geest, jouw betrokkenheid bij patiënten en 
uiteraard de dirty jokes zijn de ideale mix voor mij geweest om door te gaan ondanks allerlei 
obstakels. Dank. 
Peter, it was a privilege to be trained by you in the field of science. You challenged me to look 
at the raw data without stretching them to fit the truth. Your criticism was never unjustified 
although it did hurt, only occasionally, however. You taught me how to make attractive power 
point presentations and, in addition, showed me how to perform and how to present my results 
and contemplations; cool, calm and collected. When I experienced a turbulent change in my 
personal life, you were always there to support me. I feel much obliged. I admit that I am proud 
to share a room with you, a former Red-handed Scotsman. We are not only a perfect team in 
supportive care management; we also share our humour that makes life pleasant.
Ton, het is maar goed dat wij géén kamer samen delen want jouw gezelschap is uitermate 
aangenaam. Jouw enthousiasme voor het vak en met name voor de behandeling van patiënten 
met een stamceltransplantatie is altijd zeer motiverend geweest voor mij. Tezamen met John heb 
jij ervoor gezorgd dat mijn interventie studie op de afdeling kon worden uitgevoerd.
Toine, je weet het, je bent niet voor niets mijn paranimf, zonder jouw motivatie van het 
verpleegkundig team en patiënten zou mijn boekje er zeker anders hebben uitgezien.
Theo, dank dat je de “supportive care business” hebt laten bloeien binnen de afdeling 
Hematologie.
Marie-José, jouw doortastendheid in de verpleegkundige leiding van de verpleegafdeling werpt 
haar vruchten af, samen maken we de zorg nog beter.
Staf Hematologie, dank voor het door jullie in mij gestelde vertrouwen.
Ralph, writing is a family asset after all.
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Pa en Ma, bedankt dat jullie mij altijd gestimuleerd hebben om door te leren en ik ben blij dat 
jullie beiden dit mogen meemaken. 
Mariëtte, jouw liefde en hartverwarmende zorgzaamheid laten mij leven, elke dag opnieuw. 
